<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="0" size="14" family="Times" color="#000000"/>
	<fontspec id="1" size="11" family="Times" color="#000000"/>
	<fontspec id="2" size="16" family="Times" color="#000000"/>
	<fontspec id="3" size="19" family="Times" color="#365f91"/>
<text top="789" left="1126" width="12" height="21" font="0">1 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="69" left="288" width="617" height="24" font="2"><b>2016 Duration of Dual Antiplatelet Therapy Guideline Focused Update Data Supplement </b></text>
<text top="100" left="54" width="4" height="21" font="0"> </text>
<text top="143" left="525" width="141" height="16" font="2"><b>Table of Contents </b></text>
<text top="157" left="594" width="5" height="28" font="3"><b> </b></text>
<text top="187" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#2">Data Supplement 1. RCTs of Shorter (3–6 Month) Duration of DAPT in Patients Treated With Stent Implantation   .......................................................................... 2 </a></text>
<text top="206" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#4">Data Supplement 2. RCTs of Prolonged/Extended (&gt;12 Month) Duration of DAPT in Patients Treated With Stent Implantation ....................................................... 4 </a></text>
<text top="225" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#6">Data Supplement 3. Meta-Analyses of Duration of DAPT ...................................................................................................................................................................... 6 </a></text>
<text top="244" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#9">Data Supplement 4. RCTs, RCT Subgroup Analyses, and Meta-Analyses of RCTs of DAPT Post–MI or Post–ACS .......................................................................... 9 </a></text>
<text top="263" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#15">Data Supplement 5. RCTs and RCT Subgroup Analyses Comparing Clopidogel With Prasugrel or Ticagrelor In Patients With ACS .............................................. 15 </a></text>
<text top="282" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#17">Data Supplement 6.  Studies and Comparisons of Short-Term or Chronic Aspirin Dose in Patients With Coronary Artery Disease .................................................. 17 </a></text>
<text top="301" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#20">Data Supplement 7.  RCTs Comparing Antiplatelet Therapy With Anticoagulant Therapy in Patients Undergoing Coronary Stenting ............................................. 20 </a></text>
<text top="320" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#21">Data Supplement 8.  Nonrandomized Studies of DAPT Duration After BMS or DES ......................................................................................................................... 21 </a></text>
<text top="339" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#22">Data Supplement 9.  Randomized Studies of 1 Versus 12 Months of DAPT After BMS ..................................................................................................................... 22 </a></text>
<text top="358" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#22">Data Supplement 10.  Studies and Meta-Analyses Comparing Graft Patency Post–CABG in Patients Treated With Either Antiplatelet Monotherapy or DAPT ..... 22 </a></text>
<text top="377" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#25">Data Supplement 11.  Studies Comparing Outcome Post–CABG in Patients Treated With Either Aspirin or DAPT.......................................................................... 25 </a></text>
<text top="396" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#26">Data Supplement 12. Studies of Timing of Noncardiac Surgery After PCI .......................................................................................................................................... 27 </a></text>
<text top="415" left="54" width="1083" height="15" font="0"><a href="DAPT_Data_Supplement_1.html#31">References .............................................................................................................................................................................................................................................. 31 </a></text>
<text top="430" left="54" width="4" height="21" font="0"> </text>
<text top="450" left="54" width="4" height="21" font="0"> </text>
<text top="488" left="54" width="4" height="21" font="0"> </text>
<text top="526" left="54" width="4" height="21" font="0"> </text>
<text top="565" left="54" width="4" height="21" font="0"> </text>
<text top="603" left="54" width="4" height="21" font="0"> </text>
<text top="641" left="54" width="4" height="21" font="0"> </text>
<text top="679" left="54" width="4" height="21" font="0"> </text>
<text top="717" left="54" width="4" height="21" font="0"> </text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="4" size="12" family="Times" color="#000000"/>
	<fontspec id="5" size="12" family="Times" color="#000000"/>
	<fontspec id="6" size="12" family="Times" color="#0000ff"/>
	<fontspec id="7" size="7" family="Times" color="#000000"/>
	<fontspec id="8" size="12" family="Times" color="#131313"/>
<text top="789" left="1126" width="12" height="21" font="0">2 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="51" left="54" width="786" height="24" font="2"><b>Data Supplement 1. RCTs of Shorter (3–6 Month) Duration of DAPT in Patients Treated With Stent Implantation   </b></text>
<text top="81" left="84" width="38" height="20" font="4"><b>Study </b></text>
<text top="98" left="72" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="115" left="78" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="133" left="56" width="96" height="20" font="4"><b>Year Published  </b></text>
<text top="81" left="190" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="98" left="194" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="115" left="188" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="81" left="344" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="81" left="513" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="98" left="530" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="115" left="513" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="133" left="534" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="81" left="692" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="98" left="675" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="115" left="678" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="133" left="720" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="82" left="891" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="99" left="925" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="117" left="879" width="150" height="20" font="4"><b>                Adverse Events </b></text>
<text top="155" left="54" width="324" height="20" font="4"><b>Studies of shorter (3-6 mo) vs. 12 mo duration of DAPT </b></text>
<text top="178" left="54" width="70" height="20" font="4"><b>ISAR-SAFE </b></text>
<text top="195" left="54" width="92" height="20" font="5">Schulz-Schupke </text>
<text top="213" left="54" width="49" height="20" font="5">S, et al., </text>
<text top="230" left="54" width="31" height="20" font="5">2015 </text>
<text top="247" left="54" width="19" height="20" font="5">(1) </text>
<text top="264" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25616646">25616646</a></text>
<text top="264" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25616646"> </a></text>
<text top="178" left="163" width="135" height="20" font="4"><b>Aim:</b> Test if 6 mo DAPT </text>
<text top="195" left="163" width="125" height="20" font="5">is noninferior to 12 mo </text>
<text top="213" left="163" width="36" height="20" font="5">DAPT </text>
<text top="230" left="163" width="3" height="20" font="5"> </text>
<text top="247" left="163" width="103" height="20" font="4"><b>Study type:</b> RCT, </text>
<text top="264" left="163" width="97" height="20" font="5">noninferiority trial </text>
<text top="281" left="163" width="3" height="20" font="5"> </text>
<text top="299" left="163" width="124" height="20" font="4"><b>Size:</b> 6,000 pts (4,005 </text>
<text top="316" left="163" width="115" height="20" font="5">pts actually enrolled, </text>
<text top="333" left="163" width="114" height="20" font="5">4,000 pts analyzed)  </text>
<text top="178" left="312" width="161" height="20" font="4"><b>Inclusion criteria:</b> Pts being </text>
<text top="195" left="312" width="162" height="20" font="5">treated with DAPT 6 mo after </text>
<text top="213" left="312" width="32" height="20" font="5">DES  </text>
<text top="230" left="312" width="3" height="20" font="5"> </text>
<text top="247" left="312" width="164" height="20" font="4"><b>Exclusion criteria:</b> Left main </text>
<text top="264" left="312" width="168" height="20" font="5">PCI, MI in the initial 6 mo after </text>
<text top="281" left="312" width="113" height="20" font="5">stent, previous stent </text>
<text top="299" left="312" width="64" height="20" font="5">thrombosis </text>
<text top="178" left="501" width="88" height="20" font="4"><b>Intervention:</b> 6 </text>
<text top="195" left="501" width="113" height="20" font="5">additional mo DAPT </text>
<text top="213" left="501" width="104" height="20" font="5">after initial 6 mo of </text>
<text top="230" left="501" width="93" height="20" font="5">DAPT (n=2,003) </text>
<text top="247" left="501" width="7" height="20" font="5">  </text>
<text top="264" left="501" width="135" height="20" font="4"><b>Comparator:</b> No further </text>
<text top="281" left="501" width="132" height="20" font="5">clopidogrel after initial 6 </text>
<text top="299" left="501" width="80" height="20" font="5">mo (n=1,997) <b> </b></text>
<text top="180" left="649" width="189" height="20" font="4"><b>1</b>°<b> endpoint:</b> Composite endpoint </text>
<text top="197" left="649" width="169" height="20" font="5">of death, MI, stent thrombosis, </text>
<text top="214" left="649" width="189" height="20" font="5">CVA, or TIMI major bleeding 9 mo </text>
<text top="231" left="649" width="179" height="20" font="5">after randomization (15 mo after </text>
<text top="248" left="649" width="34" height="20" font="5">stent) </text>
<text top="267" left="649" width="7" height="18" font="5">•</text>
<text top="267" left="656" width="170" height="20" font="5"> 1.5% with no additional DAPT </text>
<text top="284" left="649" width="152" height="20" font="5">(6 mo total) vs. 1.6% with 6 </text>
<text top="301" left="649" width="185" height="20" font="5">additional mo DAPT (12 mo total) </text>
<text top="318" left="649" width="148" height="20" font="5">(p&lt;0.001 for noninferiority) </text>
<text top="180" left="852" width="7" height="18" font="5">•</text>
<text top="180" left="859" width="239" height="20" font="5"> Trial stopped early due to slow recruitment </text>
<text top="199" left="852" width="7" height="18" font="5">•</text>
<text top="198" left="859" width="185" height="20" font="5"> Lower than expected event rates </text>
<text top="217" left="852" width="7" height="18" font="5">•</text>
<text top="216" left="859" width="235" height="20" font="5"> Stent thrombosis and TIMI major bleeding </text>
<text top="233" left="852" width="208" height="20" font="5">rates low and not statistically different </text>
<text top="251" left="852" width="3" height="20" font="5"> </text>
<text top="268" left="852" width="3" height="20" font="5"> </text>
<text top="351" left="54" width="66" height="20" font="4"><b>SECURITY</b> </text>
<text top="368" left="54" width="81" height="20" font="5">Colombo A, et </text>
<text top="386" left="54" width="20" height="20" font="5">al.,<b> </b></text>
<text top="403" left="54" width="31" height="20" font="5">2014 </text>
<text top="420" left="54" width="19" height="20" font="5">(2) </text>
<text top="437" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25236346">25236346</a></text>
<text top="437" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25236346"> </a></text>
<text top="351" left="163" width="132" height="20" font="4"><b>Aim:</b> Test noninferiority </text>
<text top="368" left="163" width="117" height="20" font="5">of 6 vs. 12 mo DAPT </text>
<text top="386" left="163" width="35" height="20" font="5">after 2</text>
<text top="387" left="198" width="9" height="13" font="7">nd</text>
<text top="386" left="207" width="65" height="20" font="5"> generation </text>
<text top="403" left="163" width="29" height="20" font="5">DES </text>
<text top="420" left="163" width="3" height="20" font="5"> </text>
<text top="437" left="163" width="103" height="20" font="4"><b>Study type:</b> RCT, </text>
<text top="454" left="163" width="97" height="20" font="5">noninferiority trial </text>
<text top="472" left="163" width="3" height="20" font="5"> </text>
<text top="489" left="163" width="86" height="20" font="4"><b>Size:</b> 1,399 pts </text>
<text top="351" left="312" width="152" height="20" font="4"><b>Inclusion criteria:</b> Pts with </text>
<text top="368" left="312" width="174" height="20" font="5">stable angina, unstable angina, </text>
<text top="386" left="312" width="98" height="20" font="5">or silent ischemia </text>
<text top="403" left="312" width="3" height="20" font="5"> </text>
<text top="420" left="312" width="152" height="20" font="4"><b>Exclusion criteria:</b> Recent </text>
<text top="437" left="312" width="158" height="20" font="5">STEMI or NSTEMI, left main </text>
<text top="454" left="312" width="156" height="20" font="5">PCI , SVG PCI, CKD, active </text>
<text top="472" left="312" width="172" height="20" font="5">bleeding or significant bleeding </text>
<text top="489" left="312" width="22" height="20" font="5">risk </text>
<text top="351" left="501" width="109" height="20" font="4"><b>Intervention:</b> 6 mo </text>
<text top="368" left="501" width="82" height="20" font="5">DAPT (n=682) </text>
<text top="386" left="501" width="7" height="20" font="5">  </text>
<text top="403" left="501" width="115" height="20" font="4"><b>Comparator:</b> 12 mo </text>
<text top="420" left="501" width="89" height="20" font="5">DAPT (n=717)<b>   </b></text>
<text top="352" left="649" width="180" height="20" font="4"><b>1</b>°<b> endpoint:</b> Cardiac death, MI, </text>
<text top="370" left="649" width="178" height="20" font="5">CVA, stent thrombosis or BARC </text>
<text top="387" left="649" width="111" height="20" font="5">type 3 or 5 bleeding </text>
<text top="406" left="649" width="7" height="18" font="5">•</text>
<text top="405" left="656" width="178" height="20" font="5"> 4.5% with 6 mo DAPT vs. 3.7% </text>
<text top="422" left="649" width="183" height="20" font="5">with 12 mo DAPT (risk difference </text>
<text top="442" left="649" width="114" height="20" font="5">0.8%; 95% CI: -2.4%</text>
<text top="442" left="763" width="7" height="19" font="8">–</text>
<text top="442" left="771" width="35" height="20" font="5">1.7%; </text>
<text top="460" left="649" width="49" height="20" font="5">p=0.469)</text>
<text top="460" left="698" width="4" height="19" font="8"> </text>
<text top="479" left="649" width="7" height="18" font="5">•</text>
<text top="478" left="656" width="136" height="20" font="5"> p&lt;0.05 for noninferiority </text>
<text top="495" left="649" width="3" height="20" font="4"><b> </b></text>
<text top="353" left="852" width="7" height="18" font="5">•</text>
<text top="352" left="859" width="196" height="20" font="5"> Stent thrombosis rates low and not </text>
<text top="370" left="852" width="115" height="20" font="5">significantly different </text>
<text top="389" left="852" width="7" height="18" font="5">•</text>
<text top="388" left="859" width="213" height="20" font="5"> Relatively low-risk population enrolled </text>
<text top="405" left="852" width="3" height="20" font="5"> </text>
<text top="521" left="54" width="62" height="20" font="4"><b>OPTIMIZE </b></text>
<text top="538" left="54" width="72" height="20" font="5">Feres, et al., </text>
<text top="555" left="54" width="31" height="20" font="5">2013 </text>
<text top="572" left="54" width="19" height="20" font="5">(3) </text>
<text top="589" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24177257">24177257</a></text>
<text top="589" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24177257"> </a></text>
<text top="607" left="81" width="3" height="20" font="5"> </text>
<text top="624" left="81" width="3" height="20" font="5"> </text>
<text top="641" left="81" width="3" height="20" font="5"> </text>
<text top="658" left="81" width="3" height="20" font="5"> </text>
<text top="521" left="163" width="131" height="20" font="4"><b>Aim:</b> Assess whether 3 </text>
<text top="538" left="163" width="132" height="20" font="5">mo of DAPT is clinically </text>
<text top="555" left="163" width="126" height="20" font="5">noninferior to 12 mo in </text>
<text top="572" left="163" width="134" height="20" font="5">pts undergoing PCI with </text>
<text top="589" left="163" width="27" height="20" font="5">ZES<b> </b></text>
<text top="607" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="624" left="163" width="103" height="20" font="4"><b>Study type: </b>RCT, </text>
<text top="641" left="163" width="97" height="20" font="5">noninferiority trial<b> </b></text>
<text top="658" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="676" left="163" width="86" height="20" font="4"><b>Size:</b> 3,211 pts<b> </b></text>
<text top="521" left="312" width="144" height="20" font="4"><b>Inclusion criteria:</b> Stable </text>
<text top="538" left="312" width="118" height="20" font="5">angina, low-risk ACS </text>
<text top="555" left="312" width="3" height="20" font="4"><b> </b></text>
<text top="572" left="312" width="169" height="20" font="4"><b>Exclusion criteria: </b>STEMI for </text>
<text top="589" left="312" width="175" height="20" font="5">primary or rescue PCI, PCI with </text>
<text top="607" left="312" width="172" height="20" font="5">BMS in nontarget lesion &lt;6 mo </text>
<text top="624" left="312" width="137" height="20" font="5">prior to index procedure, </text>
<text top="641" left="312" width="156" height="20" font="5">previous DES Rx., schedule </text>
<text top="658" left="312" width="162" height="20" font="5">elective surgery within 12 mo </text>
<text top="676" left="312" width="146" height="20" font="5">after index procedure, any </text>
<text top="693" left="312" width="155" height="20" font="5">contraindication to ASA and </text>
<text top="710" left="312" width="163" height="20" font="5">clopidogrel, SVG lesion, DES </text>
<text top="727" left="312" width="49" height="20" font="5">stenosis<b> </b></text>
<text top="521" left="501" width="109" height="20" font="4"><b>Intervention: </b>3 mo </text>
<text top="538" left="501" width="79" height="20" font="5">DAPT (1,605) </text>
<text top="555" left="501" width="3" height="20" font="4"><b> </b></text>
<text top="572" left="501" width="115" height="20" font="4"><b>Comparator: </b>12 mo </text>
<text top="589" left="501" width="85" height="20" font="5">DAPT (1,606)<b>   </b></text>
<text top="522" left="649" width="160" height="20" font="4"><b>1</b>°<b> endpoint:</b> NACCE. At 1 y </text>
<text top="539" left="649" width="53" height="20" font="5">follow-up<b> </b></text>
<text top="558" left="649" width="7" height="18" font="5">•</text>
<text top="557" left="656" width="171" height="20" font="5"> 93 pts with 3 mo Rx vs. 90 pts </text>
<text top="575" left="649" width="167" height="20" font="5">with 12 mo Rx (95%  CI: 1.52–</text>
<text top="592" left="649" width="35" height="20" font="5">1.86)  </text>
<text top="611" left="649" width="7" height="18" font="5">•</text>
<text top="610" left="656" width="143" height="20" font="5"> p=0.002 for noninferiority </text>
<text top="627" left="649" width="3" height="20" font="5"> </text>
<text top="645" left="649" width="181" height="20" font="4"><b>Safety endpoint: </b>GUSTO major </text>
<text top="662" left="649" width="50" height="20" font="5">bleeding </text>
<text top="681" left="649" width="7" height="18" font="5">•</text>
<text top="680" left="656" width="160" height="20" font="5"> 0.2% with 3 mo Rx vs. 0.4% </text>
<text top="697" left="649" width="186" height="20" font="5">with long term Rx (HR: 0.50, 95% </text>
<text top="715" left="649" width="81" height="20" font="5">CI: 0.16–1.11) </text>
<text top="522" left="852" width="7" height="18" font="5">•</text>
<text top="522" left="859" width="234" height="20" font="5"> Stent thrombosis (5 pts in short term vs. 4 </text>
<text top="539" left="852" width="92" height="20" font="5">pts in long term) </text>
<text top="558" left="852" width="7" height="18" font="5">•</text>
<text top="557" left="859" width="192" height="20" font="5"> Study not powered to detect small </text>
<text top="575" left="852" width="241" height="20" font="5">differences in ischemic and bleeding events </text>
<text top="592" left="852" width="59" height="20" font="5">after 90 d. </text>
<text top="611" left="852" width="7" height="18" font="5">•</text>
<text top="610" left="859" width="226" height="20" font="5"> Overall event rate for NACCE was lower </text>
<text top="627" left="852" width="94" height="20" font="5">than anticipated. </text>
<text top="645" left="852" width="3" height="20" font="4"><b> </b></text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1126" width="12" height="21" font="0">3 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="44" height="20" font="4"><b>RESET </b></text>
<text top="70" left="54" width="81" height="20" font="5">Kim BK, et al., </text>
<text top="87" left="54" width="31" height="20" font="5">2012 </text>
<text top="104" left="54" width="19" height="20" font="5">(4) </text>
<text top="122" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22999717">22999717</a></text>
<text top="122" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22999717"> </a></text>
<text top="139" left="54" width="7" height="20" font="5">  </text>
<text top="53" left="163" width="82" height="20" font="4"><b>Aim:</b> Evaluate </text>
<text top="70" left="163" width="129" height="20" font="5">noninferiority of shorter </text>
<text top="87" left="163" width="93" height="20" font="5">DAPT after DES </text>
<text top="104" left="163" width="3" height="20" font="5"> </text>
<text top="122" left="163" width="133" height="20" font="4"><b>Study type:</b> RCT, open </text>
<text top="139" left="163" width="130" height="20" font="5">label, noninferiority trial </text>
<text top="156" left="163" width="3" height="20" font="5"> </text>
<text top="173" left="163" width="86" height="20" font="4"><b>Size:</b> 2,117 pts </text>
<text top="53" left="312" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="70" left="312" width="163" height="20" font="5">undergoing DES implantation </text>
<text top="87" left="312" width="3" height="20" font="5"> </text>
<text top="104" left="312" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="122" left="312" width="169" height="20" font="5">Contraindication to antiplatelet </text>
<text top="139" left="312" width="173" height="20" font="5">agents, bleeding, STEMI within </text>
<text top="156" left="312" width="167" height="20" font="5">48 h or cardiogenic shock, left </text>
<text top="173" left="312" width="54" height="20" font="5">main PCI </text>
<text top="53" left="501" width="109" height="20" font="4"><b>Intervention:</b> 3 mo </text>
<text top="70" left="501" width="101" height="20" font="5">DAPT with E-ZES </text>
<text top="87" left="501" width="53" height="20" font="5">(n=1059) </text>
<text top="104" left="501" width="7" height="20" font="5">  </text>
<text top="122" left="501" width="118" height="20" font="4"><b>Comparator:</b>  12 mo </text>
<text top="139" left="501" width="122" height="20" font="5">DAPT with other DES </text>
<text top="156" left="501" width="60" height="20" font="5">(n=1058)<b>   </b></text>
<text top="54" left="649" width="184" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV death, MI, stent </text>
<text top="71" left="649" width="192" height="20" font="5">thrombosis, TVR, bleeding at 1 y.   </text>
<text top="90" left="649" width="7" height="18" font="5">•</text>
<text top="90" left="656" width="167" height="20" font="5"> 4.7% with 3 mo DAPT/E-ZES </text>
<text top="107" left="649" width="181" height="20" font="5">vs. 4.7% with 12 mo DAPT/other </text>
<text top="124" left="649" width="176" height="20" font="5">DES (difference 0.0%; 95% CI: -</text>
<text top="141" left="649" width="93" height="20" font="5">2.5–2.5; p=0.84) </text>
<text top="160" left="649" width="7" height="18" font="5">•</text>
<text top="160" left="656" width="143" height="20" font="5"> p&lt;0.001 for noninferiority </text>
<text top="55" left="852" width="7" height="18" font="5">•</text>
<text top="54" left="859" width="232" height="20" font="5"> No significant differences in rates of stent </text>
<text top="71" left="852" width="159" height="20" font="5">thrombosis, bleeding or TVR </text>
<text top="90" left="852" width="7" height="18" font="5">•</text>
<text top="90" left="859" width="244" height="20" font="5"> Study underpowered due to low event rates </text>
<text top="109" left="852" width="7" height="18" font="5">•</text>
<text top="108" left="859" width="250" height="20" font="5"> Same stents not used in the 2 randomization </text>
<text top="125" left="852" width="31" height="20" font="5">arms </text>
<text top="142" left="852" width="3" height="20" font="5"> </text>
<text top="191" left="54" width="76" height="20" font="4"><b>EXCELLENT </b></text>
<text top="208" left="54" width="93" height="20" font="5">Gwon HC, et al., </text>
<text top="226" left="54" width="31" height="20" font="5">2012 </text>
<text top="243" left="54" width="19" height="20" font="5">(5) </text>
<text top="260" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22179532">22179532</a></text>
<text top="260" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22179532"> </a></text>
<text top="191" left="163" width="129" height="20" font="4"><b>Aim:</b> Evaluate whether </text>
<text top="208" left="163" width="120" height="20" font="5">6 mo DAPT would be </text>
<text top="226" left="163" width="113" height="20" font="5">noninferior to 12 mo </text>
<text top="243" left="163" width="93" height="20" font="5">DAPT after DES </text>
<text top="260" left="163" width="3" height="20" font="5"> </text>
<text top="277" left="163" width="133" height="20" font="4"><b>Study type:</b> RCT, open </text>
<text top="294" left="163" width="133" height="20" font="5">label, noninferiority trial  </text>
<text top="312" left="163" width="3" height="20" font="5"> </text>
<text top="329" left="163" width="86" height="20" font="4"><b>Size:</b> 1,443 pts </text>
<text top="191" left="312" width="145" height="20" font="4"><b>Inclusion criteria:</b>  &gt;50% </text>
<text top="208" left="312" width="127" height="20" font="5">lesion with evidence of </text>
<text top="226" left="312" width="164" height="20" font="5">myocardial ischemia or &gt;75% </text>
<text top="243" left="312" width="121" height="20" font="5">lesion (with or without </text>
<text top="260" left="312" width="131" height="20" font="5">documented  ischemia) </text>
<text top="277" left="312" width="3" height="20" font="5"> </text>
<text top="294" left="312" width="162" height="20" font="4"><b>Exclusion criteria:</b> MI within </text>
<text top="312" left="312" width="111" height="20" font="5">72 h, LVEF&lt;25% or </text>
<text top="329" left="312" width="143" height="20" font="5">cardiogenic shock, recent </text>
<text top="346" left="312" width="143" height="20" font="5">major bleeding or surgery </text>
<text top="191" left="501" width="109" height="20" font="4"><b>Intervention:</b> 6 mo </text>
<text top="208" left="501" width="93" height="20" font="5">DAPT after DES </text>
<text top="226" left="501" width="46" height="20" font="5">(n=722) </text>
<text top="243" left="501" width="7" height="20" font="5">  </text>
<text top="260" left="501" width="115" height="20" font="4"><b>Comparator:</b> 12 mo </text>
<text top="277" left="501" width="93" height="20" font="5">DAPT after DES </text>
<text top="294" left="501" width="46" height="20" font="5">(n=721)<b> </b></text>
<text top="192" left="649" width="153" height="20" font="4"><b>1</b>°<b> endpoint:</b> Target vessel </text>
<text top="209" left="649" width="142" height="20" font="5">failure (cardiac death, MI, </text>
<text top="227" left="649" width="173" height="20" font="5">ischemia-driven TVR) at 12 mo </text>
<text top="246" left="649" width="7" height="18" font="5">•</text>
<text top="245" left="656" width="178" height="20" font="5"> 4.8% with 6 mo DAPT vs. 4.3% </text>
<text top="262" left="649" width="169" height="20" font="5">with 12 mo DAPT (p=0.001 for </text>
<text top="280" left="649" width="78" height="20" font="5">noninferiority) </text>
<text top="297" left="649" width="3" height="20" font="4"><b> </b></text>
<text top="193" left="852" width="7" height="18" font="5">•</text>
<text top="192" left="859" width="242" height="20" font="5"> Stent thrombosis 0.9% with 6 mo DAPT vs. </text>
<text top="209" left="852" width="237" height="20" font="5">0.1% with 12 mo DAPT (HR: 6.02; 95% CI: </text>
<text top="227" left="852" width="114" height="20" font="5">0.72–49.96; p=0.10) </text>
<text top="246" left="852" width="7" height="18" font="5">•</text>
<text top="245" left="859" width="239" height="20" font="5"> TIMI major bleeding 0.3% with 6 mo DAPT </text>
<text top="262" left="852" width="256" height="20" font="5">vs. 0.6% with 12 mo DAPT (HR: 0.50; 95% CI: </text>
<text top="280" left="852" width="107" height="20" font="5">0.09–2.73; p=0.42) </text>
<text top="299" left="852" width="7" height="18" font="5">•</text>
<text top="298" left="859" width="201" height="20" font="5"> Target vessel failure occurred more </text>
<text top="315" left="852" width="228" height="20" font="5">frequently with 6 mo DAPT in diabetic pts </text>
<text top="334" left="852" width="7" height="18" font="5">•</text>
<text top="334" left="859" width="204" height="20" font="5"> Study underpowered for death or MI </text>
<text top="351" left="852" width="3" height="20" font="5"> </text>
<text top="371" left="54" width="313" height="20" font="4"><b>Studies of shorter (6 mo) vs. 24 mo duration of DAPT</b> </text>
<text top="392" left="54" width="43" height="20" font="4"><b>ITALIC </b></text>
<text top="409" left="54" width="87" height="20" font="5">Gilard M, et al., </text>
<text top="426" left="54" width="34" height="20" font="5">2015  </text>
<text top="443" left="54" width="19" height="20" font="5">(6) </text>
<text top="461" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25461690">25461690</a></text>
<text top="461" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25461690"> </a></text>
<text top="392" left="163" width="82" height="20" font="4"><b>Aim:</b> Evaluate </text>
<text top="409" left="163" width="118" height="20" font="5">noninferiority of 6 mo </text>
<text top="426" left="163" width="129" height="20" font="5">DAPT vs. 24 mo DAPT </text>
<text top="443" left="163" width="124" height="20" font="5">with newer generation </text>
<text top="461" left="163" width="78" height="20" font="5">(Xience) DES </text>
<text top="478" left="163" width="3" height="20" font="5"> </text>
<text top="495" left="163" width="133" height="20" font="4"><b>Study type:</b> RCT, open </text>
<text top="512" left="163" width="133" height="20" font="5">label, noninferiority trial  </text>
<text top="529" left="163" width="3" height="20" font="5"> </text>
<text top="547" left="163" width="126" height="20" font="4"><b>Size:</b> 2,031 pts (actual </text>
<text top="564" left="163" width="58" height="20" font="5">1,850 pts) </text>
<text top="392" left="312" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="409" left="312" width="89" height="20" font="5">undergoing PCI </text>
<text top="426" left="312" width="3" height="20" font="5"> </text>
<text top="443" left="312" width="156" height="20" font="4"><b>Exclusion criteria:</b> Primary </text>
<text top="461" left="312" width="163" height="20" font="5">PCI for STEMI, left main PCI, </text>
<text top="478" left="312" width="107" height="20" font="5">ASA nonresponder </text>
<text top="392" left="501" width="109" height="20" font="4"><b>Intervention:</b> 6 mo </text>
<text top="409" left="501" width="82" height="20" font="5">DAPT (n=926) </text>
<text top="426" left="501" width="7" height="20" font="5">  </text>
<text top="443" left="501" width="115" height="20" font="4"><b>Comparator:</b> 24 mo </text>
<text top="461" left="501" width="86" height="20" font="5">DAPT (n=924)<b>  </b></text>
<text top="393" left="649" width="174" height="20" font="4"><b>1</b>°<b> endpoint:</b> Death, MI, urgent </text>
<text top="410" left="649" width="178" height="20" font="5">TVR, CVA, major bleeding at 12 </text>
<text top="427" left="649" width="94" height="20" font="5">mo post-stenting </text>
<text top="446" left="649" width="7" height="18" font="5">•</text>
<text top="446" left="656" width="167" height="20" font="5"> 1.6% with 6 mo vs. 1.5% with </text>
<text top="463" left="649" width="87" height="20" font="5">24 mo (p=0.85) </text>
<text top="482" left="649" width="7" height="18" font="5">•</text>
<text top="481" left="656" width="157" height="20" font="5"> p&lt;0.00002 for noninferiority </text>
<text top="498" left="649" width="176" height="20" font="5">(absolute risk difference 0.11%; </text>
<text top="516" left="649" width="124" height="20" font="5">95% CI: -1.04–1.26%) </text>
<text top="394" left="852" width="7" height="18" font="5">•</text>
<text top="393" left="859" width="233" height="20" font="5"> Study terminated early due to recruitment </text>
<text top="410" left="852" width="54" height="20" font="5">problems </text>
<text top="429" left="852" width="7" height="18" font="5">•</text>
<text top="429" left="859" width="187" height="20" font="5"> No significant differences in stent </text>
<text top="446" left="852" width="206" height="20" font="5">thrombosis or bleeding complications </text>
<text top="465" left="852" width="7" height="18" font="5">•</text>
<text top="464" left="859" width="215" height="20" font="5"> Low event rates (lower than expected) </text>
<text top="481" left="852" width="3" height="20" font="5"> </text>
<text top="582" left="54" width="60" height="20" font="4"><b>PRODIGY </b></text>
<text top="599" left="54" width="87" height="20" font="5">Valgimigli M, et </text>
<text top="616" left="54" width="20" height="20" font="5">al., </text>
<text top="633" left="54" width="31" height="20" font="5">2012 </text>
<text top="651" left="54" width="19" height="20" font="5">(7) </text>
<text top="668" left="54" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22438530"> </a></text>
<text top="668" left="57" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22438530">22438530</a></text>
<text top="668" left="112" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22438530"> </a></text>
<text top="582" left="163" width="119" height="20" font="4"><b>Aim:</b> To evaluate the </text>
<text top="599" left="163" width="133" height="20" font="5">impact of up 6 or 24 mo </text>
<text top="616" left="163" width="109" height="20" font="5">DAPT after BMS or </text>
<text top="633" left="163" width="29" height="20" font="5">DES </text>
<text top="651" left="163" width="3" height="20" font="5"> </text>
<text top="668" left="163" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="685" left="163" width="3" height="20" font="5"> </text>
<text top="702" left="163" width="121" height="20" font="4"><b>Size:</b> 2,013 pts (1970 </text>
<text top="719" left="163" width="59" height="20" font="5">eligible for </text>
<text top="737" left="163" width="126" height="20" font="5">randomization at 30 d) </text>
<text top="582" left="312" width="153" height="20" font="4"><b>Inclusion criteria:</b> SIHD or </text>
<text top="599" left="312" width="138" height="20" font="5">ACS pts undergoing PCI </text>
<text top="616" left="312" width="3" height="20" font="5"> </text>
<text top="633" left="312" width="161" height="20" font="4"><b>Exclusion criteria:</b> Bleeding </text>
<text top="651" left="312" width="156" height="20" font="5">diathesis, bleeding or stroke </text>
<text top="668" left="312" width="169" height="20" font="5">within 6 mo, oral anticoagulant </text>
<text top="685" left="312" width="44" height="20" font="5">therapy </text>
<text top="582" left="501" width="116" height="20" font="4"><b>Intervention:</b> 24 mo </text>
<text top="599" left="501" width="93" height="20" font="5">DAPT (n=987)<b>  </b>  </text>
<text top="616" left="501" width="7" height="20" font="5">  </text>
<text top="633" left="501" width="108" height="20" font="4"><b>Comparator:</b> 6 mo </text>
<text top="651" left="501" width="82" height="20" font="5">DAPT (n=983)<b> </b></text>
<text top="583" left="649" width="189" height="20" font="4"><b>1</b>°<b> endpoint:</b> Death, MI or CVA at </text>
<text top="600" left="649" width="20" height="20" font="5">2 y </text>
<text top="619" left="649" width="7" height="18" font="5">•</text>
<text top="619" left="656" width="160" height="20" font="5"> 10.1% with 24 mo DAPT vs. </text>
<text top="636" left="649" width="159" height="20" font="5">10.0% with 6 mo DAPT (HR: </text>
<text top="655" left="649" width="102" height="20" font="5">0.98; 95% CI: 0.74</text>
<text top="655" left="751" width="7" height="19" font="8">–</text>
<text top="655" left="759" width="73" height="20" font="5">1.29; p=0.91)</text>
<text top="655" left="832" width="4" height="19" font="8"> </text>
<text top="673" left="649" width="3" height="20" font="5"> </text>
<text top="691" left="649" width="187" height="20" font="4"><b>1</b>°<b>  Safety endpoint:</b>  BARC type </text>
<text top="708" left="649" width="98" height="20" font="5">2, 3 or 5 bleeding </text>
<text top="728" left="649" width="7" height="18" font="5">•</text>
<text top="727" left="656" width="153" height="20" font="5"> 7.4% with 24 mo DAPT vs. </text>
<text top="744" left="649" width="183" height="20" font="5">3.5% with 6 mo DAPT (HR:0.46;  </text>
<text top="761" left="649" width="171" height="20" font="5">95% CI 0.31–0.69; p=0.00018) </text>
<text top="584" left="852" width="7" height="18" font="5">•</text>
<text top="583" left="859" width="196" height="20" font="5"> Stent thrombosis rates low and not </text>
<text top="600" left="852" width="220" height="20" font="5">significantly different between treatment </text>
<text top="617" left="852" width="41" height="20" font="5">groups </text>
<text top="634" left="852" width="3" height="20" font="5"> </text>
<text top="652" left="852" width="3" height="20" font="5"> </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1126" width="12" height="21" font="0">4 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="52" left="54" width="1068" height="20" font="5">ACS indicates acute coronary syndrome; ASA, aspirin; BARC, Bleeding Academic Research Consortium; BMS, bare metal stent; CKD, chronic kidney disease; CVA, cerebrovascular accident; CV, </text>
<text top="72" left="54" width="1031" height="20" font="5">cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NACCE, Net Adverse Clinical and Cerebral Events; </text>
<text top="92" left="54" width="1048" height="20" font="5">NSTEMI, non–ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; Rx, prescription; STEMI, ST-elevation myocardial infarction; SIHD, </text>
<text top="111" left="54" width="793" height="20" font="5">stable ischemic heart disease; SVG, saphenous vein graft; TIMI, Thrombolysis In Myocardial Infarction; and TVR, target-vessel revascularization. </text>
<text top="133" left="54" width="4" height="21" font="0"> </text>
<text top="172" left="54" width="869" height="24" font="2"><b>Data Supplement 2. RCTs of Prolonged/Extended (&gt;12 Month) Duration of DAPT in Patients Treated With Stent Implantation </b></text>
<text top="201" left="55" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="218" left="78" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="236" left="56" width="96" height="20" font="4"><b>Year Published  </b></text>
<text top="201" left="196" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="218" left="201" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="236" left="195" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="201" left="339" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="201" left="486" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="218" left="504" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="236" left="486" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="253" left="507" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="201" left="683" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="218" left="667" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="236" left="669" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="253" left="712" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="203" left="891" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="220" left="925" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="237" left="892" width="140" height="20" font="4"><b>             Adverse Events </b></text>
<text top="271" left="54" width="66" height="20" font="4"><b>OPTIDUAL </b></text>
<text top="288" left="54" width="79" height="20" font="5">Helft G, et al., </text>
<text top="305" left="54" width="34" height="20" font="5">2015  </text>
<text top="323" left="54" width="19" height="20" font="5">(8) </text>
<text top="340" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26364288">26364288</a></text>
<text top="340" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26364288"> </a></text>
<text top="357" left="54" width="3" height="20" font="5"> </text>
<text top="374" left="54" width="3" height="20" font="5"> </text>
<text top="271" left="163" width="148" height="20" font="4"><b>Aim:</b>  Evaluate hypothesis </text>
<text top="288" left="163" width="146" height="20" font="5">that continuing clopidogrel </text>
<text top="305" left="163" width="114" height="20" font="5">would be superior to </text>
<text top="323" left="163" width="143" height="20" font="5">stopping clopidogrel at 12 </text>
<text top="340" left="163" width="100" height="20" font="5">mo following DES </text>
<text top="357" left="163" width="3" height="20" font="5"> </text>
<text top="374" left="163" width="137" height="20" font="4"><b>Study type:</b>  RCT, open </text>
<text top="391" left="163" width="120" height="20" font="5">label, superiority trial  </text>
<text top="409" left="163" width="3" height="20" font="5"> </text>
<text top="426" left="163" width="121" height="20" font="4"><b>Size:</b> 1,966 pts (1385 </text>
<text top="443" left="163" width="136" height="20" font="5">included in ITT analysis) </text>
<text top="271" left="325" width="130" height="20" font="4"><b>Inclusion criteria:</b>  Pts </text>
<text top="288" left="325" width="84" height="20" font="5">(SIHD or ACS) </text>
<text top="305" left="325" width="114" height="20" font="5">undergoing PCI with </text>
<text top="323" left="325" width="129" height="20" font="5">DES free of MACCE or </text>
<text top="340" left="325" width="129" height="20" font="5">major bleeding after 12 </text>
<text top="357" left="325" width="57" height="20" font="5">mo DAPT </text>
<text top="374" left="325" width="3" height="20" font="5"> </text>
<text top="391" left="325" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="409" left="325" width="75" height="20" font="5">Need for oral </text>
<text top="426" left="325" width="89" height="20" font="5">anticoagulation, </text>
<text top="443" left="325" width="118" height="20" font="5">unprotected left main </text>
<text top="460" left="325" width="139" height="20" font="5">PCI, life expectancy &lt;2 y </text>
<text top="271" left="478" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="288" left="478" width="95" height="20" font="5">Additional 36 mo </text>
<text top="305" left="478" width="82" height="20" font="5">DAPT (n=695) </text>
<text top="323" left="478" width="7" height="20" font="5">  </text>
<text top="340" left="478" width="105" height="20" font="4"><b>Comparator:</b> ASA </text>
<text top="357" left="478" width="128" height="20" font="5">therapy alone (n=690)<b>  </b></text>
<text top="272" left="619" width="225" height="20" font="4"><b>1</b>°<b> endpoint:</b> Net adverse clinical events </text>
<text top="289" left="619" width="193" height="20" font="5">(death, MI, CVA or major bleeding) </text>
<text top="308" left="619" width="7" height="18" font="5">•</text>
<text top="308" left="626" width="209" height="20" font="5"> 5.8% with additional 36 mo DAPT vs. </text>
<text top="325" left="619" width="225" height="20" font="5">7.5% with ASA alone (HR: 0.75; 95% CI: </text>
<text top="342" left="619" width="114" height="20" font="5">0.50–1.28; p=0.017) </text>
<text top="359" left="619" width="3" height="20" font="5"> </text>
<text top="273" left="865" width="7" height="18" font="5">•</text>
<text top="272" left="872" width="196" height="20" font="5"> Study terminated early due to slow </text>
<text top="289" left="865" width="65" height="20" font="5">recruitment </text>
<text top="308" left="865" width="7" height="18" font="5">•</text>
<text top="308" left="872" width="185" height="20" font="5"> Actual median follow-up 33.4 mo </text>
<text top="327" left="865" width="7" height="18" font="5">•</text>
<text top="326" left="872" width="198" height="20" font="5"> Rates of death 2.3% with extended </text>
<text top="343" left="865" width="202" height="20" font="5">DAPT vs. 3.5% with ASA alone (HR: </text>
<text top="361" left="865" width="185" height="20" font="5">0.65; 95% CI: 0.34–1.22; p=0.18) </text>
<text top="380" left="865" width="7" height="18" font="5">•</text>
<text top="379" left="872" width="199" height="20" font="5"> Rates of major bleeding identical at </text>
<text top="396" left="865" width="81" height="20" font="5">2.0% (p=0.95) </text>
<text top="415" left="865" width="7" height="18" font="5">•</text>
<text top="415" left="872" width="223" height="20" font="5"> Post hoc analysis of MACCE (death, MI </text>
<text top="432" left="865" width="182" height="20" font="5">or CVA) found rates of 4.2% with </text>
<text top="449" left="865" width="227" height="20" font="5">extended DAPT vs. 6.4% with ASA alone </text>
<text top="466" left="865" width="214" height="20" font="5">(HR: 0.64; 95% CI: 0.40–1.02; p=0.06) </text>
<text top="484" left="54" width="46" height="20" font="4"><b> ITALIC </b></text>
<text top="501" left="54" width="87" height="20" font="5">Gilard M, et al., </text>
<text top="519" left="54" width="31" height="20" font="5">2015 </text>
<text top="536" left="54" width="19" height="20" font="5">(6) </text>
<text top="553" left="54" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25461690"> </a></text>
<text top="553" left="57" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25461690">25461690</a></text>
<text top="553" left="112" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25461690"> </a></text>
<text top="484" left="163" width="82" height="20" font="4"><b>Aim:</b> Evaluate </text>
<text top="501" left="163" width="118" height="20" font="5">noninferiority of 6 mo </text>
<text top="519" left="163" width="129" height="20" font="5">DAPT vs. 24 mo DAPT </text>
<text top="536" left="163" width="124" height="20" font="5">with newer generation </text>
<text top="553" left="163" width="78" height="20" font="5">(Xience) DES </text>
<text top="570" left="163" width="3" height="20" font="5"> </text>
<text top="587" left="163" width="133" height="20" font="4"><b>Study type:</b> RCT, open </text>
<text top="605" left="163" width="130" height="20" font="5">label, noninferiority trial </text>
<text top="622" left="163" width="3" height="20" font="5"> </text>
<text top="639" left="163" width="126" height="20" font="4"><b>Size:</b> 2,031 pts (actual </text>
<text top="656" left="163" width="55" height="20" font="5">1850 pts) </text>
<text top="484" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="501" left="325" width="89" height="20" font="5">undergoing PCI </text>
<text top="519" left="325" width="3" height="20" font="5"> </text>
<text top="536" left="325" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="553" left="325" width="132" height="20" font="5">Primary PCI for STEMI, </text>
<text top="570" left="325" width="105" height="20" font="5">left main PCI, ASA </text>
<text top="587" left="325" width="79" height="20" font="5">nonresponder </text>
<text top="484" left="478" width="109" height="20" font="4"><b>Intervention:</b> 6 mo </text>
<text top="501" left="478" width="82" height="20" font="5">DAPT (n=926) </text>
<text top="519" left="478" width="7" height="20" font="5">  </text>
<text top="536" left="478" width="115" height="20" font="4"><b>Comparator:</b> 24 mo </text>
<text top="553" left="478" width="86" height="20" font="5">DAPT (n=924)<b>  </b></text>
<text top="485" left="619" width="209" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Death, MI, urgent TVR, </text>
<text top="502" left="619" width="195" height="20" font="5">CVA, major bleeding at 12 mo post-</text>
<text top="520" left="619" width="46" height="20" font="5">stenting </text>
<text top="539" left="619" width="7" height="18" font="5">•</text>
<text top="538" left="626" width="201" height="20" font="5">1.6% with 6 mo vs. 1.5% with 24 mo </text>
<text top="555" left="619" width="49" height="20" font="5">(p=0.85) </text>
<text top="574" left="619" width="7" height="18" font="5">•</text>
<text top="574" left="626" width="211" height="20" font="5"> p&lt;0.00002 for noninferiority (absolute </text>
<text top="591" left="619" width="204" height="20" font="5">risk difference 0.11%; 95% CI: -1.04–</text>
<text top="608" left="619" width="42" height="20" font="5">1.26%) </text>
<text top="486" left="865" width="7" height="18" font="5">•</text>
<text top="485" left="872" width="167" height="20" font="5"> Study terminated early due to </text>
<text top="502" left="865" width="119" height="20" font="5">recruitment problems </text>
<text top="522" left="865" width="7" height="18" font="5">•</text>
<text top="521" left="872" width="187" height="20" font="5"> No significant differences in stent </text>
<text top="538" left="865" width="206" height="20" font="5">thrombosis or bleeding complications </text>
<text top="557" left="865" width="7" height="18" font="5">•</text>
<text top="557" left="872" width="215" height="20" font="5"> Low event rates (lower than expected) </text>
<text top="574" left="865" width="3" height="20" font="5"> </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1126" width="12" height="21" font="0">5 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="37" height="20" font="4"><b>DAPT </b></text>
<text top="70" left="54" width="81" height="20" font="5">Mauri L, et al., </text>
<text top="87" left="54" width="31" height="20" font="5">2014 </text>
<text top="104" left="54" width="19" height="20" font="5">(9) </text>
<text top="122" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25399658">25399658</a></text>
<text top="122" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25399658"> </a></text>
<text top="53" left="163" width="137" height="20" font="4"><b>Aim:</b> To assess benefits </text>
<text top="70" left="163" width="147" height="20" font="5">and risks of &gt;12 mo DAPT </text>
<text top="87" left="163" width="101" height="20" font="5">after BMS or DES </text>
<text top="104" left="163" width="3" height="20" font="5"> </text>
<text top="122" left="163" width="103" height="20" font="4"><b>Study type:</b> RCT, </text>
<text top="139" left="163" width="111" height="20" font="5">placebo-controlled   </text>
<text top="156" left="163" width="3" height="20" font="5"> </text>
<text top="173" left="163" width="86" height="20" font="4"><b>Size:</b> 9,961 pts </text>
<text top="53" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="70" left="325" width="111" height="20" font="5">treated with BMS or </text>
<text top="87" left="325" width="108" height="20" font="5">DES, but only DES-</text>
<text top="104" left="325" width="124" height="20" font="5">treated pts included in </text>
<text top="122" left="325" width="58" height="20" font="5">this report </text>
<text top="139" left="325" width="3" height="20" font="5"> </text>
<text top="156" left="325" width="130" height="20" font="4"><b>Exclusion criteria:</b> MI, </text>
<text top="173" left="325" width="70" height="20" font="5">CVA, repeat </text>
<text top="190" left="325" width="129" height="20" font="5">revascularization, stent </text>
<text top="208" left="325" width="81" height="20" font="5">thrombosis, or </text>
<text top="225" left="325" width="96" height="20" font="5">moderate-severe </text>
<text top="242" left="325" width="115" height="20" font="5">bleeding during the 1</text>
<text top="244" left="440" width="6" height="13" font="7">st</text>
<text top="242" left="446" width="3" height="20" font="5"> </text>
<text top="259" left="325" width="130" height="20" font="5">12 mo DAPT after DES </text>
<text top="276" left="325" width="131" height="20" font="5">(before randomization); </text>
<text top="294" left="325" width="124" height="20" font="5">oral anticoagulant use </text>
<text top="53" left="478" width="82" height="20" font="4"><b>Intervention:</b>  </text>
<text top="70" left="478" width="109" height="20" font="5">Additional 18 mo of </text>
<text top="87" left="478" width="113" height="20" font="5">DAPT after initial 12 </text>
<text top="104" left="478" width="21" height="20" font="5">mo </text>
<text top="122" left="478" width="7" height="20" font="5">  </text>
<text top="139" left="478" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="156" left="478" width="108" height="20" font="5">thienopyridine after </text>
<text top="173" left="478" width="109" height="20" font="5">initial 12 mo DAPT<b>  </b></text>
<text top="54" left="619" width="212" height="20" font="4"><b>Co-1</b>°<b> endpoints (after additional 18 </b></text>
<text top="71" left="619" width="56" height="20" font="4"><b>mo Rx):</b>   </text>
<text top="90" left="619" width="7" height="18" font="5">•</text>
<text top="90" left="626" width="220" height="20" font="5"> Stent thrombosis:  0.4% with continued </text>
<text top="107" left="619" width="158" height="20" font="5">DAPT vs. 1.4% with placebo </text>
<text top="126" left="619" width="211" height="20" font="5">thienopyridine (HR: 0.29; 95% CI: 0.17</text>
<text top="126" left="830" width="7" height="19" font="8">–</text>
<text top="144" left="619" width="83" height="20" font="5">0.48; p=0.001) </text>
<text top="144" left="702" width="4" height="19" font="8"> </text>
<text top="163" left="619" width="7" height="18" font="5">•</text>
<text top="162" left="626" width="210" height="20" font="5"> MACCE (death, MI, CVA):  4.3% with </text>
<text top="179" left="619" width="215" height="20" font="5">continued DAPT vs. 5.9% with placebo </text>
<text top="197" left="619" width="217" height="20" font="5">thienopyridine (HR: 0.71; 95% CI: 0.59–</text>
<text top="214" left="619" width="83" height="20" font="5">0.85; p&lt;0.001) </text>
<text top="231" left="619" width="3" height="20" font="5"> </text>
<text top="250" left="619" width="226" height="20" font="4"><b>1</b>°<b>  Safety endpoint:</b>  GUSTO moderate </text>
<text top="267" left="619" width="105" height="20" font="5">or severe bleeding </text>
<text top="286" left="619" width="7" height="18" font="5">•</text>
<text top="285" left="626" width="204" height="20" font="5"> 2.6% with continued DAPT vs. 1.6% </text>
<text top="302" left="619" width="208" height="20" font="5">with placebo thienopyridine (p=0.001) </text>
<text top="55" left="865" width="7" height="18" font="5">•</text>
<text top="54" left="872" width="205" height="20" font="5"> All-cause death 2.0% with continued </text>
<text top="71" left="865" width="158" height="20" font="5">DAPT vs. 1.5% with placebo </text>
<text top="88" left="865" width="214" height="20" font="5">thienopyridine (HR: 1.36; 95% CI:1.00–</text>
<text top="106" left="865" width="76" height="20" font="5">1.85; p=0.05) </text>
<text top="125" left="865" width="7" height="18" font="5">•</text>
<text top="124" left="872" width="212" height="20" font="5"> Increased death due to more non–CV </text>
<text top="141" left="865" width="40" height="20" font="5">deaths </text>
<text top="160" left="865" width="7" height="18" font="5">•</text>
<text top="160" left="872" width="208" height="20" font="5"> Only DES-treated pts included in this </text>
<text top="177" left="865" width="36" height="20" font="5">report </text>
<text top="196" left="865" width="7" height="18" font="5">•</text>
<text top="195" left="872" width="88" height="20" font="5"> DES included 1</text>
<text top="197" left="960" width="6" height="13" font="7">st</text>
<text top="195" left="966" width="34" height="20" font="5"> and 2</text>
<text top="197" left="1001" width="9" height="13" font="7">nd</text>
<text top="195" left="1010" width="65" height="20" font="5"> generation </text>
<text top="212" left="865" width="36" height="20" font="5">stents </text>
<text top="229" left="865" width="3" height="20" font="5"> </text>
<text top="247" left="865" width="3" height="20" font="5"> </text>
<text top="320" left="54" width="50" height="20" font="4"><b>ARCTIC-</b></text>
<text top="337" left="54" width="72" height="20" font="4"><b>Interruption </b></text>
<text top="355" left="54" width="90" height="20" font="5">Collet JP, et al., </text>
<text top="372" left="54" width="34" height="20" font="5">2014  </text>
<text top="389" left="54" width="25" height="20" font="5">(10) </text>
<text top="406" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25037988">25037988</a></text>
<text top="406" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25037988"> </a></text>
<text top="424" left="54" width="3" height="20" font="5"> </text>
<text top="320" left="163" width="124" height="20" font="4"><b>Aim:</b>  To demonstrate </text>
<text top="337" left="163" width="130" height="20" font="5">superiority of continued </text>
<text top="355" left="163" width="134" height="20" font="5">(&gt;12 mo) vs. interrupted </text>
<text top="372" left="163" width="82" height="20" font="5">(12 mo) DAPT </text>
<text top="389" left="163" width="3" height="20" font="5"> </text>
<text top="406" left="163" width="126" height="20" font="4"><b>Study type:</b>   Planned </text>
<text top="424" left="163" width="111" height="20" font="5">extension of ARTIC-</text>
<text top="441" left="163" width="109" height="20" font="5">Monitoring trial. Pts </text>
<text top="458" left="163" width="123" height="20" font="5">treated with 1 y DAPT </text>
<text top="475" left="163" width="130" height="20" font="5">randomized to interrupt </text>
<text top="492" left="163" width="144" height="20" font="5">(stop) therapy or continue </text>
<text top="510" left="163" width="147" height="20" font="5">therapy.  RCT, open label. </text>
<text top="527" left="163" width="3" height="20" font="5"> </text>
<text top="544" left="163" width="86" height="20" font="4"><b>Size:</b> 1,259 pts </text>
<text top="320" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="337" left="325" width="88" height="20" font="5">prior enrolled in </text>
<text top="355" left="325" width="134" height="20" font="5">ARCTIC-Monitoring trial </text>
<text top="372" left="325" width="124" height="20" font="5">without an event at 12 </text>
<text top="389" left="325" width="21" height="20" font="5">mo </text>
<text top="406" left="325" width="7" height="20" font="5">  </text>
<text top="424" left="325" width="3" height="20" font="5"> </text>
<text top="441" left="325" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="458" left="325" width="123" height="20" font="5">Primary PCI, bleeding </text>
<text top="475" left="325" width="98" height="20" font="5">diathesis, chronic </text>
<text top="492" left="325" width="109" height="20" font="5">anticoagulation use </text>
<text top="320" left="478" width="82" height="20" font="4"><b>Intervention:</b>  </text>
<text top="337" left="478" width="66" height="20" font="5">Interruption </text>
<text top="355" left="478" width="113" height="20" font="5">(cessation) of DAPT </text>
<text top="372" left="478" width="84" height="20" font="5">after 12 mo Rx </text>
<text top="389" left="478" width="46" height="20" font="5">(n=624) </text>
<text top="406" left="478" width="7" height="20" font="5">  </text>
<text top="424" left="478" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="441" left="478" width="122" height="20" font="5">Continuation of DAPT </text>
<text top="458" left="478" width="119" height="20" font="5">after 12 mo Rx for an </text>
<text top="475" left="478" width="105" height="20" font="5">additional 6-18 mo </text>
<text top="492" left="478" width="46" height="20" font="5">(n=635)<b> </b></text>
<text top="321" left="619" width="170" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Death, MI, stent </text>
<text top="339" left="619" width="176" height="20" font="5">thrombosis, CVA or urgent TVR </text>
<text top="358" left="619" width="7" height="18" font="5">•</text>
<text top="357" left="626" width="192" height="20" font="5"> 4% of interruption group vs. 4% of </text>
<text top="374" left="619" width="211" height="20" font="5">continuation group (HR: 1.17; 95% CI: </text>
<text top="391" left="619" width="107" height="20" font="5">0.68–2.03; p=0.58) </text>
<text top="409" left="619" width="3" height="20" font="4"><b> </b></text>
<text top="427" left="619" width="213" height="20" font="4"><b>1</b>°<b>  Safety endpoint: </b>STEEPLE major </text>
<text top="444" left="619" width="50" height="20" font="5">bleeding<b> </b></text>
<text top="463" left="619" width="7" height="18" font="5">•</text>
<text top="463" left="626" width="210" height="20" font="5"> &lt;0.5% of interruption group vs. 1% of </text>
<text top="480" left="619" width="211" height="20" font="5">continuation group (HR: 0.15; 95% CI: </text>
<text top="497" left="619" width="124" height="20" font="5">0.02–1.20;  p=0.073)   </text>
<text top="514" left="619" width="3" height="20" font="4"><b> </b></text>
<text top="322" left="865" width="7" height="18" font="5">•</text>
<text top="321" left="872" width="143" height="20" font="5"> High-risk pts not enrolled </text>
<text top="340" left="865" width="7" height="18" font="5">•</text>
<text top="340" left="872" width="220" height="20" font="5"> No differences in secondary endpoints, </text>
<text top="357" left="865" width="146" height="20" font="5">including stent thrombosis </text>
<text top="374" left="865" width="3" height="20" font="5"> </text>
<text top="391" left="865" width="3" height="20" font="5"> </text>
<text top="562" left="54" width="65" height="20" font="4"><b>DES-LATE </b></text>
<text top="579" left="54" width="85" height="20" font="5">Lee CW, et al., </text>
<text top="596" left="54" width="34" height="20" font="5">2014  </text>
<text top="614" left="54" width="25" height="20" font="5">(11) </text>
<text top="631" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24097439">24097439</a></text>
<text top="631" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24097439"> </a></text>
<text top="562" left="163" width="138" height="20" font="4"><b>Aim:</b> To compare 12 mo </text>
<text top="579" left="163" width="131" height="20" font="5">DAPT to &gt;12 mo DAPT </text>
<text top="596" left="163" width="57" height="20" font="5">after DES </text>
<text top="614" left="163" width="3" height="20" font="5"> </text>
<text top="631" left="163" width="133" height="20" font="4"><b>Study type:</b> RCT, open </text>
<text top="648" left="163" width="33" height="20" font="5">label  </text>
<text top="665" left="163" width="3" height="20" font="5"> </text>
<text top="682" left="163" width="86" height="20" font="4"><b>Size:</b> 5,045 pts </text>
<text top="562" left="325" width="130" height="20" font="4"><b>Inclusion criteria:</b>  Pts </text>
<text top="579" left="325" width="130" height="20" font="5">treated with DES event-</text>
<text top="596" left="325" width="122" height="20" font="5">free after 12-18 mo of </text>
<text top="614" left="325" width="36" height="20" font="5">DAPT </text>
<text top="631" left="325" width="3" height="20" font="5"> </text>
<text top="648" left="325" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="665" left="325" width="126" height="20" font="5">Recent ACS, ischemic </text>
<text top="682" left="325" width="115" height="20" font="5">or bleeding event on </text>
<text top="700" left="325" width="135" height="20" font="5">DAPT before enrollment </text>
<text top="562" left="478" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="579" left="478" width="124" height="20" font="5">Continued DAPT after </text>
<text top="596" left="478" width="123" height="20" font="5">12 mo of Rx (n=2514) </text>
<text top="614" left="478" width="7" height="20" font="5">  </text>
<text top="631" left="478" width="105" height="20" font="4"><b>Comparator: </b>ASA </text>
<text top="648" left="478" width="138" height="20" font="5">monotherapy (n=2531) <b>   </b></text>
<text top="563" left="619" width="224" height="20" font="4"><b>1</b>°<b> endpoint:</b>  CV death, MI, CVA 24 mo </text>
<text top="580" left="619" width="109" height="20" font="5">after randomization </text>
<text top="600" left="619" width="7" height="18" font="5">•</text>
<text top="599" left="626" width="226" height="20" font="5"> 2.4% in ASA alone vs 2.6% in continued </text>
<text top="616" left="619" width="204" height="20" font="5">DAPT (HR: 0.94; 95% CI: 0.66–1.35; </text>
<text top="633" left="619" width="46" height="20" font="5">p=0.75) </text>
<text top="650" left="619" width="3" height="20" font="4"><b> </b></text>
<text top="564" left="865" width="7" height="18" font="5">•</text>
<text top="563" left="872" width="205" height="20" font="5"> Publications includes pts from ZEST-</text>
<text top="580" left="865" width="206" height="20" font="5">LATE and REAL-LATE (the results of </text>
<text top="598" left="865" width="220" height="20" font="5">which were first published by Park SJ in </text>
<text top="615" left="865" width="190" height="20" font="5">2010) and an additional 2,344 pts  </text>
<text top="632" left="865" width="219" height="20" font="5">TIMI major bleeding  at 24 mo follow-up </text>
<text top="649" left="865" width="224" height="20" font="5">occurred in 1.1% of ASA alone vs. 1.4 of </text>
<text top="666" left="865" width="203" height="20" font="5">continued DAPT (HR: 0.71;  95% CI: </text>
<text top="684" left="865" width="197" height="20" font="5">0.42–1.20; p=0.20);  difference was </text>
<text top="701" left="865" width="211" height="20" font="5">statistically significant by the end of all </text>
<text top="718" left="865" width="53" height="20" font="5">follow-up </text>
<text top="737" left="865" width="7" height="18" font="5">•</text>
<text top="737" left="872" width="181" height="20" font="5"> No significant difference in stent </text>
<text top="754" left="865" width="64" height="20" font="5">thrombosis </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="9" size="10" family="Times" color="#0000ff"/>
<text top="789" left="1126" width="12" height="21" font="0">6 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="60" height="20" font="4"><b>PRODIGY </b></text>
<text top="70" left="54" width="87" height="20" font="5">Valgimigli M, et </text>
<text top="87" left="54" width="20" height="20" font="5">al., </text>
<text top="104" left="54" width="31" height="20" font="5">2012 </text>
<text top="122" left="54" width="19" height="20" font="5">(7) </text>
<text top="139" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22438530">22438530</a></text>
<text top="139" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22438530"> </a></text>
<text top="53" left="163" width="122" height="20" font="4"><b>Aim:</b>  To evaluate the </text>
<text top="70" left="163" width="133" height="20" font="5">impact of up 6 or 24 mo </text>
<text top="87" left="163" width="137" height="20" font="5">DAPT after BMS or DES </text>
<text top="104" left="163" width="3" height="20" font="5"> </text>
<text top="122" left="163" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="139" left="163" width="3" height="20" font="5"> </text>
<text top="156" left="163" width="128" height="20" font="4"><b>Size:</b>  2,013 pts (1,970 </text>
<text top="173" left="163" width="140" height="20" font="5">eligible for randomization </text>
<text top="190" left="163" width="45" height="20" font="5">at 30 d) </text>
<text top="53" left="325" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="70" left="325" width="96" height="20" font="5">SIHD or ACS pts </text>
<text top="87" left="325" width="89" height="20" font="5">undergoing PCI </text>
<text top="104" left="325" width="3" height="20" font="5"> </text>
<text top="122" left="325" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="139" left="325" width="107" height="20" font="5">Bleeding diathesis, </text>
<text top="156" left="325" width="136" height="20" font="5">bleeding or stroke within </text>
<text top="173" left="325" width="135" height="20" font="5">6 mo, oral anticoagulant </text>
<text top="190" left="325" width="44" height="20" font="5">therapy </text>
<text top="53" left="478" width="116" height="20" font="4"><b>Intervention:</b> 24 mo </text>
<text top="70" left="478" width="90" height="20" font="5">DAPT (n-987)<b>  </b>  </text>
<text top="87" left="478" width="7" height="20" font="5">  </text>
<text top="104" left="478" width="108" height="20" font="4"><b>Comparator:</b> 6 mo </text>
<text top="122" left="478" width="82" height="20" font="5">DAPT (n=983)<b> </b></text>
<text top="54" left="619" width="212" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Death, MI or CVA at 2 y </text>
<text top="73" left="619" width="7" height="18" font="5">•</text>
<text top="72" left="626" width="223" height="20" font="5"> 10.1% with 24 mo DAPT vs. 10.0% with </text>
<text top="92" left="619" width="198" height="20" font="5">6 mo DAPT (HR: 0.98; 95% CI: 0.74</text>
<text top="92" left="817" width="7" height="19" font="8">–</text>
<text top="109" left="619" width="73" height="20" font="5">1.29; p=0.91)</text>
<text top="109" left="692" width="4" height="19" font="8"> </text>
<text top="127" left="619" width="3" height="20" font="5"> </text>
<text top="145" left="619" width="226" height="20" font="4"><b>1</b>°<b>  Safety endpoint:</b>  BARC type 2, 3 or </text>
<text top="162" left="619" width="60" height="20" font="5">5 bleeding </text>
<text top="181" left="619" width="7" height="18" font="5">•</text>
<text top="181" left="626" width="220" height="20" font="5"> 7.4% with 24 mo DAPT vs. 3.5% with 6 </text>
<text top="198" left="619" width="225" height="20" font="5">mo DAPT (HR: 0.46; 95% CI: 0.31–0.69; </text>
<text top="215" left="619" width="66" height="20" font="5">p=0.00018) </text>
<text top="55" left="865" width="7" height="18" font="5">•</text>
<text top="54" left="872" width="196" height="20" font="5"> Stent thrombosis rates low and not </text>
<text top="71" left="865" width="220" height="20" font="5">significantly different between treatment </text>
<text top="88" left="865" width="41" height="20" font="5">groups </text>
<text top="106" left="865" width="3" height="20" font="5"> </text>
<text top="123" left="865" width="3" height="20" font="5"> </text>
<text top="233" left="54" width="83" height="20" font="5">Park SJ, et al., </text>
<text top="250" left="54" width="31" height="20" font="5">2010 </text>
<text top="267" left="54" width="25" height="20" font="5">(12) </text>
<text top="289" left="54" width="57" height="12" font="9"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20231231">20231231</a></text>
<text top="283" left="111" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20231231"><b> </b></a></text>
<text top="299" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="233" left="163" width="127" height="20" font="4"><b>Aim:</b>  Compare ASA + </text>
<text top="250" left="163" width="138" height="20" font="5">clopidogrel to ASA alone </text>
<text top="267" left="163" width="128" height="20" font="5">in pts treated with DES </text>
<text top="285" left="163" width="149" height="20" font="5">who were event free for 12 </text>
<text top="302" left="163" width="21" height="20" font="5">mo<b> </b></text>
<text top="319" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="336" left="163" width="133" height="20" font="4"><b>Study type: </b>RCT, open </text>
<text top="353" left="163" width="29" height="20" font="5">label<b> </b></text>
<text top="371" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="388" left="163" width="90" height="20" font="4"><b>Size: </b> 2,701 pts<b> </b></text>
<text top="233" left="325" width="130" height="20" font="4"><b>Inclusion criteria:</b>  Pts </text>
<text top="250" left="325" width="121" height="20" font="5">treated with DES who </text>
<text top="267" left="325" width="123" height="20" font="5">were event free for 12 </text>
<text top="285" left="325" width="21" height="20" font="5">mo<b> </b></text>
<text top="302" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="319" left="325" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="336" left="325" width="116" height="20" font="5">Ischemic or bleeding </text>
<text top="353" left="325" width="132" height="20" font="5">event during first 12 mo </text>
<text top="371" left="325" width="106" height="20" font="5">of DAPT after DES </text>
<text top="388" left="325" width="70" height="20" font="5">implantation<b> </b></text>
<text top="233" left="478" width="117" height="20" font="4"><b>Intervention: </b>ASA + </text>
<text top="250" left="478" width="70" height="20" font="5">clopiodogrel </text>
<text top="267" left="478" width="7" height="20" font="4"><b>  </b></text>
<text top="285" left="478" width="112" height="20" font="4"><b>Comparator:</b>   ASA </text>
<text top="302" left="478" width="33" height="20" font="5">alone<b> </b></text>
<text top="234" left="619" width="221" height="20" font="4"><b>1</b>°<b> endpoint:</b>  MI or cardiac death at 2 y </text>
<text top="253" left="619" width="7" height="18" font="5">•</text>
<text top="253" left="626" width="226" height="20" font="5">1.8% with DAPT vs. 1.2% with ASA (HR: </text>
<text top="272" left="619" width="102" height="20" font="5">1.65; 95% CI: 0.80</text>
<text top="272" left="721" width="7" height="19" font="8">–</text>
<text top="272" left="728" width="73" height="20" font="5">3.36; p=0.17)</text>
<text top="272" left="801" width="4" height="19" font="8"> </text>
<text top="290" left="619" width="3" height="20" font="4"><b> </b></text>
<text top="235" left="865" width="7" height="18" font="5">•</text>
<text top="234" left="872" width="212" height="20" font="4"><b> </b>Study combined pts from ZEST-LATE </text>
<text top="251" left="865" width="94" height="20" font="5">and REAL-LATE<b> </b></text>
<text top="269" left="865" width="3" height="20" font="4"><b> </b></text>
<text top="286" left="865" width="3" height="20" font="4"><b> </b></text>
<text top="303" left="865" width="3" height="20" font="5"> </text>
<text top="406" left="54" width="1053" height="20" font="5">ACS indicates acute coronary syndrome; ASA, aspirin; BMS, bare metal stent; CI, confidence interval; CV, cardiovascular; CVA, cerebrovascular accident; DAPT, dual antiplatelet therapy; DES, </text>
<text top="423" left="54" width="1049" height="20" font="5">drug-eluting stent; f/u, follow up; HR, hazard ratio; ITT, intent to treat; MACE, major adverse cardiac event; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomized </text>
<text top="440" left="54" width="852" height="20" font="5">controlled trial; Rx, prescription;  SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; and TVR, target-vessel revascularization.  </text>
<text top="459" left="54" width="4" height="21" font="0"> </text>
<text top="498" left="54" width="398" height="24" font="2"><b>Data Supplement 3. Meta-Analyses of Duration of DAPT  </b></text>
<text top="528" left="78" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="545" left="56" width="96" height="20" font="4"><b>Year Published  </b></text>
<text top="528" left="189" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="545" left="194" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="562" left="188" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="528" left="331" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="528" left="482" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="545" left="500" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="562" left="483" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="579" left="504" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="528" left="682" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="545" left="665" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="562" left="668" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="579" left="710" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="529" left="891" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="546" left="925" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="563" left="892" width="150" height="20" font="4"><b>                Adverse Events </b></text>
<text top="597" left="54" width="86" height="20" font="5">Udell JA, et al., </text>
<text top="614" left="54" width="31" height="20" font="5">2015 </text>
<text top="632" left="54" width="25" height="20" font="5">(13) </text>
<text top="649" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26324537">26324537</a></text>
<text top="649" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26324537"> </a></text>
<text top="597" left="163" width="131" height="20" font="4"><b>Aim:</b> Compare benefits </text>
<text top="614" left="163" width="125" height="20" font="5">and risks of more than </text>
<text top="632" left="163" width="109" height="20" font="5">one y of DAPT with </text>
<text top="649" left="163" width="124" height="20" font="5">ASA alone in high-risk </text>
<text top="666" left="163" width="122" height="20" font="5">pts with Hx of prior MI </text>
<text top="683" left="163" width="3" height="20" font="5"> </text>
<text top="701" left="163" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="718" left="163" width="48" height="20" font="5">analysis </text>
<text top="735" left="163" width="3" height="20" font="5"> </text>
<text top="752" left="163" width="93" height="20" font="4"><b>Size:</b> 33,435 pts </text>
<text top="597" left="312" width="144" height="20" font="4"><b>Inclusion criteria:</b>  RCTs </text>
<text top="614" left="312" width="148" height="20" font="5">of secondary prevention in </text>
<text top="632" left="312" width="143" height="20" font="5">pts with MI randomized to </text>
<text top="649" left="312" width="130" height="20" font="5">extended duration (&gt;12 </text>
<text top="666" left="312" width="144" height="20" font="5">mo) DAPT compared with </text>
<text top="683" left="312" width="62" height="20" font="5">ASA alone </text>
<text top="701" left="312" width="3" height="20" font="5"> </text>
<text top="718" left="312" width="139" height="20" font="4"><b>Exclusion criteria:</b>  ≤12 </text>
<text top="735" left="312" width="133" height="20" font="5">mo of follow-up, trials of </text>
<text top="752" left="312" width="100" height="20" font="5">oral anticoagulant </text>
<text top="769" left="312" width="145" height="20" font="5">therapies, trials of pts with </text>
<text top="597" left="474" width="126" height="20" font="4"><b>Intervention:</b>  &gt;12 mo </text>
<text top="614" left="474" width="36" height="20" font="5">DAPT </text>
<text top="632" left="474" width="7" height="20" font="5">  </text>
<text top="649" left="474" width="105" height="20" font="4"><b>Comparator:</b> ASA </text>
<text top="666" left="474" width="78" height="20" font="5">therapy alone </text>
<text top="683" left="474" width="3" height="20" font="5"> </text>
<text top="701" left="474" width="3" height="20" font="4"><b> </b></text>
<text top="598" left="616" width="234" height="20" font="4"><b>1</b>°<b> endpoint:  MACE (CV death, nonfatal </b></text>
<text top="616" left="616" width="141" height="20" font="4"><b>MI, and nonfatal stroke)</b> </text>
<text top="635" left="616" width="7" height="18" font="5">•</text>
<text top="634" left="622" width="200" height="20" font="5"> 6.4% with DAPT vs. 7.5% with ASA </text>
<text top="651" left="616" width="202" height="20" font="5">alone (RR: 0.78; 95% CI: 0.67–0.90; </text>
<text top="669" left="616" width="52" height="20" font="5">p=0.001) </text>
<text top="686" left="616" width="3" height="20" font="5"> </text>
<text top="599" left="865" width="7" height="18" font="5">•</text>
<text top="598" left="872" width="165" height="20" font="5"> Studies included in analysis:  </text>
<text top="616" left="865" width="185" height="20" font="5">CHARISMA, PRODIGY, ARCTIC-</text>
<text top="633" left="865" width="200" height="20" font="5">Interruption, DAPT, DES-LATE, and </text>
<text top="650" left="865" width="109" height="20" font="5">PEGASUS-TIMI 54 </text>
<text top="669" left="865" width="7" height="18" font="5">•</text>
<text top="668" left="872" width="215" height="20" font="5"> For all studies except PEGASUS-TIMI </text>
<text top="686" left="865" width="213" height="20" font="5">54, a subgroup of the study population </text>
<text top="703" left="865" width="173" height="20" font="5">was used for the meta-analysis </text>
<text top="722" left="865" width="7" height="18" font="5">•</text>
<text top="721" left="872" width="202" height="20" font="5"> CV death 2.3% with DAPT vs. 2.6% </text>
<text top="739" left="865" width="224" height="20" font="5">with ASA alone (RR: 0.85; 95% CI: 0.74–</text>
<text top="756" left="865" width="83" height="20" font="5">0.98; p= 0.03), </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1126" width="12" height="21" font="0">7 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="312" width="131" height="20" font="5">SIHD alone undergoing </text>
<text top="70" left="312" width="24" height="20" font="5">PCI </text>
<text top="55" left="865" width="7" height="18" font="5">•</text>
<text top="54" left="872" width="196" height="20" font="5"> No increase in non–CV death (RR: </text>
<text top="71" left="865" width="164" height="20" font="5">1.03; CI: 0.86–1.23; p= 0.76). </text>
<text top="90" left="865" width="7" height="18" font="5">•</text>
<text top="90" left="872" width="206" height="20" font="5"> Major bleeding 1.85% with DAPT vs. </text>
<text top="107" left="865" width="198" height="20" font="5">1.09% with ASA (RR: 1.73; 95% CI: </text>
<text top="124" left="865" width="114" height="20" font="5">1.19–2.50; p=0.004) </text>
<text top="142" left="54" width="80" height="20" font="5">Elmariah S, et </text>
<text top="159" left="54" width="20" height="20" font="5">al., </text>
<text top="176" left="54" width="31" height="20" font="5">2015 </text>
<text top="193" left="54" width="25" height="20" font="5">(14) </text>
<text top="211" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25467565">25467565</a></text>
<text top="211" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25467565"> </a></text>
<text top="228" left="54" width="3" height="20" font="5"> </text>
<text top="142" left="163" width="128" height="20" font="4"><b>Aim:</b> Assess the effect </text>
<text top="159" left="163" width="116" height="20" font="5">of extended duration </text>
<text top="176" left="163" width="103" height="20" font="5">DAPT on mortality </text>
<text top="193" left="163" width="3" height="20" font="5"> </text>
<text top="211" left="163" width="77" height="20" font="4"><b>Study type:</b>   </text>
<text top="228" left="163" width="122" height="20" font="5">Hierarchical Bayesian </text>
<text top="245" left="163" width="122" height="20" font="5">random effects model </text>
<text top="262" left="163" width="134" height="20" font="5">meta-analysis, trial level </text>
<text top="280" left="163" width="27" height="20" font="5">data </text>
<text top="297" left="163" width="3" height="20" font="5"> </text>
<text top="314" left="163" width="108" height="20" font="4"><b>Size:</b> 14 RCT; total </text>
<text top="331" left="163" width="75" height="20" font="5">n=69,644 pts </text>
<text top="142" left="312" width="137" height="20" font="4"><b>Patients:</b> Pts enrolled in </text>
<text top="159" left="312" width="121" height="20" font="5">RCTs of extended vs. </text>
<text top="176" left="312" width="129" height="20" font="5">short duration DAPT or </text>
<text top="193" left="312" width="124" height="20" font="5">DAPT vs. ASA alone.  </text>
<text top="211" left="312" width="145" height="20" font="5">Clinical settings of studies </text>
<text top="228" left="312" width="131" height="20" font="5">included post-PCI, post-</text>
<text top="245" left="312" width="121" height="20" font="5">ACS, atrial fibrillation, </text>
<text top="262" left="312" width="108" height="20" font="5">lacunar stroke, and </text>
<text top="280" left="312" width="149" height="20" font="5">documented or high-risk of </text>
<text top="297" left="312" width="66" height="20" font="5">CV disease </text>
<text top="314" left="312" width="3" height="20" font="5"> </text>
<text top="142" left="474" width="120" height="20" font="4"><b>Intervention:</b> Longer </text>
<text top="159" left="474" width="84" height="20" font="5">duration DAPT </text>
<text top="176" left="474" width="7" height="20" font="5">  </text>
<text top="193" left="474" width="91" height="20" font="4"><b>Comparators:</b>  <b> </b></text>
<text top="211" left="474" width="128" height="20" font="5">Shorter duration DAPT </text>
<text top="228" left="474" width="79" height="20" font="5">or ASA alone<b>  </b></text>
<text top="142" left="616" width="232" height="20" font="4"><b>CV Mortality:</b> 4.2% with longer DAPT vs.  </text>
<text top="159" left="616" width="196" height="20" font="5">4.1% with shorter DAPT/ASA alone </text>
<text top="176" left="616" width="208" height="20" font="5">(HR:1.01; 95% credible interval: 0.93–</text>
<text top="193" left="616" width="87" height="20" font="5">1.12; p=0.81)   <b> </b></text>
<text top="211" left="616" width="3" height="20" font="4"><b> </b></text>
<text top="228" left="616" width="204" height="20" font="4"><b>Non</b>–<b>CV Mortality:</b> 1.7% with longer </text>
<text top="245" left="616" width="221" height="20" font="5">DAPT vs.  1.7% with shorter DAPT/ASA </text>
<text top="262" left="616" width="224" height="20" font="5">alone (HR: 1.04; 95% credible interval: I: </text>
<text top="280" left="616" width="107" height="20" font="5">0.90–1.26; p=0.66)<b> </b></text>
<text top="297" left="616" width="3" height="20" font="4"><b> </b></text>
<text top="314" left="616" width="212" height="20" font="4"><b>All-cause mortality:</b> 5.8% with longer </text>
<text top="331" left="616" width="221" height="20" font="5">DAPT vs.  5.7% with shorter DAPT/ASA </text>
<text top="348" left="616" width="224" height="20" font="5">alone (HR: 1.04; 95% credible interval: I: </text>
<text top="366" left="616" width="114" height="20" font="5">0.96–1.18; p=0.17)   </text>
<text top="144" left="865" width="7" height="18" font="5">•</text>
<text top="143" left="872" width="117" height="20" font="5"> Trial level data used </text>
<text top="162" left="865" width="7" height="18" font="5">•</text>
<text top="161" left="872" width="211" height="20" font="5"> Authors concluded extended-duration </text>
<text top="179" left="865" width="212" height="20" font="5">APT not associated with differences in </text>
<text top="196" left="865" width="176" height="20" font="5">all-cause, CV, or non–CV death </text>
<text top="213" left="865" width="190" height="20" font="5">compared with ASA alone or short </text>
<text top="230" left="865" width="84" height="20" font="5">duration DAPT </text>
<text top="248" left="865" width="3" height="20" font="5"> </text>
<text top="265" left="865" width="3" height="20" font="5"> </text>
<text top="384" left="54" width="83" height="20" font="5">Palmerini T, et </text>
<text top="401" left="54" width="20" height="20" font="5">al., </text>
<text top="418" left="54" width="31" height="20" font="5">2015 </text>
<text top="435" left="54" width="25" height="20" font="5">(15) </text>
<text top="457" left="54" width="57" height="12" font="9"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25790880">25790880</a></text>
<text top="451" left="111" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25790880"> </a></text>
<text top="384" left="163" width="103" height="20" font="4"><b>Aim:</b>  To compare </text>
<text top="401" left="163" width="97" height="20" font="5">clinical outcomes </text>
<text top="418" left="163" width="132" height="20" font="5">between short- (≤6 mo) </text>
<text top="435" left="163" width="107" height="20" font="5">and long-term (1 y) </text>
<text top="453" left="163" width="111" height="20" font="5">DAPT in pts treated </text>
<text top="470" left="163" width="54" height="20" font="5">with DES </text>
<text top="487" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="504" left="163" width="133" height="20" font="4"><b>Study type: </b>  Individual </text>
<text top="521" left="163" width="120" height="20" font="5">pts data pairwise and </text>
<text top="539" left="163" width="126" height="20" font="5">network meta-analysis </text>
<text top="556" left="163" width="49" height="20" font="5">of RCTs<b> </b></text>
<text top="573" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="590" left="163" width="101" height="20" font="4"><b>Size: </b>4 RCT; total </text>
<text top="607" left="163" width="68" height="20" font="5">n=8,180 pts<b> </b></text>
<text top="384" left="312" width="144" height="20" font="4"><b>Inclusion criteria:</b>  RCTs </text>
<text top="401" left="312" width="140" height="20" font="5">comparing short-duration </text>
<text top="418" left="312" width="127" height="20" font="5">(3 or 6 mo) with longer-</text>
<text top="435" left="312" width="124" height="20" font="5">duration DAPT (≥1 y). </text>
<text top="452" left="312" width="3" height="20" font="4"><b> </b></text>
<text top="470" left="312" width="3" height="20" font="4"><b> </b></text>
<text top="384" left="474" width="112" height="20" font="4"><b>Intervention:</b> Short-</text>
<text top="401" left="474" width="111" height="20" font="5">term (≤6 mo) DAPT </text>
<text top="418" left="474" width="7" height="20" font="5">  </text>
<text top="435" left="474" width="109" height="20" font="4"><b>Comparator:</b> Long-</text>
<text top="452" left="474" width="92" height="20" font="5">term (1 y) DAPT<b> </b></text>
<text top="385" left="616" width="223" height="20" font="4"><b>1</b>°<b> endpoint:</b>  MACE (cardiac death, MI, </text>
<text top="402" left="616" width="101" height="20" font="5">stent thrombosis)  </text>
<text top="421" left="616" width="7" height="18" font="5">•</text>
<text top="420" left="622" width="224" height="20" font="5">For short-term DAPT, HR: 1.11 (95% CI: </text>
<text top="440" left="616" width="24" height="20" font="5">0.86</text>
<text top="440" left="640" width="7" height="19" font="8">–</text>
<text top="440" left="647" width="76" height="20" font="5">1.42; p=0.44) </text>
<text top="458" left="616" width="3" height="20" font="5"> </text>
<text top="475" left="616" width="154" height="20" font="4"><b>Safety endpoint:</b> Bleeding  </text>
<text top="494" left="616" width="7" height="18" font="5">•</text>
<text top="493" left="622" width="224" height="20" font="5">For short-term DAPT, HR: 0.66 (95% CI: </text>
<text top="513" left="616" width="24" height="20" font="5">0.46</text>
<text top="513" left="640" width="7" height="19" font="8">–</text>
<text top="513" left="647" width="76" height="20" font="5">0.94; p=0.03) </text>
<text top="530" left="616" width="3" height="20" font="5"> </text>
<text top="548" left="616" width="3" height="20" font="4"><b> </b></text>
<text top="385" left="865" width="7" height="18" font="5">•</text>
<text top="385" left="872" width="4" height="21" font="0"> </text>
<text top="385" left="876" width="218" height="20" font="5">No significant differences in 1 y rates of </text>
<text top="402" left="865" width="221" height="20" font="5">MACE among 3 mo vs. 1 y DAPT, 6-mo </text>
<text top="419" left="865" width="210" height="20" font="5">vs. 1 y DAPT, or 3 mo vs. 6 mo DAPT<b> </b></text>
<text top="436" left="865" width="3" height="20" font="4"><b> </b></text>
<text top="454" left="865" width="3" height="20" font="4"><b> </b></text>
<text top="471" left="865" width="3" height="20" font="5"> </text>
<text top="625" left="54" width="78" height="20" font="5">Giustino G, et </text>
<text top="643" left="54" width="20" height="20" font="5">al.,<b> </b></text>
<text top="660" left="54" width="31" height="20" font="5">2015 </text>
<text top="677" left="54" width="25" height="20" font="5">(16) </text>
<text top="694" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25681754">25681754</a></text>
<text top="694" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25681754"> </a></text>
<text top="711" left="54" width="3" height="20" font="5"> </text>
<text top="625" left="163" width="102" height="20" font="4"><b>Aim:</b> Evaluate the </text>
<text top="643" left="163" width="119" height="20" font="5">efficacy and safety of </text>
<text top="660" left="163" width="93" height="20" font="5">DAPT after DES </text>
<text top="677" left="163" width="3" height="20" font="5"> </text>
<text top="694" left="163" width="109" height="20" font="4"><b>Study type:</b>   Meta-</text>
<text top="711" left="163" width="117" height="20" font="5">analysis of RCT, trial </text>
<text top="729" left="163" width="56" height="20" font="5">level data </text>
<text top="746" left="163" width="3" height="20" font="5"> </text>
<text top="763" left="163" width="108" height="20" font="4"><b>Size:</b> 10 RCT; total </text>
<text top="625" left="312" width="143" height="20" font="4"><b>Patients:</b> Pts treated with </text>
<text top="643" left="312" width="137" height="20" font="5">DES enrolled in RCTs of </text>
<text top="660" left="312" width="146" height="20" font="5">shorter vs. longer duration </text>
<text top="677" left="312" width="36" height="20" font="5">DAPT </text>
<text top="694" left="312" width="3" height="20" font="5"> </text>
<text top="625" left="474" width="87" height="20" font="4"><b>Comparators:</b>  </text>
<text top="643" left="474" width="111" height="20" font="5">Shorter duration vs. </text>
<text top="660" left="474" width="146" height="20" font="5">Longer duration DAPT<b>  </b>  <b>   </b></text>
<text top="625" left="616" width="230" height="20" font="4"><b>Stent thrombosis:</b>  0.9% with shorter vs. </text>
<text top="643" left="616" width="229" height="20" font="5">0.5% with longer (OR: 1.71; 95% CI:1.26–</text>
<text top="660" left="616" width="83" height="20" font="5">2.32, p=0.001) </text>
<text top="677" left="616" width="3" height="20" font="5"> </text>
<text top="694" left="616" width="219" height="20" font="4"><b>Clinically significant bleeding:</b> <b>  </b>1.2% </text>
<text top="711" left="616" width="210" height="20" font="5">with shorter vs. 1.9% with longer (OR: </text>
<text top="729" left="616" width="188" height="20" font="5">0.63, 95% CI: 0.52–0.75; p&lt;0.001<b> </b></text>
<text top="627" left="865" width="7" height="18" font="5">•</text>
<text top="627" left="872" width="117" height="20" font="5"> Trial level data used </text>
<text top="646" left="865" width="7" height="18" font="5">•</text>
<text top="645" left="872" width="200" height="20" font="5"> The effect of shorter DAPT on stent </text>
<text top="662" left="865" width="219" height="20" font="5">thrombosis was attenuated with the use </text>
<text top="679" left="865" width="208" height="20" font="5">of second-generation DES (OR: 1.54; </text>
<text top="697" left="865" width="213" height="20" font="5">95% CI: 0.96–2.47) compared with the </text>
<text top="714" left="865" width="211" height="20" font="5">use of first-generation DES (OR: 3.94; </text>
<text top="731" left="865" width="141" height="20" font="5">95% CI: 2.20–7.05); p for </text>
<text top="748" left="865" width="102" height="20" font="5">interaction=0.008. </text>
<text top="767" left="865" width="7" height="18" font="5">•</text>
<text top="767" left="872" width="206" height="20" font="5"> All-cause mortality 2.0% with shorter </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1126" width="12" height="21" font="0">8 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="163" width="75" height="20" font="5">n=32,135 pts </text>
<text top="53" left="865" width="221" height="20" font="5">vs. 2.2% with longer (OR: 0.87; 95% CI: </text>
<text top="70" left="865" width="114" height="20" font="5">0.74–1.01; p=0.073) </text>
<text top="93" left="54" width="93" height="20" font="5">Navarese, et al.,<b> </b></text>
<text top="110" left="54" width="34" height="20" font="5">2015  </text>
<text top="128" left="54" width="25" height="20" font="5">(17) </text>
<text top="145" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25883067">25883067</a></text>
<text top="145" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25883067"> </a></text>
<text top="93" left="163" width="114" height="20" font="4"><b>Aim:</b>  To assess the </text>
<text top="110" left="163" width="113" height="20" font="5">benefits and risks of </text>
<text top="128" left="163" width="126" height="20" font="5">short term (&lt;12 mo) or </text>
<text top="145" left="163" width="107" height="20" font="5">extended (&gt;12 mo) </text>
<text top="162" left="163" width="129" height="20" font="5">DAPT vs. 12 mo DAPT </text>
<text top="179" left="163" width="60" height="20" font="5">after DES. </text>
<text top="197" left="163" width="3" height="20" font="5"> </text>
<text top="214" left="163" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="231" left="163" width="117" height="20" font="5">analysis of RCT, trial </text>
<text top="248" left="163" width="56" height="20" font="5">level data </text>
<text top="265" left="163" width="3" height="20" font="5"> </text>
<text top="283" left="163" width="108" height="20" font="4"><b>Size: </b>10 RCT; total </text>
<text top="300" left="163" width="55" height="20" font="5">n=32,287 </text>
<text top="93" left="312" width="143" height="20" font="4"><b>Patients:</b> Pts treated with </text>
<text top="110" left="312" width="131" height="20" font="5">DES enrolled in RCT of </text>
<text top="128" left="312" width="146" height="20" font="5">shorter vs. longer duration </text>
<text top="145" left="312" width="36" height="20" font="5">DAPT </text>
<text top="162" left="312" width="3" height="20" font="5"> </text>
<text top="179" left="312" width="3" height="20" font="5"> </text>
<text top="93" left="474" width="121" height="20" font="4"><b>Comparator:</b> Shorter </text>
<text top="110" left="474" width="100" height="20" font="5">or longer duration </text>
<text top="128" left="474" width="125" height="20" font="5">DAPT compared to 12 </text>
<text top="145" left="474" width="60" height="20" font="5">mo DAPT<b> </b> </text>
<text top="93" left="616" width="21" height="20" font="4"><b>MI:</b> </text>
<text top="112" left="616" width="7" height="18" font="5">•</text>
<text top="112" left="622" width="221" height="20" font="5"> Short vs. 12 mo: 1.65% vs. 1.50% (OR: </text>
<text top="131" left="616" width="98" height="20" font="5">1.11; 95% CI: 087</text>
<text top="131" left="714" width="7" height="19" font="8">–</text>
<text top="131" left="721" width="76" height="20" font="5">1.43; p=0.40) </text>
<text top="151" left="616" width="7" height="18" font="5">•</text>
<text top="150" left="622" width="215" height="20" font="5"> Extended vs. 12 mo: 1.55% vs. 2.89% </text>
<text top="167" left="616" width="221" height="20" font="5">(OR: 0.53; 95% CI: 0.42–0.66; p&lt;0.001) </text>
<text top="184" left="616" width="3" height="20" font="5"> </text>
<text top="202" left="616" width="109" height="20" font="4"><b>Stent thrombosis:</b> </text>
<text top="221" left="616" width="7" height="18" font="5">•</text>
<text top="220" left="622" width="225" height="20" font="5"> Short vs. 12 mo:  0.53% vs. 0.40% (OR: </text>
<text top="237" left="616" width="185" height="20" font="5">1.32; 95% CI: 0.83–2.08; p=0.24) </text>
<text top="256" left="616" width="7" height="18" font="5">•</text>
<text top="256" left="622" width="218" height="20" font="5"> Extended vs. 12 mo:  0.32% vs. 0.98% </text>
<text top="273" left="616" width="221" height="20" font="5">(OR: 0.33; 95% CI: 0.21–0.51; p&lt;0.001) </text>
<text top="290" left="616" width="3" height="20" font="5"> </text>
<text top="307" left="616" width="94" height="20" font="4"><b>Major bleeding:</b> </text>
<text top="326" left="616" width="7" height="18" font="5">•</text>
<text top="326" left="622" width="195" height="20" font="5"> Short vs. 12 mo:  0.35% vs. 0.61% </text>
<text top="343" left="616" width="211" height="20" font="5">(OR:0.58; 95% CI: 0.36–0.92, p=0.02) </text>
<text top="362" left="616" width="7" height="18" font="5">•</text>
<text top="361" left="622" width="215" height="20" font="5"> Extended vs. 12 mo: 1.95% vs. 1.21% </text>
<text top="378" left="616" width="218" height="20" font="5">(OR:1.62; 95% CI: 1.26–2.09; p&lt;0.001) </text>
<text top="396" left="616" width="3" height="20" font="5"> </text>
<text top="413" left="616" width="80" height="20" font="4"><b>CV mortality:</b> </text>
<text top="432" left="616" width="7" height="18" font="5">•</text>
<text top="431" left="622" width="225" height="20" font="5"> Short vs. 12 mo:  1.13% vs. 1.20% (OR: </text>
<text top="448" left="616" width="185" height="20" font="5">0.95; 95% CI: 0.68–1.33; p=0.76) </text>
<text top="468" left="616" width="7" height="18" font="5">•</text>
<text top="467" left="622" width="215" height="20" font="5"> Extended vs. 12 mo: 1.03% vs. 0.95% </text>
<text top="484" left="616" width="211" height="20" font="5">(OR:1.09; 95% CI: 0.79–1.50; p=0.62) </text>
<text top="501" left="616" width="3" height="20" font="5"> </text>
<text top="518" left="616" width="118" height="20" font="4"><b>All-cause mortality:</b> </text>
<text top="538" left="616" width="7" height="18" font="5">•</text>
<text top="537" left="622" width="225" height="20" font="5"> Short vs. 12 mo:  1.43% vs. 1.56% (OR: </text>
<text top="554" left="616" width="192" height="20" font="5">0.91; 95% CI: 0.781–1.18; p=0.49) </text>
<text top="573" left="616" width="7" height="18" font="5">•</text>
<text top="572" left="622" width="218" height="20" font="5"> Extended vs. 12 mo:  1.84% vs. 1.42% </text>
<text top="589" left="616" width="214" height="20" font="5">(OR: 1.30; 95% CI: 1.02–1.66; p=0.03) </text>
<text top="95" left="865" width="7" height="18" font="5">•</text>
<text top="94" left="872" width="117" height="20" font="5"> Trial level data used </text>
<text top="114" left="865" width="7" height="18" font="5">•</text>
<text top="113" left="872" width="216" height="20" font="5"> Authors concluded that compared with </text>
<text top="130" left="865" width="218" height="20" font="5">standard 12 mo DAPT, shorter duration </text>
<text top="147" left="865" width="192" height="20" font="5">reduced bleeding with no apparent </text>
<text top="165" left="865" width="216" height="20" font="5">increase in ischemic complications and </text>
<text top="182" left="865" width="202" height="20" font="5">could be considered for most pts.  In </text>
<text top="199" left="865" width="213" height="20" font="5">selected pts with low bleeding risk and </text>
<text top="216" left="865" width="221" height="20" font="5">very high ischemic risk, extended DAPT </text>
<text top="233" left="865" width="114" height="20" font="5">could be considered </text>
<text top="607" left="54" width="83" height="20" font="5">Palmerini T, et </text>
<text top="625" left="54" width="20" height="20" font="5">al.,<b> </b></text>
<text top="642" left="54" width="31" height="20" font="5">2015 </text>
<text top="659" left="54" width="25" height="20" font="5">(18) </text>
<text top="676" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26065988">26065988</a></text>
<text top="676" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26065988"> </a></text>
<text top="694" left="54" width="3" height="20" font="5"> </text>
<text top="607" left="163" width="97" height="20" font="4"><b>Aim:</b>  Investigate </text>
<text top="625" left="163" width="105" height="20" font="5">mortality and other </text>
<text top="642" left="163" width="122" height="20" font="5">clinical outcomes with </text>
<text top="659" left="163" width="84" height="20" font="5">different DAPT </text>
<text top="676" left="163" width="57" height="20" font="5">strategies </text>
<text top="694" left="163" width="3" height="20" font="5"> </text>
<text top="711" left="163" width="124" height="20" font="4"><b>Study type:</b> Pair wise </text>
<text top="728" left="163" width="124" height="20" font="5">and Bayesian network </text>
<text top="745" left="163" width="125" height="20" font="5">meta-analysis of RCT, </text>
<text top="762" left="163" width="83" height="20" font="5">trial level data  </text>
<text top="607" left="312" width="143" height="20" font="4"><b>Patients:</b> Pts treated with </text>
<text top="625" left="312" width="131" height="20" font="5">DES enrolled in RCT of </text>
<text top="642" left="312" width="146" height="20" font="5">shorter vs. longer duration </text>
<text top="659" left="312" width="36" height="20" font="5">DAPT </text>
<text top="607" left="474" width="87" height="20" font="4"><b>Comparators:</b>  </text>
<text top="625" left="474" width="111" height="20" font="5">Shorter duration vs. </text>
<text top="642" left="474" width="135" height="20" font="5">longer duration DAPT<b>     </b></text>
<text top="607" left="616" width="218" height="20" font="4"><b>All-cause mortality: </b>Shorter vs. longer </text>
<text top="625" left="616" width="204" height="20" font="5">DAPT: HR: 0.82; 95% CI: 0.69–0.98; </text>
<text top="642" left="616" width="101" height="20" font="5">p=0.02; NNT=325<b> </b></text>
<text top="609" left="865" width="7" height="18" font="5">•</text>
<text top="609" left="872" width="117" height="20" font="5"> Trial level data used </text>
<text top="628" left="865" width="7" height="18" font="5">•</text>
<text top="627" left="872" width="173" height="20" font="5"> Reduced mortality with shorter </text>
<text top="644" left="865" width="224" height="20" font="5">compared to longer DAPT attributable to </text>
<text top="661" left="865" width="213" height="20" font="5">lower non–cardiac mortality (HR: 0.67; </text>
<text top="679" left="865" width="221" height="20" font="5">95% CI: 0.51–0.89; p=0.006; NNT=347) </text>
<text top="696" left="865" width="217" height="20" font="5">with similar cardiac mortality (HR: 0.93; </text>
<text top="713" left="865" width="154" height="20" font="5">95% CI: 0.73–1.17; p=0.52) </text>
<text top="732" left="865" width="7" height="18" font="5">•</text>
<text top="732" left="872" width="204" height="20" font="5"> Shorter DAPT associated with lower </text>
<text top="749" left="865" width="228" height="20" font="5">risk of major bleeding, but a higher risk of </text>
<text top="766" left="865" width="135" height="20" font="5">MI and stent thrombosis </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1126" width="12" height="21" font="0">9 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="163" width="3" height="20" font="5"> </text>
<text top="70" left="163" width="108" height="20" font="4"><b>Size:</b> 10 RCT; total </text>
<text top="87" left="163" width="75" height="20" font="5">n=31,666 pts </text>
<text top="107" left="54" width="85" height="20" font="5">Spencer FA, et </text>
<text top="124" left="54" width="20" height="20" font="5">al.,<b> </b></text>
<text top="141" left="54" width="31" height="20" font="5">2015 </text>
<text top="158" left="54" width="25" height="20" font="5">(19) </text>
<text top="176" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26005909">26005909</a></text>
<text top="176" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26005909"> </a></text>
<text top="107" left="163" width="112" height="20" font="4"><b>Aim:</b> To summarize </text>
<text top="124" left="163" width="135" height="20" font="5">data on clinical outcome </text>
<text top="141" left="163" width="124" height="20" font="5">with longer vs. shorter </text>
<text top="158" left="163" width="112" height="20" font="5">duration DAPT after </text>
<text top="176" left="163" width="29" height="20" font="5">DES </text>
<text top="193" left="163" width="3" height="20" font="5"> </text>
<text top="210" left="163" width="109" height="20" font="4"><b>Study type:</b>   Meta-</text>
<text top="227" left="163" width="117" height="20" font="5">analysis of RCT, trial </text>
<text top="244" left="163" width="56" height="20" font="5">level data </text>
<text top="262" left="163" width="3" height="20" font="5"> </text>
<text top="279" left="163" width="101" height="20" font="4"><b>Size:</b> 9 RCT; total </text>
<text top="296" left="163" width="55" height="20" font="5">n=28,808 </text>
<text top="107" left="312" width="143" height="20" font="4"><b>Patients:</b> Pts treated with </text>
<text top="124" left="312" width="131" height="20" font="5">DES enrolled in RCT of </text>
<text top="141" left="312" width="146" height="20" font="5">shorter vs. longer duration </text>
<text top="158" left="312" width="36" height="20" font="5">DAPT </text>
<text top="176" left="312" width="3" height="20" font="5"> </text>
<text top="107" left="474" width="87" height="20" font="4"><b>Comparators:</b>  </text>
<text top="124" left="474" width="111" height="20" font="5">Shorter duration vs. </text>
<text top="141" left="474" width="129" height="20" font="5">longer duration DAPT<b>   </b></text>
<text top="107" left="616" width="233" height="20" font="4"><b>MI:</b> 1.7% with longer vs. 2.6% with shorter </text>
<text top="124" left="616" width="141" height="20" font="5">(RR: 0.73; CI: 0.58–0.92) </text>
<text top="141" left="616" width="3" height="20" font="5"> </text>
<text top="158" left="616" width="208" height="20" font="4"><b>Major Bleeding</b>: 1.4% with longer vs. </text>
<text top="176" left="616" width="205" height="20" font="5">0.8% with shorter (RR: 1.66; 95% CI: </text>
<text top="193" left="616" width="62" height="20" font="5">1.34–1.99) </text>
<text top="210" left="616" width="3" height="20" font="5"> </text>
<text top="227" left="616" width="208" height="20" font="4"><b>Total Mortality:</b>  2.0% with longer vs. </text>
<text top="244" left="616" width="205" height="20" font="5">1.7% with shorter (RR–1.19; 95% CI: </text>
<text top="262" left="616" width="62" height="20" font="5">1.04–1.36) </text>
<text top="279" left="616" width="3" height="20" font="5"> </text>
<text top="296" left="616" width="3" height="20" font="4"><b> </b></text>
<text top="109" left="865" width="7" height="18" font="5">•</text>
<text top="108" left="872" width="117" height="20" font="5"> Trial level data used </text>
<text top="127" left="865" width="7" height="18" font="5">•</text>
<text top="126" left="872" width="204" height="20" font="5"> Authors concluded moderate-quality </text>
<text top="143" left="865" width="209" height="20" font="5">evidence showed that longer-duration </text>
<text top="161" left="865" width="178" height="20" font="5">DAPT decreased risk for MI and </text>
<text top="178" left="865" width="224" height="20" font="5">increased mortality, and that high-quality </text>
<text top="195" left="865" width="215" height="20" font="5">evidence showed that DAPT increased </text>
<text top="212" left="865" width="124" height="20" font="5">risk for major bleeding </text>
<text top="231" left="865" width="7" height="18" font="5">•</text>
<text top="231" left="872" width="222" height="20" font="5"> Authors calculated that extended DAPT </text>
<text top="248" left="865" width="200" height="20" font="5">associated with 8 fewer MI per 1000 </text>
<text top="265" left="865" width="187" height="20" font="5">treated per year but 6 more major </text>
<text top="282" left="865" width="208" height="20" font="5">bleeding events per year than shorter-</text>
<text top="299" left="865" width="84" height="20" font="5">duration DAPT </text>
<text top="317" left="54" width="1054" height="20" font="5">ACS indicates acute coronary syndrome; ASA, aspirin; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; HR, hazard ratio; Hx, history; MACE, major adverse cardiac  </text>
<text top="335" left="54" width="1083" height="20" font="5">events; MI, myocardial infarction; NNT, number need to treat; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; SIHD, stable ischemic heart disease; and TIMI, Thrombolysis </text>
<text top="352" left="54" width="141" height="20" font="5">In Myocardial Infarction.   </text>
<text top="371" left="54" width="4" height="21" font="0"> </text>
<text top="410" left="54" width="662" height="24" font="2"><b>Data Supplement 4. RCTs, RCT Subgroup Analyses, and Meta-Analyses of RCTs of DAPT Post</b></text>
<text top="413" left="716" width="7" height="20" font="4"><b>–</b></text>
<text top="410" left="723" width="71" height="24" font="2"><b>MI or Post</b></text>
<text top="413" left="794" width="7" height="20" font="4"><b>–</b></text>
<text top="410" left="801" width="35" height="24" font="2"><b>ACS </b></text>
<text top="435" left="55" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="452" left="78" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="469" left="56" width="96" height="20" font="4"><b>Year Published  </b></text>
<text top="435" left="196" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="452" left="201" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="469" left="195" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="435" left="358" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="435" left="523" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="452" left="541" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="469" left="523" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="487" left="544" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="435" left="716" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="452" left="699" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="469" left="701" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="487" left="744" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="436" left="904" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="453" left="939" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="470" left="919" width="147" height="20" font="4"><b>               Adverse Events </b></text>
<text top="505" left="54" width="86" height="20" font="5">Udell JA, et al., </text>
<text top="522" left="54" width="31" height="20" font="5">2015 </text>
<text top="539" left="54" width="25" height="20" font="5">(13) </text>
<text top="556" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26324537">26324537</a></text>
<text top="556" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26324537"> </a></text>
<text top="505" left="163" width="135" height="20" font="4"><b>Aim:</b>  Compare benefits </text>
<text top="522" left="163" width="149" height="20" font="5">and risks of more than one </text>
<text top="539" left="163" width="146" height="20" font="5">y of DAPT with ASA alone </text>
<text top="556" left="163" width="140" height="20" font="5">in high-risk pts with Hx of </text>
<text top="573" left="163" width="45" height="20" font="5">prior MI </text>
<text top="591" left="163" width="3" height="20" font="5"> </text>
<text top="608" left="163" width="102" height="20" font="4"><b>Study type:</b> Meta-</text>
<text top="625" left="163" width="48" height="20" font="5">analysis </text>
<text top="642" left="163" width="3" height="20" font="5"> </text>
<text top="659" left="163" width="93" height="20" font="4"><b>Size:</b> 33,435 pts </text>
<text top="505" left="325" width="158" height="20" font="4"><b>Inclusion criteria:</b>  RCTs of </text>
<text top="522" left="325" width="154" height="20" font="5">secondary prevention in pts </text>
<text top="539" left="325" width="124" height="20" font="5">with MI randomized to </text>
<text top="556" left="325" width="155" height="20" font="5">extended duration (&gt;12 mo) </text>
<text top="573" left="325" width="147" height="20" font="5">DAPT compared with ASA </text>
<text top="591" left="325" width="33" height="20" font="5">alone </text>
<text top="608" left="325" width="3" height="20" font="5"> </text>
<text top="625" left="325" width="173" height="20" font="4"><b>Exclusion criteria:</b>  ≤12 mo of </text>
<text top="642" left="325" width="123" height="20" font="5">follow-up, trials of oral </text>
<text top="659" left="325" width="163" height="20" font="5">anticoagulant therapies, trials </text>
<text top="677" left="325" width="125" height="20" font="5">of pts with SIHD alone </text>
<text top="694" left="325" width="89" height="20" font="5">undergoing PCI </text>
<text top="505" left="514" width="126" height="20" font="4"><b>Intervention:</b>  &gt;12 mo </text>
<text top="522" left="514" width="36" height="20" font="5">DAPT </text>
<text top="539" left="514" width="7" height="20" font="5">  </text>
<text top="556" left="514" width="105" height="20" font="4"><b>Comparator:</b> ASA </text>
<text top="573" left="514" width="78" height="20" font="5">therapy alone </text>
<text top="591" left="514" width="3" height="20" font="5"> </text>
<text top="608" left="514" width="3" height="20" font="4"><b> </b></text>
<text top="506" left="656" width="183" height="20" font="4"><b>1</b>°<b> endpoint:  MACE (CV death, </b></text>
<text top="523" left="656" width="193" height="20" font="4"><b>nonfatal MI, and nonfatal stroke)</b> </text>
<text top="542" left="656" width="7" height="18" font="5">•</text>
<text top="541" left="663" width="200" height="20" font="5"> 6.4% with DAPT vs. 7.5% with ASA </text>
<text top="558" left="656" width="202" height="20" font="5">alone (RR: 0.78; 95% CI: 0.67–0.90; </text>
<text top="576" left="656" width="52" height="20" font="5">p=0.001) </text>
<text top="593" left="656" width="3" height="20" font="5"> </text>
<text top="506" left="892" width="7" height="18" font="5">•</text>
<text top="506" left="899" width="165" height="20" font="5"> Studies included in analysis:  </text>
<text top="523" left="892" width="185" height="20" font="5">CHARISMA, PRODIGY, ARCTIC-</text>
<text top="540" left="892" width="171" height="20" font="5">Interruption, DAPT,-LATE, and </text>
<text top="557" left="892" width="109" height="20" font="5">PEGASUS-TIMI 54 </text>
<text top="576" left="892" width="7" height="18" font="5">•</text>
<text top="576" left="899" width="187" height="20" font="5"> For all studies except PEGASUS-</text>
<text top="593" left="892" width="181" height="20" font="5">TIMI 54, a subgroup of the study </text>
<text top="610" left="892" width="185" height="20" font="5">population was used for the meta-</text>
<text top="627" left="892" width="48" height="20" font="5">analysis </text>
<text top="646" left="892" width="7" height="18" font="5">•</text>
<text top="646" left="899" width="170" height="20" font="5"> CV death 2.3% with DAPT vs. </text>
<text top="663" left="892" width="178" height="20" font="5">2.6% with ASA alone (RR: 0.85; </text>
<text top="680" left="892" width="158" height="20" font="5">95% CI: 0.74–0.98; p=0.03), </text>
<text top="699" left="892" width="7" height="18" font="5">•</text>
<text top="699" left="899" width="196" height="20" font="5"> No increase in non–CV death (RR: </text>
<text top="716" left="892" width="188" height="20" font="5">1.03; 95% CI: 0.86–1.23; p=0.76). </text>
<text top="735" left="892" width="7" height="18" font="5">•</text>
<text top="734" left="899" width="187" height="20" font="5"> Major bleeding 1.85% with DAPT </text>
<text top="751" left="892" width="195" height="20" font="5">vs 1.09% with ASA (RR: 1.73; 95% </text>
<text top="768" left="892" width="130" height="20" font="5">CI:1.19–2.50; p=0.004) </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">10 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="58" height="20" font="4"><b>DAPT (MI </b></text>
<text top="70" left="54" width="60" height="20" font="4"><b>subgroup </b></text>
<text top="87" left="54" width="56" height="20" font="4"><b>analysis) </b></text>
<text top="104" left="54" width="86" height="20" font="5">Yeh RW, et al.,<b> </b></text>
<text top="122" left="54" width="31" height="20" font="5">2015 </text>
<text top="139" left="54" width="25" height="20" font="5">(20) </text>
<text top="156" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25787199">25787199</a></text>
<text top="156" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25787199"> </a></text>
<text top="53" left="163" width="148" height="20" font="4"><b>Aim:</b>  Assess benefits and </text>
<text top="70" left="163" width="145" height="20" font="5">risks of extended DAPT in </text>
<text top="87" left="163" width="128" height="20" font="5">subgroups of pts in the </text>
<text top="104" left="163" width="135" height="20" font="5">DAPT study with MI and </text>
<text top="122" left="163" width="114" height="20" font="5">stable presentations </text>
<text top="139" left="163" width="3" height="20" font="5"> </text>
<text top="156" left="163" width="122" height="20" font="4"><b>Study type:</b> Post-hoc </text>
<text top="173" left="163" width="141" height="20" font="5">analysis of the DAPT trial </text>
<text top="190" left="163" width="3" height="20" font="5"> </text>
<text top="208" left="163" width="93" height="20" font="4"><b>Size:</b> 11,648 pts </text>
<text top="53" left="325" width="130" height="20" font="4"><b>Inclusion criteria:</b>  Pts </text>
<text top="70" left="325" width="161" height="20" font="5">enrolled in DAPT trial treated </text>
<text top="87" left="325" width="133" height="20" font="5">with either BMS or DES </text>
<text top="104" left="325" width="3" height="20" font="5"> </text>
<text top="122" left="325" width="137" height="20" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="53" left="514" width="82" height="20" font="4"><b>Intervention:</b>  </text>
<text top="70" left="514" width="95" height="20" font="5">Additional 18 mo </text>
<text top="87" left="514" width="113" height="20" font="5">DAPT after initial 12 </text>
<text top="104" left="514" width="21" height="20" font="5">mo </text>
<text top="122" left="514" width="7" height="20" font="5">  </text>
<text top="139" left="514" width="125" height="20" font="4"><b>Comparator:</b> Placebo </text>
<text top="156" left="514" width="108" height="20" font="5">thienopyridine after </text>
<text top="173" left="514" width="105" height="20" font="5">initial 12 mo DAPT </text>
<text top="190" left="514" width="3" height="20" font="5"> </text>
<text top="208" left="514" width="118" height="20" font="4"><b>Subgroup analysis:</b> </text>
<text top="225" left="514" width="120" height="20" font="5">Pts with MI (n=3,576) </text>
<text top="242" left="514" width="83" height="20" font="5">and without MI </text>
<text top="259" left="514" width="56" height="20" font="5">(n=8,072)<b> </b></text>
<text top="54" left="656" width="212" height="20" font="4"><b>Co-1</b>°<b> endpoints (after additional 18 </b></text>
<text top="71" left="656" width="56" height="20" font="4"><b>mo Rx):</b>   </text>
<text top="90" left="656" width="7" height="18" font="5">•</text>
<text top="90" left="663" width="202" height="20" font="5"> Stent thrombosis in MI group:  0.5% </text>
<text top="107" left="656" width="192" height="20" font="5">with extended DAPT vs. 1.9% with </text>
<text top="124" left="656" width="205" height="20" font="5">placebo thienopyridine (HR: 0.27; CI: </text>
<text top="141" left="656" width="114" height="20" font="5">0.13–0.57, p&lt;0.001) </text>
<text top="160" left="656" width="7" height="18" font="5">•</text>
<text top="160" left="663" width="218" height="20" font="5"> MACCE (death, MI, CVA) in MI group:  </text>
<text top="177" left="656" width="200" height="20" font="5">3.9% with continued DAPT vs. 6.8% </text>
<text top="194" left="656" width="211" height="20" font="5">with placebo thienopyridine (HR: 0.56; </text>
<text top="211" left="656" width="133" height="20" font="5">CI: 0.42–0.76; p&lt;0.001) </text>
<text top="228" left="656" width="3" height="20" font="5"> </text>
<text top="247" left="656" width="170" height="20" font="4"><b>1</b>°<b>  Safety endpoint:</b>  GUSTO </text>
<text top="264" left="656" width="160" height="20" font="5">moderate or severe bleeding </text>
<text top="283" left="656" width="7" height="18" font="5">•</text>
<text top="282" left="663" width="200" height="20" font="5"> In pts with MI:  1.9% with continued </text>
<text top="299" left="656" width="158" height="20" font="5">DAPT vs. 0.8% with placebo </text>
<text top="317" left="656" width="220" height="20" font="5">thienopyridine (HR: 2.38; CI: 1.28–4.43, </text>
<text top="334" left="656" width="52" height="20" font="5">p=0.005) </text>
<text top="55" left="892" width="7" height="18" font="5">•</text>
<text top="54" left="899" width="148" height="20" font="5"> All cause death 1.4% with </text>
<text top="71" left="892" width="166" height="20" font="5">extended DAPT vs. 1.6% with </text>
<text top="88" left="892" width="186" height="20" font="5">placebo thienopyridine (HR: 0.87; </text>
<text top="106" left="892" width="126" height="20" font="5">CI: 0.50–1.50, p=0.61) </text>
<text top="123" left="892" width="3" height="20" font="5"> </text>
<text top="352" left="54" width="92" height="20" font="4"><b>PEGASUS-TIMI </b></text>
<text top="369" left="54" width="17" height="20" font="4"><b>54 </b></text>
<text top="386" left="54" width="84" height="20" font="5">Bonaca MP, et </text>
<text top="404" left="54" width="20" height="20" font="5">al., </text>
<text top="421" left="54" width="31" height="20" font="5">2015 </text>
<text top="438" left="54" width="25" height="20" font="5">(21) </text>
<text top="455" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25773268">25773268</a></text>
<text top="455" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25773268"> </a></text>
<text top="472" left="54" width="7" height="20" font="5">  </text>
<text top="352" left="163" width="135" height="20" font="4"><b>Aim:</b>  To investigate the </text>
<text top="369" left="163" width="119" height="20" font="5">efficacy and safety of </text>
<text top="386" left="163" width="146" height="20" font="5">ticagrelor beyond 1 y after </text>
<text top="404" left="163" width="27" height="20" font="5">a MI </text>
<text top="421" left="163" width="3" height="20" font="5"> </text>
<text top="438" left="163" width="149" height="20" font="4"><b>Study type:</b> RCT, placebo </text>
<text top="455" left="163" width="57" height="20" font="5">controlled </text>
<text top="472" left="163" width="3" height="20" font="5"> </text>
<text top="490" left="163" width="93" height="20" font="4"><b>Size:</b> 21,162 pts </text>
<text top="352" left="325" width="157" height="20" font="4"><b>Inclusion criteria: </b> MI 1-3 y </text>
<text top="369" left="325" width="125" height="20" font="5">prior, age ≥50, and an </text>
<text top="386" left="325" width="148" height="20" font="5">additional high-risk feature </text>
<text top="404" left="325" width="3" height="20" font="5"> </text>
<text top="421" left="325" width="165" height="20" font="4"><b>Exclusion criteria:</b>  Bleeding </text>
<text top="438" left="325" width="171" height="20" font="5">disorder, Hx of ischemic stroke </text>
<text top="455" left="325" width="175" height="20" font="5">of ICH, CNS tumor, GI bleeding </text>
<text top="472" left="325" width="148" height="20" font="5">within 6 mo, major surgery </text>
<text top="490" left="325" width="166" height="20" font="5">within 30 d, oral anticoagulant </text>
<text top="507" left="325" width="23" height="20" font="5">use </text>
<text top="352" left="514" width="82" height="20" font="4"><b>Intervention:</b>  </text>
<text top="369" left="514" width="96" height="20" font="5">Ticagrelor 90 mg </text>
<text top="386" left="514" width="122" height="20" font="5">(n=7050) or ticagrelor </text>
<text top="404" left="514" width="91" height="20" font="5">60 mg (n=7045) </text>
<text top="421" left="514" width="7" height="20" font="5">  </text>
<text top="438" left="514" width="84" height="20" font="4"><b>Comparator:</b>  <b> </b></text>
<text top="455" left="514" width="101" height="20" font="5">Placebo<b> </b>(n=7067)<b> </b></text>
<text top="353" left="656" width="219" height="20" font="4"><b>1</b>°<b> endpoint:</b>  CV death, MI or stroke at </text>
<text top="370" left="656" width="134" height="20" font="5">median 33 mo follow-up </text>
<text top="389" left="656" width="7" height="18" font="5">•</text>
<text top="389" left="663" width="200" height="20" font="5"> 7.85% with 90 mg ticagrelor, 7.77% </text>
<text top="406" left="656" width="208" height="20" font="5">with 60 mg ticagrelor, and 9.04% with </text>
<text top="424" left="656" width="199" height="20" font="5">placebo •HR for 90 mg vs. placebo: </text>
<text top="442" left="656" width="188" height="20" font="5">0.85; 95% CI: 0.75–0.96; p=0.008 </text>
<text top="461" left="656" width="7" height="18" font="5">•</text>
<text top="460" left="663" width="208" height="20" font="5"> HR for 60 mg vs. placebo: 0.84; 95% </text>
<text top="477" left="656" width="129" height="20" font="5">CI: 0.74–0.95; p=0.004 </text>
<text top="494" left="656" width="3" height="20" font="5"> </text>
<text top="513" left="656" width="185" height="20" font="4"><b>1</b>°<b>  Safety endpoint: </b> TIMI major </text>
<text top="530" left="656" width="50" height="20" font="5">bleeding<b> </b></text>
<text top="549" left="656" width="7" height="18" font="5">•</text>
<text top="548" left="663" width="204" height="20" font="5"> 2.60 with 90 mg ticagrelor, 2.30 with </text>
<text top="566" left="656" width="182" height="20" font="5">60 mg ticagrelor, and 1.06% with </text>
<text top="583" left="656" width="196" height="20" font="5">placebo (p&lt;0.001 for each dose vs. </text>
<text top="600" left="656" width="51" height="20" font="5">placebo) </text>
<text top="354" left="892" width="7" height="18" font="5">•</text>
<text top="353" left="899" width="136" height="20" font="5"> All pts treated with ASA </text>
<text top="372" left="892" width="7" height="18" font="5">•</text>
<text top="371" left="899" width="183" height="20" font="5"> No differences in death between </text>
<text top="389" left="892" width="176" height="20" font="5">the either dose of ticagrelor and </text>
<text top="406" left="892" width="46" height="20" font="5">placebo </text>
<text top="423" left="892" width="3" height="20" font="5"> </text>
<text top="440" left="892" width="3" height="20" font="5"> </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">11 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="58" height="20" font="4"><b>TRILOGY </b></text>
<text top="70" left="54" width="86" height="20" font="5">Row MT, et al., </text>
<text top="87" left="54" width="31" height="20" font="5">2012 </text>
<text top="104" left="54" width="25" height="20" font="5">(22) </text>
<text top="122" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22920930">22920930</a></text>
<text top="122" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22920930"> </a></text>
<text top="139" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="53" left="163" width="103" height="20" font="4"><b>Aim:</b>  To compare </text>
<text top="70" left="163" width="143" height="20" font="5">prasugrel with clopidogrel </text>
<text top="87" left="163" width="144" height="20" font="5">in pts with NSTE-ACS not </text>
<text top="104" left="163" width="65" height="20" font="5">undergoing </text>
<text top="122" left="163" width="96" height="20" font="5">revascularization<b> </b></text>
<text top="139" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="156" left="163" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="173" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="190" left="163" width="86" height="20" font="4"><b>Size: </b>7,243 pts<b> </b></text>
<text top="53" left="325" width="156" height="20" font="4"><b>Inclusion criteria:</b>  Pts with </text>
<text top="70" left="325" width="132" height="20" font="5">NSTE-ACS selected for </text>
<text top="87" left="325" width="163" height="20" font="5">medical management without </text>
<text top="104" left="325" width="96" height="20" font="5">revascularization<b> </b></text>
<text top="122" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="139" left="325" width="175" height="20" font="4"><b>Exclusion criteria:</b>  Hx CVA or </text>
<text top="156" left="325" width="165" height="20" font="5">TIA, PCI or CABG within prior </text>
<text top="173" left="325" width="150" height="20" font="5">30 d, renal failure requiring </text>
<text top="190" left="325" width="141" height="20" font="5">dialysis, concomitant oral </text>
<text top="208" left="325" width="142" height="20" font="5">anticoagulation treatment<b> </b></text>
<text top="53" left="514" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="70" left="514" width="56" height="20" font="5">Prasugrel </text>
<text top="87" left="514" width="7" height="20" font="4"><b>  </b></text>
<text top="104" left="514" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="122" left="514" width="66" height="20" font="5">Clopidogrel<b> </b></text>
<text top="54" left="656" width="208" height="20" font="4"><b>1</b>°<b> endpoint:</b> MACE (CV death, MI or </text>
<text top="71" left="656" width="151" height="20" font="5">CVA) in pts &lt;75 y at 30 mo </text>
<text top="90" left="656" width="7" height="18" font="5">•</text>
<text top="90" left="663" width="204" height="20" font="5"> 13.9% with prasugrel vs. 16.0% with </text>
<text top="109" left="656" width="193" height="20" font="5">clopidogrel (HR: 0.91; 95% CI: 0.79</text>
<text top="109" left="850" width="7" height="19" font="8">–</text>
<text top="127" left="656" width="76" height="20" font="5">1.05; p=0.21) </text>
<text top="144" left="656" width="3" height="20" font="5"> </text>
<text top="161" left="656" width="206" height="20" font="4"><b>Safety endpoint): </b>GUSTO severe or </text>
<text top="178" left="656" width="142" height="20" font="5">life-threatening bleeding   </text>
<text top="197" left="656" width="7" height="18" font="5">•</text>
<text top="197" left="663" width="191" height="20" font="5"> 0.9% with prasugrel vs. 0.6% with </text>
<text top="216" left="656" width="193" height="20" font="5">clopidogrel (HR: 0.94; 95% CI: 0.44</text>
<text top="216" left="850" width="7" height="19" font="8">–</text>
<text top="234" left="656" width="80" height="20" font="5">1.99; p=0.87) <b> </b></text>
<text top="55" left="892" width="7" height="18" font="5">•</text>
<text top="54" left="899" width="135" height="20" font="4"><b> </b>All pts treated with ASA </text>
<text top="71" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="88" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="106" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="123" left="892" width="3" height="20" font="5"> </text>
<text top="256" left="54" width="45" height="20" font="4"><b>PLATO </b></text>
<text top="273" left="54" width="96" height="20" font="5">James SK, et al., </text>
<text top="290" left="54" width="31" height="20" font="5">2011 </text>
<text top="308" left="54" width="25" height="20" font="5">(23) </text>
<text top="325" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21685437">21685437</a></text>
<text top="325" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21685437"> </a></text>
<text top="342" left="54" width="3" height="20" font="5"> </text>
<text top="359" left="54" width="3" height="20" font="5"> </text>
<text top="256" left="163" width="143" height="20" font="4"><b>Aim:</b> To evaluate efficacy </text>
<text top="273" left="163" width="130" height="20" font="5">and safety outcomes in </text>
<text top="290" left="163" width="116" height="20" font="5">pts in PLATO who at </text>
<text top="308" left="163" width="111" height="20" font="5">randomization were </text>
<text top="325" left="163" width="143" height="20" font="5">planned for a noninvasive </text>
<text top="342" left="163" width="106" height="20" font="5">treatment strategy. </text>
<text top="359" left="163" width="3" height="20" font="5"> </text>
<text top="376" left="163" width="149" height="20" font="4"><b>Study type:</b>  Pre-specified </text>
<text top="394" left="163" width="137" height="20" font="5">subgroup analysis of the </text>
<text top="411" left="163" width="72" height="20" font="5">PLATO RCT </text>
<text top="428" left="163" width="3" height="20" font="5"> </text>
<text top="445" left="163" width="86" height="20" font="4"><b>Size:</b> 5,216 pts </text>
<text top="256" left="325" width="152" height="20" font="4"><b>Inclusion criteria: </b>Pts with </text>
<text top="273" left="325" width="164" height="20" font="5">ACS admitted to hospital with </text>
<text top="290" left="325" width="115" height="20" font="5">planned noninvasive </text>
<text top="308" left="325" width="79" height="20" font="5">management  </text>
<text top="325" left="325" width="3" height="20" font="5"> </text>
<text top="342" left="325" width="144" height="20" font="4"><b>Exclusion criteria:</b> Pts in </text>
<text top="359" left="325" width="164" height="20" font="5">PLATO with planned invasive </text>
<text top="376" left="325" width="75" height="20" font="5">management </text>
<text top="256" left="514" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="273" left="514" width="124" height="20" font="5">Ticagrelor (90 mg bid) </text>
<text top="290" left="514" width="7" height="20" font="5">  </text>
<text top="308" left="514" width="87" height="20" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="325" left="514" width="107" height="20" font="5">Clopidogrel (75 mg </text>
<text top="342" left="514" width="23" height="20" font="5">qD)<b> </b></text>
<text top="257" left="656" width="196" height="20" font="4"><b>1</b>°<b> endpoint: </b>Vascular death, MI or </text>
<text top="274" left="656" width="35" height="20" font="5">CVA   </text>
<text top="294" left="656" width="7" height="18" font="5">•</text>
<text top="293" left="663" width="193" height="20" font="5"> 12.0% with ticagrelor compared to </text>
<text top="310" left="656" width="217" height="20" font="5">14.3% with clopidogrel  (HR: 0.85; 95% </text>
<text top="329" left="656" width="43" height="20" font="5">CI: 0.73</text>
<text top="329" left="699" width="7" height="19" font="8">–</text>
<text top="329" left="707" width="76" height="20" font="5">1.00; p=0.04) </text>
<text top="347" left="656" width="3" height="20" font="5"> </text>
<text top="364" left="656" width="96" height="20" font="4"><b>Safety endpoint:</b></text>
<text top="364" left="753" width="7" height="21" font="0">  </text>
<text top="383" left="656" width="7" height="18" font="5">•</text>
<text top="383" left="663" width="193" height="20" font="5"> Total major bleeding:  (11.9% with </text>
<text top="400" left="656" width="200" height="20" font="5">ticagrelor vs. 10.3% with clopidogrel </text>
<text top="419" left="656" width="130" height="20" font="5">(HR: 1.17; 95% CI: 0.98</text>
<text top="419" left="787" width="7" height="19" font="8">–</text>
<text top="419" left="794" width="76" height="20" font="5">1.39; p=0.08) </text>
<text top="439" left="656" width="7" height="18" font="5">•</text>
<text top="438" left="663" width="215" height="20" font="5"> Non–CABG major bleeding: 4.0% with </text>
<text top="455" left="656" width="221" height="20" font="5">ticagrelor vs. 3.1% with clopidogrel (HR: </text>
<text top="475" left="656" width="98" height="20" font="5">1.30, 95% CI:0.95</text>
<text top="475" left="754" width="7" height="19" font="8">–</text>
<text top="475" left="762" width="80" height="20" font="5">1.77; p=0.10)  </text>
<text top="493" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="258" left="892" width="7" height="18" font="5">•</text>
<text top="257" left="899" width="27" height="20" font="4"><b> </b>N/A </text>
<text top="510" left="54" width="45" height="20" font="4"><b>PLATO </b></text>
<text top="528" left="54" width="87" height="20" font="5">Steg PG, et al., </text>
<text top="545" left="54" width="31" height="20" font="5">2010 </text>
<text top="562" left="54" width="25" height="20" font="5">(24) </text>
<text top="579" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21060072">21060072</a></text>
<text top="579" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21060072"> </a></text>
<text top="596" left="54" width="3" height="20" font="5"> </text>
<text top="614" left="54" width="3" height="20" font="5"> </text>
<text top="510" left="163" width="119" height="20" font="4"><b>Aim:</b> To examine the </text>
<text top="528" left="163" width="119" height="20" font="5">efficacy and safety of </text>
<text top="545" left="163" width="112" height="20" font="5">ticagrelor compared </text>
<text top="562" left="163" width="146" height="20" font="5">with clopidogrel in pts with </text>
<text top="579" left="163" width="125" height="20" font="5">STE-ACS intended for </text>
<text top="597" left="163" width="135" height="20" font="5">reperfusion with primary </text>
<text top="614" left="163" width="27" height="20" font="5">PCI. </text>
<text top="631" left="163" width="3" height="20" font="5"> </text>
<text top="648" left="163" width="145" height="20" font="4"><b>Study type:</b> Pre specified </text>
<text top="665" left="163" width="116" height="20" font="5">subgroup analysis of </text>
<text top="683" left="163" width="79" height="20" font="5">PLATO;  RCT </text>
<text top="700" left="163" width="3" height="20" font="5"> </text>
<text top="717" left="163" width="86" height="20" font="4"><b>Size:</b> 7,544 pts </text>
<text top="510" left="325" width="174" height="20" font="4"><b>Inclusion criteria:</b> Pts enrolled </text>
<text top="528" left="325" width="123" height="20" font="5">in PLATO with STEMI </text>
<text top="545" left="325" width="3" height="20" font="5"> </text>
<text top="562" left="325" width="162" height="20" font="4"><b>Exclusion criteria:</b> Same as </text>
<text top="579" left="325" width="76" height="20" font="5">PLATO study </text>
<text top="510" left="514" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="528" left="514" width="58" height="20" font="5">Ticagrelor </text>
<text top="545" left="514" width="7" height="20" font="5">  </text>
<text top="562" left="514" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="579" left="514" width="66" height="20" font="5">Clopidogrel<b> </b></text>
<text top="512" left="656" width="201" height="20" font="4"><b>1</b>°<b> endpoint:</b>  MACE (CV death, MI, </text>
<text top="529" left="656" width="33" height="20" font="5">CVA) </text>
<text top="548" left="656" width="7" height="18" font="5">•</text>
<text top="547" left="663" width="197" height="20" font="5"> 9.4% with ticagrelor vs. 10.8% with </text>
<text top="567" left="656" width="200" height="20" font="5">clopdiogrel;  (HR: 0.87; 95% CI: 0.75</text>
<text top="567" left="856" width="7" height="19" font="8">–</text>
<text top="584" left="656" width="76" height="20" font="5">1.01; p=0.07) </text>
<text top="602" left="656" width="3" height="20" font="5"> </text>
<text top="619" left="656" width="191" height="20" font="4"><b>Safety endpoint: </b>major bleeding   </text>
<text top="638" left="656" width="7" height="18" font="5">•</text>
<text top="637" left="663" width="206" height="20" font="5"> No difference in major bleeding (HR: </text>
<text top="654" left="656" width="80" height="20" font="5">0.98; p=0.76). </text>
<text top="672" left="656" width="3" height="20" font="5"> </text>
<text top="689" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="512" left="892" width="7" height="18" font="5">•</text>
<text top="512" left="899" width="192" height="20" font="5"> 72% of pts with STEMI underwent </text>
<text top="529" left="892" width="68" height="20" font="5">primary PCI </text>
<text top="548" left="892" width="7" height="18" font="5">•</text>
<text top="547" left="899" width="175" height="20" font="5"> Definite stent thrombosis lower </text>
<text top="564" left="892" width="188" height="20" font="5">with ticagrelor (HR: 0.66; p=0.03). </text>
<text top="584" left="892" width="7" height="18" font="5">•</text>
<text top="583" left="899" width="144" height="20" font="5"> Risk of stroke higher with </text>
<text top="600" left="892" width="199" height="20" font="5">ticagrelor (1.7% vs. 1.0%; HR: 1.63; </text>
<text top="617" left="892" width="158" height="20" font="5">95% CI: 1.07–2.48; p=0.02). </text>
<text top="634" left="892" width="3" height="20" font="5"> </text>
<text top="652" left="892" width="3" height="20" font="5"> </text>
<text top="669" left="892" width="3" height="20" font="5"> </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="10" size="12" family="Times" color="#565656"/>
<text top="789" left="1117" width="20" height="21" font="0">12 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="95" height="20" font="4"><b>TRITON-TIMI 38 </b></text>
<text top="70" left="54" width="87" height="20" font="5">Montalescot, et </text>
<text top="87" left="54" width="20" height="20" font="5">al., </text>
<text top="104" left="54" width="31" height="20" font="5">2009 </text>
<text top="122" left="54" width="25" height="20" font="5">(25) </text>
<text top="139" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19249633">19249633</a></text>
<text top="139" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19249633"> </a></text>
<text top="156" left="54" width="3" height="20" font="5"> </text>
<text top="53" left="163" width="139" height="20" font="4"><b>Aim:</b> To asses prasugrel </text>
<text top="70" left="163" width="115" height="20" font="5">vs. clopidogrel in pts </text>
<text top="87" left="163" width="148" height="20" font="5">undergoing PCI for STEMI </text>
<text top="104" left="163" width="138" height="20" font="5">enrolled in TRITON-TIMI </text>
<text top="122" left="163" width="17" height="20" font="5">38 </text>
<text top="139" left="163" width="3" height="20" font="5"> </text>
<text top="156" left="163" width="143" height="20" font="4"><b>Study type:</b> Double-blind </text>
<text top="173" left="163" width="29" height="20" font="5">RCT </text>
<text top="190" left="163" width="3" height="20" font="5"> </text>
<text top="208" left="163" width="86" height="20" font="4"><b>Size:</b> 3,534 pts </text>
<text top="53" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="70" left="325" width="148" height="20" font="5">undergoing PCI for STEMI </text>
<text top="87" left="325" width="3" height="20" font="5"> </text>
<text top="104" left="325" width="167" height="20" font="4"><b>Exclusion criteria:</b> Increased </text>
<text top="122" left="325" width="174" height="20" font="5">risk of bleeding, anemia, recent </text>
<text top="139" left="325" width="172" height="20" font="5">fibrinolytic administration, need </text>
<text top="156" left="325" width="95" height="20" font="5">from chronic oral </text>
<text top="173" left="325" width="152" height="20" font="5">anticoagulants, cardiogenic </text>
<text top="190" left="325" width="133" height="20" font="5">shock, or thienopyridine </text>
<text top="208" left="325" width="124" height="20" font="5">treatment within 5 d of </text>
<text top="225" left="325" width="87" height="20" font="5">randomization.  </text>
<text top="53" left="514" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="70" left="514" width="116" height="20" font="5">Prasugrel (n=1,769)  </text>
<text top="87" left="514" width="7" height="20" font="5">  </text>
<text top="104" left="514" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="122" left="514" width="122" height="20" font="5">Clopidogrel (n=1,765)<b> </b></text>
<text top="54" left="656" width="202" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV death, nonfatal MI, </text>
<text top="71" left="656" width="142" height="20" font="5">nonfatal stroke at 15 mo.  </text>
<text top="90" left="656" width="7" height="18" font="5">•</text>
<text top="90" left="663" width="204" height="20" font="5"> 10.0% with prasugrel vs. 12.4% with </text>
<text top="107" left="656" width="198" height="20" font="5">clopidogrel (HR: 0.79; 95% CI: 0.65-</text>
<text top="124" left="656" width="90" height="20" font="5">0.97; p=0.0221) </text>
<text top="141" left="656" width="3" height="20" font="5"> </text>
<text top="158" left="656" width="107" height="20" font="4"><b>Safety endpoint:</b>   </text>
<text top="177" left="656" width="7" height="18" font="5">•</text>
<text top="177" left="663" width="207" height="20" font="5"> No significant different in non–CABG </text>
<text top="194" left="656" width="209" height="20" font="5">related TIMI major bleeding at 30 d or </text>
<text top="211" left="656" width="38" height="20" font="5">15 mo </text>
<text top="55" left="892" width="7" height="18" font="5">•</text>
<text top="54" left="899" width="188" height="20" font="5"> Secondary endpoint of CV death, </text>
<text top="71" left="892" width="152" height="20" font="5">nonfatal MI or target vessel </text>
<text top="88" left="892" width="194" height="20" font="5">revascularization at 30 d 6.5% with </text>
<text top="106" left="892" width="194" height="20" font="5">prasugrel vs. 9.5% with clopidogrel </text>
<text top="123" left="892" width="168" height="20" font="5">(HR: 0.75; 95% CI: 0.59–0.96; </text>
<text top="140" left="892" width="59" height="20" font="5">p=0.0205) </text>
<text top="157" left="892" width="3" height="20" font="5"> </text>
<text top="174" left="892" width="3" height="20" font="5"> </text>
<text top="246" left="54" width="49" height="20" font="4"><b>TRITON </b></text>
<text top="263" left="54" width="78" height="20" font="5">Wiviott SD, et </text>
<text top="280" left="54" width="20" height="20" font="5">al., </text>
<text top="298" left="54" width="31" height="20" font="5">2007 </text>
<text top="315" left="54" width="25" height="20" font="5">(26) </text>
<text top="332" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17982182">17982182</a></text>
<text top="332" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17982182"> </a></text>
<text top="246" left="163" width="100" height="20" font="4"><b>Aim:</b> To compare </text>
<text top="263" left="163" width="143" height="20" font="5">prasugrel with clopidogrel </text>
<text top="280" left="163" width="146" height="20" font="5">in pts with ACS scheduled </text>
<text top="298" left="163" width="42" height="20" font="5">for PCI </text>
<text top="315" left="163" width="3" height="20" font="5"> </text>
<text top="332" left="163" width="144" height="20" font="4"><b>Study type:</b> RCT, double-</text>
<text top="349" left="163" width="118" height="20" font="5">blind, double-dummy </text>
<text top="366" left="163" width="40" height="20" font="5">design </text>
<text top="384" left="163" width="3" height="20" font="5"> </text>
<text top="401" left="163" width="93" height="20" font="4"><b>Size:</b> 13,608 pts </text>
<text top="246" left="325" width="138" height="20" font="4"><b>Inclusion criteria:</b>  ACS </text>
<text top="263" left="325" width="149" height="20" font="5">(NSTE-ACS or STEMI) pts </text>
<text top="280" left="325" width="136" height="20" font="5">undergoing planned PCI </text>
<text top="298" left="325" width="3" height="20" font="5"> </text>
<text top="315" left="325" width="171" height="20" font="4"><b>Exclusion criteria:</b>  Increased </text>
<text top="332" left="325" width="137" height="20" font="5">risk of bleeding, anemia, </text>
<text top="349" left="325" width="101" height="20" font="5">thrombocytopenia </text>
<text top="246" left="514" width="85" height="20" font="4"><b>Intervention:</b>   </text>
<text top="263" left="514" width="121" height="20" font="5">Prasugrel (10 mg qD) </text>
<text top="280" left="514" width="56" height="20" font="5">(n=6,813) </text>
<text top="298" left="514" width="7" height="20" font="5">  </text>
<text top="315" left="514" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="332" left="514" width="107" height="20" font="5">Clopidogrel (75 mg </text>
<text top="349" left="514" width="83" height="20" font="5">qD) (n=6,795)<b>  </b></text>
<text top="247" left="656" width="183" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV death, MI, CVA </text>
<text top="266" left="656" width="7" height="18" font="5">•</text>
<text top="265" left="663" width="198" height="20" font="5"> 9.9% with prasugrel vs. 12.1% with </text>
<text top="283" left="656" width="203" height="20" font="5">clopidogrel (HR: 0.81; CI: 0.73–0.90; </text>
<text top="300" left="656" width="52" height="20" font="5">p&lt;0.001) </text>
<text top="317" left="656" width="3" height="20" font="5"> </text>
<text top="335" left="656" width="187" height="20" font="4"><b>1</b>°<b>  Safety endpoint: </b>Non–CABG </text>
<text top="353" left="656" width="153" height="20" font="5">related TIMI major bleeding<b> </b></text>
<text top="372" left="656" width="7" height="18" font="5">•</text>
<text top="371" left="663" width="191" height="20" font="5"> 2.4% with prasugrel vs. 1.8% with </text>
<text top="388" left="656" width="200" height="20" font="5">clopidogrel (HR: 1.32; 95% CI: 1.03–</text>
<text top="405" left="656" width="76" height="20" font="5">1.68, p=0.03) </text>
<text top="423" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="248" left="892" width="7" height="18" font="5">•</text>
<text top="247" left="899" width="182" height="20" font="5"> Stent thrombosis rate lower with </text>
<text top="264" left="892" width="197" height="20" font="5">prasugrel (1.1% vs. 2.4%, p=0.001) </text>
<text top="283" left="892" width="7" height="18" font="5">•</text>
<text top="283" left="899" width="180" height="20" font="5"> Life-threatening bleeding higher </text>
<text top="300" left="892" width="169" height="20" font="5">with prasugrel (1.4% vs. 0.9%, </text>
<text top="317" left="892" width="46" height="20" font="5">p=0.01) </text>
<text top="336" left="892" width="7" height="18" font="5">•</text>
<text top="336" left="899" width="147" height="20" font="5"> Fatal bleeding higher with </text>
<text top="353" left="892" width="197" height="20" font="5">prasugrel (0.4% vs. 0.1%, p=0.002) </text>
<text top="372" left="892" width="7" height="18" font="5">•</text>
<text top="371" left="899" width="170" height="20" font="5"> Increased rate of ICH in those </text>
<text top="388" left="892" width="179" height="20" font="5">treated with prasugrel with Hx of </text>
<text top="405" left="892" width="66" height="20" font="5">CVA or TIA </text>
<text top="425" left="892" width="7" height="18" font="5">•</text>
<text top="424" left="899" width="193" height="20" font="5"> Increased risk of bleeding in those </text>
<text top="441" left="892" width="195" height="20" font="5">with Hx CVA or TIA, elderly (≥75 y) </text>
<text top="458" left="892" width="134" height="20" font="5">and body weight &lt;60 kg </text>
<text top="476" left="54" width="70" height="20" font="4"><b>CHARISMA </b></text>
<text top="493" left="54" width="88" height="20" font="5">Bhatt DL, et al., </text>
<text top="511" left="54" width="65" height="20" font="5">2006, 2007 </text>
<text top="528" left="54" width="42" height="20" font="5">(27,28) </text>
<text top="545" left="54" width="48" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17498584?">7498584</a></text>
<text top="545" left="102" width="3" height="20" font="10"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17498584?"> </a></text>
<text top="562" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16531616">16531616</a></text>
<text top="562" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16531616"> </a></text>
<text top="476" left="163" width="121" height="20" font="4"><b>Aim:</b> Assess effect of </text>
<text top="493" left="163" width="94" height="20" font="5">DAPT in a broad </text>
<text top="511" left="163" width="134" height="20" font="5">population of pts at high </text>
<text top="528" left="163" width="136" height="20" font="5">risk for atherothrombotic </text>
<text top="545" left="163" width="40" height="20" font="5">events </text>
<text top="562" left="163" width="3" height="20" font="5"> </text>
<text top="579" left="163" width="149" height="20" font="4"><b>Study type:</b> RCT, placebo </text>
<text top="597" left="163" width="57" height="20" font="5">controlled </text>
<text top="614" left="163" width="3" height="20" font="5"> </text>
<text top="631" left="163" width="93" height="20" font="4"><b>Size:</b> 15,603 pts </text>
<text top="476" left="325" width="157" height="20" font="4"><b>Inclusion criteria:</b> Age ≥45 </text>
<text top="493" left="325" width="167" height="20" font="5">with multiple atherothrombotic </text>
<text top="511" left="325" width="172" height="20" font="5">risk factors and/or documented </text>
<text top="528" left="325" width="173" height="20" font="5">CAD, cerebrovascular disease, </text>
<text top="545" left="325" width="43" height="20" font="5">or PAD </text>
<text top="562" left="325" width="3" height="20" font="5"> </text>
<text top="579" left="325" width="169" height="20" font="4"><b>Exclusion criteria:</b> Long-term </text>
<text top="597" left="325" width="141" height="20" font="5">use of oral antithrombotic </text>
<text top="614" left="325" width="165" height="20" font="5">medications of NSAID, recent </text>
<text top="631" left="325" width="29" height="20" font="5">ACS </text>
<text top="476" left="514" width="117" height="20" font="4"><b>Intervention:</b> ASA + </text>
<text top="493" left="514" width="119" height="20" font="5">clopidogrel (n=7,802) </text>
<text top="511" left="514" width="7" height="20" font="5">  </text>
<text top="528" left="514" width="116" height="20" font="4"><b>Comparator:</b> ASA + </text>
<text top="545" left="514" width="110" height="20" font="5">placebo (n=7,801)<b>   </b></text>
<text top="477" left="656" width="194" height="20" font="4"><b>1</b>°<b> endpoint: </b>CV death, MI or CVA </text>
<text top="494" left="656" width="142" height="20" font="5">(median follow-up 28 mo) </text>
<text top="514" left="656" width="7" height="18" font="5">•</text>
<text top="513" left="663" width="206" height="20" font="5"> 6.8% with ASA+clopidogrel vs. 7.4% </text>
<text top="530" left="656" width="210" height="20" font="5">with ASA+placebo (RR: 0.93; 95% CI: </text>
<text top="547" left="656" width="107" height="20" font="5">0.83–1.05; p=0.22) </text>
<text top="564" left="656" width="3" height="20" font="5"> </text>
<text top="583" left="656" width="210" height="20" font="4"><b>1</b>°<b>  Safety endpoint:</b>  GUSTO severe </text>
<text top="600" left="656" width="50" height="20" font="5">bleeding </text>
<text top="619" left="656" width="7" height="18" font="5">•</text>
<text top="619" left="663" width="206" height="20" font="5"> 1.7% with ASA+clopidogrel vs. 1.3% </text>
<text top="636" left="656" width="210" height="20" font="5">with ASA+placebo (RR: 1.25; 95% CI: </text>
<text top="653" left="656" width="107" height="20" font="5">0.97–1.61; p=0.09) </text>
<text top="478" left="892" width="7" height="18" font="5">•</text>
<text top="477" left="899" width="194" height="20" font="5"> In a post hoc subgroup analysis of </text>
<text top="494" left="892" width="199" height="20" font="5">those with Hx of prior MI, composite </text>
<text top="512" left="892" width="192" height="20" font="5">endpoint of CV death, MI and CVA </text>
<text top="529" left="892" width="198" height="20" font="5">occurred in 8.3% of placebo-treated </text>
<text top="546" left="892" width="194" height="20" font="5">pts and 6.6% of clopidogrel-treated </text>
<text top="563" left="892" width="171" height="20" font="5">pts (HR: 0.774; 95% CI: 0.613–</text>
<text top="581" left="892" width="90" height="20" font="5">0.978; p=0.031) </text>
<text top="598" left="892" width="3" height="20" font="5"> </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">13 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="94" height="20" font="4"><b>COMMIT-CCS 2 </b></text>
<text top="70" left="54" width="94" height="20" font="5">Chen ZM, et al.,  </text>
<text top="87" left="54" width="31" height="20" font="5">2005 </text>
<text top="104" left="54" width="25" height="20" font="5">(29) </text>
<text top="122" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16271642">16271642</a></text>
<text top="122" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16271642"> </a></text>
<text top="139" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="156" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="53" left="163" width="128" height="20" font="4"><b>Aim:</b> To compare ASA </text>
<text top="70" left="163" width="149" height="20" font="5">alone to ASA + clopidogrel </text>
<text top="87" left="163" width="99" height="20" font="5">in pts with STEMI<b> </b></text>
<text top="104" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="122" left="163" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="139" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="156" left="163" width="93" height="20" font="4"><b>Size: </b>45,852 pts<b> </b></text>
<text top="53" left="325" width="152" height="20" font="4"><b>Inclusion criteria:</b> Pts with </text>
<text top="70" left="325" width="141" height="20" font="5">suspected MI within 24 H<b> </b></text>
<text top="87" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="104" left="325" width="131" height="20" font="4"><b>Exclusion criteria:</b> Pts </text>
<text top="122" left="325" width="164" height="20" font="5">undergoing primary PCI, high-</text>
<text top="139" left="325" width="175" height="20" font="5">risk of adverse event with study </text>
<text top="156" left="325" width="62" height="20" font="5">treatments<b> </b></text>
<text top="53" left="514" width="120" height="20" font="4"><b>Intervention:  </b>ASA + </text>
<text top="70" left="514" width="63" height="20" font="5">clopidogrel </text>
<text top="87" left="514" width="7" height="20" font="4"><b>  </b></text>
<text top="104" left="514" width="109" height="20" font="4"><b>Comparator:  </b>ASA </text>
<text top="122" left="514" width="47" height="20" font="5">alone    <b> </b></text>
<text top="54" left="656" width="209" height="20" font="4"><b>Co-1</b>°<b> endpoints (during scheduled </b></text>
<text top="71" left="656" width="190" height="20" font="4"><b>treatment – discharge or d 28):</b>   </text>
<text top="90" left="656" width="7" height="18" font="5">•</text>
<text top="90" left="663" width="192" height="20" font="5"> MACE (death, reinfarction, CVA):  </text>
<text top="107" left="656" width="204" height="20" font="5">9.2% with DAPT vs. 10.1% with ASA </text>
<text top="124" left="656" width="221" height="20" font="5">(RRR: 9%; 95% CI: 3%–14%; p=0.002)  </text>
<text top="143" left="656" width="7" height="18" font="5">•</text>
<text top="142" left="663" width="215" height="20" font="5"> Death:  7.5% with DAPT vs. 8.1% with </text>
<text top="159" left="656" width="194" height="20" font="5">ASA (RRR: 7%; 95% CI: 1%–13%; </text>
<text top="177" left="656" width="46" height="20" font="5">p=0.03) </text>
<text top="194" left="656" width="3" height="20" font="5"> </text>
<text top="211" left="656" width="192" height="20" font="4"><b>Safety endpoint:  </b>Life-threatening </text>
<text top="228" left="656" width="57" height="20" font="5">bleeding   </text>
<text top="247" left="656" width="7" height="18" font="5">•</text>
<text top="247" left="663" width="214" height="20" font="5"> 0.58% with DAPT vs. 0.55% with ASA </text>
<text top="264" left="656" width="49" height="20" font="5">(p=0.59)<b> </b></text>
<text top="55" left="892" width="7" height="18" font="5">•</text>
<text top="54" left="899" width="182" height="20" font="4"><b> </b>87% with ST elevation;  6% with </text>
<text top="71" left="892" width="191" height="20" font="5">bundle branch block;  and 7% with </text>
<text top="88" left="892" width="83" height="20" font="5">ST depression<b> </b></text>
<text top="106" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="123" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="140" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="282" left="54" width="81" height="20" font="4"><b>PCI-CLARITY </b></text>
<text top="299" left="54" width="91" height="20" font="5">Sabatine MS, et </text>
<text top="316" left="54" width="20" height="20" font="5">al., </text>
<text top="334" left="54" width="31" height="20" font="5">2005 </text>
<text top="351" left="54" width="25" height="20" font="5">(30) </text>
<text top="368" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16143698">16143698</a></text>
<text top="368" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16143698"> </a></text>
<text top="385" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="402" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="282" left="163" width="104" height="20" font="4"><b>Aim:  </b>Determine if </text>
<text top="299" left="163" width="136" height="20" font="5">clopidogrel pretreatment </text>
<text top="316" left="163" width="120" height="20" font="5">before PCI in pts with </text>
<text top="334" left="163" width="139" height="20" font="5">recent STEMI is superior </text>
<text top="351" left="163" width="132" height="20" font="5">to clopidogrel treatment </text>
<text top="368" left="163" width="144" height="20" font="5">initiated at the time of PCI </text>
<text top="385" left="163" width="113" height="20" font="5">in preventing MACE </text>
<text top="402" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="420" left="163" width="106" height="20" font="4"><b>Study type: </b>RCT;  </text>
<text top="437" left="163" width="124" height="20" font="5">prespecified subgroup </text>
<text top="454" left="163" width="94" height="20" font="5">analysis of pts in </text>
<text top="471" left="163" width="127" height="20" font="5">CLARITY-TIMI 28 who </text>
<text top="489" left="163" width="95" height="20" font="5">underwent PCI<b>    </b></text>
<text top="506" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="523" left="163" width="86" height="20" font="4"><b>Size: </b>1,863 pts<b> </b></text>
<text top="282" left="325" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="299" left="325" width="175" height="20" font="5">receiving fibrinolytics for STEMI </text>
<text top="316" left="325" width="132" height="20" font="5">undergoing subsequent </text>
<text top="334" left="325" width="166" height="20" font="5">angiography and PCI enrolled </text>
<text top="351" left="325" width="68" height="20" font="5">in CLARITY<b> </b></text>
<text top="368" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="385" left="325" width="158" height="20" font="4"><b>Exclusion criteria: </b>Planned </text>
<text top="402" left="325" width="168" height="20" font="5">treatment with clopidogrel or a </text>
<text top="420" left="325" width="137" height="20" font="5">GPI before angiography, </text>
<text top="437" left="325" width="172" height="20" font="5">cardiogenic shock, prior CABG<b> </b></text>
<text top="282" left="514" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="299" left="514" width="65" height="20" font="5">Clopidogrel </text>
<text top="316" left="514" width="70" height="20" font="5">pretreament<b> </b></text>
<text top="334" left="514" width="7" height="20" font="4"><b>  </b></text>
<text top="351" left="514" width="81" height="20" font="4"><b>Comparator:  </b></text>
<text top="368" left="514" width="98" height="20" font="5">Standard therapy </text>
<text top="385" left="514" width="128" height="20" font="5">(clopidogrel at the time </text>
<text top="402" left="514" width="55" height="20" font="5">of PCI)<b>     </b></text>
<text top="283" left="656" width="159" height="20" font="4"><b>1</b>°<b> endpoint:</b>  MACE at 30 d </text>
<text top="302" left="656" width="7" height="18" font="5">•</text>
<text top="301" left="663" width="209" height="20" font="5"> 3.6% with pretreatment vs. 6.2% with </text>
<text top="319" left="656" width="212" height="20" font="5">standard Rx; (adjusted OR=0.54; 95% </text>
<text top="336" left="656" width="133" height="20" font="5">CI: 0.35–0.85; p=0.008) </text>
<text top="353" left="656" width="3" height="20" font="5"> </text>
<text top="370" left="656" width="3" height="20" font="5"> </text>
<text top="388" left="656" width="214" height="20" font="4"><b>Safety endpoint:</b>  TIMI major or minor </text>
<text top="405" left="656" width="50" height="20" font="5">bleeding </text>
<text top="424" left="656" width="7" height="18" font="5">•</text>
<text top="423" left="663" width="209" height="20" font="5"> 2.0% with pretreatment vs. 1.9% with </text>
<text top="440" left="656" width="119" height="20" font="5">standard Rx (p&gt;0.99) </text>
<text top="458" left="656" width="3" height="20" font="5"> </text>
<text top="475" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="284" left="892" width="7" height="18" font="5">•</text>
<text top="283" left="899" width="192" height="20" font="4"><b> </b>Pretreatment with clopidogrel also </text>
<text top="300" left="892" width="169" height="20" font="5">reduced the incidence of MI or </text>
<text top="317" left="892" width="192" height="20" font="5">stroke prior to PCI (4.0% vs. 6.2%; </text>
<text top="335" left="892" width="168" height="20" font="5">OR: 0.62; 95% CI: 0.40–0.95;  </text>
<text top="352" left="892" width="46" height="20" font="5">p=0.03)<b> </b></text>
<text top="369" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="386" left="892" width="3" height="20" font="5"> </text>
<text top="541" left="54" width="91" height="20" font="5">Sabatine MS, et </text>
<text top="558" left="54" width="20" height="20" font="5">al., </text>
<text top="575" left="54" width="34" height="20" font="5">2005  </text>
<text top="593" left="54" width="25" height="20" font="5">(31) </text>
<text top="610" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15758000">15758000</a></text>
<text top="610" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15758000"> </a></text>
<text top="627" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="541" left="163" width="144" height="20" font="4"><b>Aim:</b> To assess benefit of </text>
<text top="558" left="163" width="137" height="20" font="5">addition of clopidogrel to </text>
<text top="575" left="163" width="127" height="20" font="5">ASA in pts with STEMI </text>
<text top="593" left="163" width="125" height="20" font="5">treated with fibrinolytic </text>
<text top="610" left="163" width="44" height="20" font="5">therapy<b> </b></text>
<text top="627" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="644" left="163" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="661" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="679" left="163" width="86" height="20" font="4"><b>Size: </b>3,491 pts<b> </b></text>
<text top="541" left="325" width="152" height="20" font="4"><b>Inclusion criteria:</b> Pts with </text>
<text top="558" left="325" width="141" height="20" font="5">STEMI being treated with </text>
<text top="575" left="325" width="155" height="20" font="5">fibrinolytic therapy and ASA<b> </b></text>
<text top="593" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="610" left="325" width="151" height="20" font="4"><b>Exclusion criteria:</b>  recent </text>
<text top="627" left="325" width="161" height="20" font="5">clopidogrel treatment or GPI, </text>
<text top="644" left="325" width="133" height="20" font="5">planned performance of </text>
<text top="661" left="325" width="165" height="20" font="5">angiography within 48 h, prior </text>
<text top="679" left="325" width="144" height="20" font="5">CABG, cardiogenic shock<b> </b></text>
<text top="541" left="514" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="558" left="514" width="104" height="20" font="5">Clopidogrel + ASA </text>
<text top="575" left="514" width="7" height="20" font="4"><b>  </b></text>
<text top="593" left="514" width="101" height="20" font="4"><b>Comparator:        </b></text>
<text top="610" left="514" width="87" height="20" font="5">Placebo + ASA<b> </b></text>
<text top="542" left="656" width="208" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Composite of occluded </text>
<text top="559" left="656" width="216" height="20" font="5">infarct-related artery (TIMI flow grade 0 </text>
<text top="577" left="656" width="177" height="20" font="5">or1) at angiography, or death or </text>
<text top="594" left="656" width="179" height="20" font="5">recurrent MI before angiography </text>
<text top="613" left="656" width="7" height="18" font="5">•</text>
<text top="612" left="663" width="214" height="20" font="5"> 15.0% with DAPT vs. 21.7% with ASA </text>
<text top="629" left="656" width="215" height="20" font="5">(absolute reduction 6.7%;  RRR: 36%;  </text>
<text top="646" left="656" width="162" height="20" font="5">95% CI: 24%–47%; p&lt;0.001) </text>
<text top="664" left="656" width="3" height="20" font="5"> </text>
<text top="681" left="656" width="3" height="20" font="5"> </text>
<text top="698" left="656" width="226" height="20" font="4"><b>Safety endpoint: TIMI major bleeding</b>   </text>
<text top="717" left="656" width="7" height="18" font="5">•</text>
<text top="717" left="663" width="200" height="20" font="5"> 1.3% with DAPT vs. 1.1% with ASA </text>
<text top="734" left="656" width="49" height="20" font="5">(p=0.64) </text>
<text top="543" left="892" width="7" height="18" font="5">•</text>
<text top="542" left="899" width="193" height="20" font="5"> At 30 d, DAPT reduced composite </text>
<text top="559" left="892" width="192" height="20" font="5">endpoint of CV death, recurrent MI </text>
<text top="577" left="892" width="176" height="20" font="5">or recurrent ischemia leading to </text>
<text top="594" left="892" width="188" height="20" font="5">urgent TVR by 20% (from 14.1% –</text>
<text top="611" left="892" width="87" height="20" font="5">11.6%; p=0.03) </text>
<text top="630" left="892" width="7" height="18" font="5">•</text>
<text top="629" left="899" width="187" height="20" font="5"> Angiography performed 48-192 h </text>
<text top="646" left="892" width="143" height="20" font="5">after the start of the study </text>
<text top="664" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="681" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="698" left="892" width="3" height="20" font="4"><b> </b></text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">14 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="38" height="20" font="4"><b>CURE </b></text>
<text top="70" left="54" width="84" height="20" font="5">Fox KA, et al.,  </text>
<text top="87" left="54" width="31" height="20" font="5">2004 </text>
<text top="104" left="54" width="25" height="20" font="5">(32) </text>
<text top="122" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15313956">15313956</a></text>
<text top="122" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15313956"> </a></text>
<text top="139" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="53" left="163" width="137" height="20" font="4"><b>Aim:</b> To assess benefits </text>
<text top="70" left="163" width="120" height="20" font="5">and risks of ASA plus </text>
<text top="87" left="163" width="96" height="20" font="5">clopidogrel in pts </text>
<text top="104" left="163" width="121" height="20" font="5">undergoing CABG for </text>
<text top="122" left="163" width="66" height="20" font="5">NSTE-ACS </text>
<text top="139" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="156" left="163" width="122" height="20" font="4"><b>Study type: </b>Post hoc </text>
<text top="173" left="163" width="116" height="20" font="5">subgroup analysis of </text>
<text top="190" left="163" width="77" height="20" font="5">CURE;<b>  </b>RCT  </text>
<text top="208" left="163" width="10" height="20" font="4"><b>   </b></text>
<text top="225" left="163" width="127" height="20" font="4"><b>Size: </b>12,562 pts entire </text>
<text top="242" left="163" width="134" height="20" font="5">study population;  1,061 </text>
<text top="259" left="163" width="126" height="20" font="5">pts underwent CABG<b>   </b></text>
<text top="53" left="325" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="70" left="325" width="138" height="20" font="5">NSTE-ACS within &lt;24 h  </text>
<text top="87" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="104" left="325" width="117" height="20" font="4"><b>Exclusion criteria:   </b></text>
<text top="122" left="325" width="146" height="20" font="5">NYHA class IV HF, PCI or </text>
<text top="139" left="325" width="172" height="20" font="5">CABG &lt;3 mo,  contraindication </text>
<text top="156" left="325" width="107" height="20" font="5">to antiplatelets and </text>
<text top="173" left="325" width="162" height="20" font="5">antithrombotics, hemorrhagic </text>
<text top="190" left="325" width="111" height="20" font="5">or IC stroke, severe </text>
<text top="208" left="325" width="101" height="20" font="5">thrombocytopenia </text>
<text top="225" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="53" left="514" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="70" left="514" width="108" height="20" font="5">Clopidogrel + ASA  </text>
<text top="87" left="514" width="3" height="20" font="4"><b> </b></text>
<text top="104" left="514" width="7" height="20" font="4"><b>  </b></text>
<text top="122" left="514" width="91" height="20" font="4"><b>Comparator:     </b></text>
<text top="139" left="514" width="90" height="20" font="5">Placebo + ASA <b> </b></text>
<text top="54" left="656" width="212" height="20" font="4"><b>1</b>°<b> endpoint:  MACE (</b>CV death, MI or </text>
<text top="71" left="656" width="41" height="20" font="5">stroke) </text>
<text top="90" left="656" width="7" height="18" font="5">•</text>
<text top="90" left="663" width="189" height="20" font="4"><b> </b>14.5% with DAPT  vs. 16.2% with </text>
<text top="107" left="656" width="197" height="20" font="5">ASA (RR: 0.89; 95% CI: 0.71–1.11) </text>
<text top="124" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="141" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="55" left="892" width="7" height="18" font="5">•</text>
<text top="54" left="899" width="195" height="20" font="4"><b> </b>Benefits of DAPT with CABG were </text>
<text top="71" left="892" width="160" height="20" font="5">deemed “consistent” (test for </text>
<text top="88" left="892" width="192" height="20" font="5">interaction among strata 0.53) with </text>
<text top="106" left="892" width="189" height="20" font="5">the benefits in pts undergoing PCI </text>
<text top="123" left="892" width="180" height="20" font="5">(9.6% with DAPT vs. 13.2% with </text>
<text top="140" left="892" width="196" height="20" font="5">ASA; RR: 0.72; 95% CI: 0.47–0.90) </text>
<text top="157" left="892" width="183" height="20" font="5">and in those treated with medical </text>
<text top="174" left="892" width="194" height="20" font="5">therapy alone (8.1% with DAPT vs. </text>
<text top="192" left="892" width="201" height="20" font="5">10.0% with ASA; RR: 0.80;  95% CI: </text>
<text top="209" left="892" width="62" height="20" font="5">0.69–0.92) </text>
<text top="226" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="243" left="892" width="3" height="20" font="4"><b> </b></text>
<text top="260" left="892" width="3" height="20" font="5"> </text>
<text top="278" left="54" width="38" height="20" font="4"><b>CURE </b></text>
<text top="296" left="54" width="38" height="20" font="5">CURE </text>
<text top="313" left="54" width="77" height="20" font="5">Investigators, </text>
<text top="330" left="54" width="31" height="20" font="5">2001 </text>
<text top="347" left="54" width="25" height="20" font="5">(33) </text>
<text top="364" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11519503">11519503</a></text>
<text top="364" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11519503"> </a></text>
<text top="278" left="163" width="130" height="20" font="4"><b>Aim:</b> Compare efficacy </text>
<text top="296" left="163" width="143" height="20" font="5">and safety of DAPT in pts </text>
<text top="313" left="163" width="143" height="20" font="5">with NSTE-ACS treated 3-</text>
<text top="330" left="163" width="38" height="20" font="5">12 mo </text>
<text top="347" left="163" width="3" height="20" font="5"> </text>
<text top="364" left="163" width="77" height="20" font="4"><b>Study type:</b>   </text>
<text top="382" left="163" width="117" height="20" font="5">Randomized, double-</text>
<text top="399" left="163" width="136" height="20" font="5">blind, placebo controlled </text>
<text top="416" left="163" width="23" height="20" font="5">trial </text>
<text top="433" left="163" width="3" height="20" font="5"> </text>
<text top="451" left="163" width="93" height="20" font="4"><b>Size:</b> 12,562 pts </text>
<text top="278" left="325" width="152" height="20" font="4"><b>Inclusion criteria:</b> Pts with </text>
<text top="296" left="325" width="169" height="20" font="5">NSTE-ACS hospitalized within </text>
<text top="313" left="325" width="128" height="20" font="5">24 h of symptom onset </text>
<text top="330" left="325" width="3" height="20" font="5"> </text>
<text top="347" left="325" width="158" height="20" font="4"><b>Exclusion criteria:</b>  STEMI, </text>
<text top="364" left="325" width="126" height="20" font="5">high bleeding risk, oral </text>
<text top="382" left="325" width="100" height="20" font="5">anticoagulant use </text>
<text top="278" left="514" width="120" height="20" font="4"><b>Intervention:</b>  ASA + </text>
<text top="296" left="514" width="107" height="20" font="5">clopidogrel (DAPT) </text>
<text top="313" left="514" width="56" height="20" font="5">(n=6,259) </text>
<text top="330" left="514" width="7" height="20" font="5">  </text>
<text top="347" left="514" width="116" height="20" font="4"><b>Comparator:</b> ASA + </text>
<text top="364" left="514" width="103" height="20" font="5">placebo (n=6,303)<b> </b></text>
<text top="280" left="656" width="197" height="20" font="4"><b>1</b>°<b> endpoint:</b>  CV death, MI or CVA </text>
<text top="299" left="656" width="7" height="18" font="5">•</text>
<text top="298" left="663" width="207" height="20" font="5"> 9.3% with DAPT vs. 11.4% with ASA </text>
<text top="315" left="656" width="202" height="20" font="5">alone (RR: 0.80; 95% CI: 0.72–0.90; </text>
<text top="332" left="656" width="46" height="20" font="5">p&lt;0.01) </text>
<text top="350" left="656" width="3" height="20" font="5"> </text>
<text top="368" left="656" width="207" height="20" font="4"><b>1</b>°<b>  Safety endpoint:</b>  Major bleeding </text>
<text top="387" left="656" width="7" height="18" font="5">•</text>
<text top="386" left="663" width="200" height="20" font="5"> 3.7% with DAPT vs. 2.7% with ASA </text>
<text top="404" left="656" width="145" height="20" font="5">alone (RR: 1.38; p=0.001) </text>
<text top="421" left="656" width="3" height="20" font="5"> </text>
<text top="438" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="280" left="892" width="7" height="18" font="5">•</text>
<text top="280" left="899" width="190" height="20" font="5"> Mean duration of treatment was 9 </text>
<text top="297" left="892" width="21" height="20" font="5">mo </text>
<text top="316" left="892" width="7" height="18" font="5">•</text>
<text top="315" left="899" width="187" height="20" font="5"> Results comparable in those with </text>
<text top="332" left="892" width="134" height="20" font="5">and without a Dx of “MI” </text>
<text top="350" left="892" width="3" height="20" font="5"> </text>
<text top="469" left="54" width="63" height="20" font="4"><b>PCI-CURE </b></text>
<text top="486" left="54" width="95" height="20" font="5">Mehta SR, et al., </text>
<text top="503" left="54" width="31" height="20" font="5">2001 </text>
<text top="520" left="54" width="25" height="20" font="5">(34) </text>
<text top="537" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11520521">11520521</a></text>
<text top="537" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11520521"> </a></text>
<text top="469" left="163" width="137" height="20" font="4"><b>Aim:</b> To assess whether </text>
<text top="486" left="163" width="98" height="20" font="5">pretreatment with </text>
<text top="503" left="163" width="128" height="20" font="5">clopidogrel followed by </text>
<text top="520" left="163" width="138" height="20" font="5">long-term Rx after PCI is </text>
<text top="537" left="163" width="79" height="20" font="5">superior to no </text>
<text top="555" left="163" width="144" height="20" font="5">pretreatment and 4 wk Rx </text>
<text top="572" left="163" width="3" height="20" font="5"> </text>
<text top="589" left="163" width="133" height="20" font="4"><b>Study type:</b> Analysis of </text>
<text top="606" left="163" width="130" height="20" font="5">those pts in CURE who </text>
<text top="623" left="163" width="121" height="20" font="5">were treated with PCI </text>
<text top="641" left="163" width="3" height="20" font="5"> </text>
<text top="658" left="163" width="86" height="20" font="4"><b>Size:</b> 2,658 pts </text>
<text top="469" left="325" width="174" height="20" font="4"><b>Inclusion criteria:</b> Pts enrolled </text>
<text top="486" left="325" width="140" height="20" font="5">in CURE undergoing PCI </text>
<text top="503" left="325" width="3" height="20" font="5"> </text>
<text top="520" left="325" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="469" left="514" width="120" height="20" font="4"><b>Intervention:</b>  ASA + </text>
<text top="486" left="514" width="107" height="20" font="5">clopidogrel (DAPT) </text>
<text top="503" left="514" width="56" height="20" font="5">(n=1,313) </text>
<text top="520" left="514" width="7" height="20" font="5">  </text>
<text top="537" left="514" width="116" height="20" font="4"><b>Comparator:</b> ASA + </text>
<text top="555" left="514" width="103" height="20" font="5">placebo (n=1,345)<b> </b></text>
<text top="470" left="656" width="207" height="20" font="4"><b>1</b>°<b> endpoint:</b>  CV death, MI or urgent </text>
<text top="487" left="656" width="128" height="20" font="5">TVR within 30 d of PCI </text>
<text top="506" left="656" width="7" height="18" font="5">•</text>
<text top="505" left="663" width="206" height="20" font="5"> 4.5% with ASA+clopidogrel vs. 6.4% </text>
<text top="523" left="656" width="210" height="20" font="5">with ASA+placebo (RR: 0.70; 95% CI: </text>
<text top="540" left="656" width="107" height="20" font="5">0.50–0.97; p=0.03) </text>
<text top="557" left="656" width="3" height="20" font="5"> </text>
<text top="574" left="656" width="3" height="20" font="4"><b> </b></text>
<text top="470" left="892" width="7" height="18" font="5">•</text>
<text top="470" left="899" width="188" height="20" font="5"> CV death or MI rate between PCI </text>
<text top="487" left="892" width="178" height="20" font="5">and end of follow-up:  6.0% with </text>
<text top="504" left="892" width="171" height="20" font="5">ASA+clopidogrel vs. 8.0% with </text>
<text top="521" left="892" width="185" height="20" font="5">ASA+placebo (RR: 0.75; 95% CI: </text>
<text top="539" left="892" width="114" height="20" font="5">0.56–1.00; p=0.047) </text>
<text top="556" left="892" width="3" height="20" font="5"> </text>
<text top="573" left="892" width="3" height="20" font="5"> </text>
<text top="676" left="54" width="1054" height="20" font="5">ACS indicates acute coronary syndrome; ASA, aspirin; bid, two times per day; BMS, bare metal stent; CABG, coronary artery bypass graft; CAD, coronary artery disease; CI, confidence interval; </text>
<text top="695" left="54" width="1051" height="20" font="5">CNS, central nervous system; CVA, cerebrovascular accident; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; Dx, diagnosis; GI; gastrointestinal; GPI, glycoprotein </text>
<text top="715" left="54" width="1055" height="20" font="5">inhibitor; HR, hazard ratio; Hx, history; ICH, intracerebral hemorrhage;  MACE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; NSTE-ACS, non–ST-elevation acute </text>
<text top="735" left="54" width="1058" height="20" font="5">coronary syndrome; NSAID, nonsteroidal anti-inflammatory drug; NYHA, New York Heart Association; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RCT, randomized </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="11" size="14" family="Times" color="#000000"/>
<text top="789" left="1117" width="20" height="21" font="0">15 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="52" left="54" width="1053" height="20" font="5">controlled trial; RR, relative risk; Rx, prescription;  TIA, transient ischemic attack; TIMI, Thrombolysis In Myocardial Infarction; SIHD, stable ischemic heart disease; STE-ACS, ST-elevation acute </text>
<text top="72" left="54" width="577" height="20" font="5">coronary syndrome; STEMI, ST-elevation myocardial infarction; and TVR, target-vessel revascularization. </text>
<text top="97" left="54" width="5" height="15" font="11"><b> </b></text>
<text top="128" left="54" width="906" height="24" font="2"><b>Data Supplement 5. RCTs and RCT Subgroup Analyses Comparing Clopidogel With Prasugrel or Ticagrelor In Patients With ACS </b></text>
<text top="157" left="55" width="94" height="20" font="4"><b>Study Acronym </b></text>
<text top="175" left="78" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="192" left="56" width="96" height="20" font="4"><b>Year Published  </b></text>
<text top="157" left="186" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="175" left="191" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="192" left="185" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="157" left="331" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="157" left="496" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="175" left="514" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="192" left="496" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="209" left="517" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="157" left="685" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="175" left="669" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="192" left="671" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="209" left="713" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="159" left="884" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="176" left="918" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="193" left="879" width="147" height="20" font="4"><b>               Adverse Events </b></text>
<text top="227" left="54" width="58" height="20" font="4"><b>TRILOGY </b></text>
<text top="244" left="54" width="90" height="20" font="5">Row MT, et al.,  </text>
<text top="262" left="54" width="31" height="20" font="5">2012 </text>
<text top="279" left="54" width="25" height="20" font="5">(22) </text>
<text top="296" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22920930">22920930</a></text>
<text top="296" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22920930"> </a></text>
<text top="313" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="227" left="163" width="100" height="20" font="4"><b>Aim:</b> To compare </text>
<text top="244" left="163" width="80" height="20" font="5">prasugrel with </text>
<text top="262" left="163" width="121" height="20" font="5">clopidogrel in pts with </text>
<text top="279" left="163" width="86" height="20" font="5">NSTE-ACS not </text>
<text top="296" left="163" width="65" height="20" font="5">undergoing </text>
<text top="313" left="163" width="96" height="20" font="5">revascularization<b> </b></text>
<text top="330" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="348" left="163" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="365" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="382" left="163" width="86" height="20" font="4"><b>Size: </b>7,243 pts<b> </b></text>
<text top="227" left="305" width="152" height="20" font="4"><b>Inclusion criteria: </b>Pts with </text>
<text top="244" left="305" width="132" height="20" font="5">NSTE-ACS selected for </text>
<text top="262" left="305" width="121" height="20" font="5">medical management </text>
<text top="279" left="305" width="138" height="20" font="5">without revascularization<b> </b></text>
<text top="296" left="305" width="3" height="20" font="4"><b> </b></text>
<text top="313" left="305" width="157" height="20" font="4"><b>Exclusion criteria:</b> Hx CVA </text>
<text top="330" left="305" width="152" height="20" font="5">or TIA, PCI or CABG within </text>
<text top="348" left="305" width="127" height="20" font="5">prior 30 d, renal failure </text>
<text top="365" left="305" width="98" height="20" font="5">requiring dialysis, </text>
<text top="382" left="305" width="94" height="20" font="5">concomitant oral </text>
<text top="399" left="305" width="142" height="20" font="5">anticoagulation treatment<b> </b></text>
<text top="227" left="481" width="134" height="20" font="4"><b>Intervention: </b>Prasugrel </text>
<text top="244" left="481" width="7" height="20" font="4"><b>  </b></text>
<text top="262" left="481" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="279" left="481" width="66" height="20" font="5">Clopidogrel<b> </b></text>
<text top="228" left="636" width="194" height="20" font="4"><b>1</b>°<b> endpoint:</b> MACE (CV death, MI </text>
<text top="245" left="636" width="165" height="20" font="5">or CVA) in pts &lt;75 y at 30 mo </text>
<text top="265" left="636" width="7" height="18" font="5">•</text>
<text top="264" left="643" width="176" height="20" font="5">13.9% with prasugrel vs. 16.0% </text>
<text top="281" left="636" width="195" height="20" font="5">with clopidogrel (HR: 0.91; 95% CI: </text>
<text top="298" left="636" width="107" height="20" font="5">0.79–1.05; p=0.21) </text>
<text top="316" left="636" width="3" height="20" font="5"> </text>
<text top="333" left="636" width="191" height="20" font="4"><b>Safety endpoint): </b>GUSTO severe </text>
<text top="350" left="636" width="156" height="20" font="5">or life-threatening bleeding   </text>
<text top="369" left="636" width="7" height="18" font="5">•</text>
<text top="368" left="643" width="191" height="20" font="5"> 0.9% with prasugrel vs. 0.6% with </text>
<text top="386" left="636" width="169" height="20" font="5">clopidogrel (HR: 0.94; 95% CI: </text>
<text top="403" left="636" width="111" height="20" font="5">0.44–1.99; p=0.87) <b> </b></text>
<text top="229" left="852" width="7" height="18" font="5">•</text>
<text top="228" left="859" width="135" height="20" font="4"><b> </b>All pts treated with ASA </text>
<text top="245" left="852" width="3" height="20" font="4"><b> </b></text>
<text top="263" left="852" width="3" height="20" font="4"><b> </b></text>
<text top="280" left="852" width="3" height="20" font="4"><b> </b></text>
<text top="297" left="852" width="3" height="20" font="5"> </text>
<text top="421" left="54" width="45" height="20" font="4"><b>PLATO </b></text>
<text top="438" left="54" width="96" height="20" font="5">James SK, et al., </text>
<text top="455" left="54" width="31" height="20" font="5">2011 </text>
<text top="472" left="54" width="25" height="20" font="5">(23) </text>
<text top="490" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21685437">21685437</a></text>
<text top="490" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21685437"> </a></text>
<text top="507" left="54" width="3" height="20" font="5"> </text>
<text top="524" left="54" width="3" height="20" font="5"> </text>
<text top="421" left="163" width="98" height="20" font="4"><b>Aim:</b> To evaluate </text>
<text top="438" left="163" width="105" height="20" font="5">efficacy and safety </text>
<text top="455" left="163" width="102" height="20" font="5">outcomes in pts in </text>
<text top="472" left="163" width="83" height="20" font="5">PLATO who at </text>
<text top="490" left="163" width="111" height="20" font="5">randomization were </text>
<text top="507" left="163" width="75" height="20" font="5">planned for a </text>
<text top="524" left="163" width="124" height="20" font="5">noninvasive treatment </text>
<text top="541" left="163" width="51" height="20" font="5">strategy. </text>
<text top="559" left="163" width="3" height="20" font="5"> </text>
<text top="576" left="163" width="74" height="20" font="4"><b>Study type:</b>  </text>
<text top="593" left="163" width="126" height="20" font="5">Prespecified subgroup </text>
<text top="610" left="163" width="126" height="20" font="5">analysis of the PLATO </text>
<text top="627" left="163" width="29" height="20" font="5">RCT </text>
<text top="645" left="163" width="3" height="20" font="5"> </text>
<text top="662" left="163" width="86" height="20" font="4"><b>Size:</b> 5,216 pts </text>
<text top="421" left="305" width="152" height="20" font="4"><b>Inclusion criteria: </b>Pts with </text>
<text top="438" left="305" width="139" height="20" font="5">ACS admitted to hospital </text>
<text top="455" left="305" width="141" height="20" font="5">with planned noninvasive </text>
<text top="472" left="305" width="79" height="20" font="5">management  </text>
<text top="490" left="305" width="3" height="20" font="5"> </text>
<text top="507" left="305" width="144" height="20" font="4"><b>Exclusion criteria:</b> Pts in </text>
<text top="524" left="305" width="116" height="20" font="5">PLATO with planned </text>
<text top="541" left="305" width="123" height="20" font="5">invasive management </text>
<text top="559" left="305" width="3" height="20" font="5"> </text>
<text top="576" left="305" width="3" height="20" font="5"> </text>
<text top="593" left="305" width="3" height="20" font="5"> </text>
<text top="610" left="305" width="3" height="20" font="5"> </text>
<text top="627" left="305" width="3" height="20" font="5"> </text>
<text top="645" left="305" width="3" height="20" font="5"> </text>
<text top="662" left="359" width="3" height="20" font="5"> </text>
<text top="421" left="481" width="136" height="20" font="4"><b>Intervention:</b> Ticagrelor </text>
<text top="438" left="481" width="66" height="20" font="5">(90 mg bid) </text>
<text top="455" left="481" width="7" height="20" font="5">  </text>
<text top="472" left="481" width="87" height="20" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="490" left="481" width="130" height="20" font="5">Clopidogrel (75 mg qD)<b> </b></text>
<text top="422" left="636" width="196" height="20" font="4"><b>1</b>°<b> endpoint: </b>Vascular death, MI or </text>
<text top="439" left="636" width="35" height="20" font="5">CVA   </text>
<text top="458" left="636" width="7" height="18" font="5">•</text>
<text top="458" left="643" width="193" height="20" font="5"> 12.0% with ticagrelor compared to </text>
<text top="475" left="636" width="189" height="20" font="5">14.3% with clopidogrel  (HR: 0.85; </text>
<text top="492" left="636" width="154" height="20" font="5">95% CI: 0.73–1.00; p=0.04) </text>
<text top="509" left="636" width="3" height="20" font="5"> </text>
<text top="526" left="636" width="96" height="20" font="4"><b>Safety endpoint:</b></text>
<text top="526" left="732" width="7" height="21" font="0">  </text>
<text top="546" left="636" width="7" height="18" font="5">•</text>
<text top="545" left="643" width="190" height="20" font="5"> Total major bleeding: (11.9% with </text>
<text top="562" left="636" width="200" height="20" font="5">ticagrelor vs. 10.3% with clopidogrel </text>
<text top="579" left="636" width="168" height="20" font="5">(HR: 1.17; 95% CI: 0.98–1.39; </text>
<text top="596" left="636" width="46" height="20" font="5">p=0.08) </text>
<text top="616" left="636" width="7" height="18" font="5">•</text>
<text top="615" left="643" width="190" height="20" font="5"> Non–CABG major bleeding: 4.0% </text>
<text top="632" left="636" width="155" height="20" font="5">with ticagrelor vs. 3.1% with </text>
<text top="649" left="636" width="169" height="20" font="5">clopidogrel (HR: 1.30, 95% CI: </text>
<text top="666" left="636" width="111" height="20" font="5">0.95–1.77; p=0.10)  </text>
<text top="684" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="423" left="852" width="7" height="18" font="5">•</text>
<text top="422" left="859" width="27" height="20" font="4"><b> </b>N/A </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">16 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="45" height="20" font="4"><b>PLATO </b></text>
<text top="70" left="54" width="87" height="20" font="5">Steg PG, et al., </text>
<text top="87" left="54" width="31" height="20" font="5">2010 </text>
<text top="104" left="54" width="25" height="20" font="5">(24) </text>
<text top="122" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21060072">21060072</a></text>
<text top="122" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21060072"> </a></text>
<text top="139" left="54" width="3" height="20" font="5"> </text>
<text top="156" left="54" width="3" height="20" font="5"> </text>
<text top="53" left="163" width="119" height="20" font="4"><b>Aim:</b> To examine the </text>
<text top="70" left="163" width="119" height="20" font="5">efficacy and safety of </text>
<text top="87" left="163" width="112" height="20" font="5">ticagrelor compared </text>
<text top="104" left="163" width="121" height="20" font="5">with clopidogrel in pts </text>
<text top="122" left="163" width="82" height="20" font="5">with STE-ACS </text>
<text top="139" left="163" width="68" height="20" font="5">intended for </text>
<text top="156" left="163" width="90" height="20" font="5">reperfusion with </text>
<text top="173" left="163" width="72" height="20" font="5">primary PCI. </text>
<text top="190" left="163" width="3" height="20" font="5"> </text>
<text top="208" left="163" width="77" height="20" font="4"><b>Study type:</b>   </text>
<text top="225" left="163" width="126" height="20" font="5">Prespecified subgroup </text>
<text top="242" left="163" width="112" height="20" font="5">analysis of PLATO;  </text>
<text top="259" left="163" width="29" height="20" font="5">RCT </text>
<text top="276" left="163" width="3" height="20" font="5"> </text>
<text top="294" left="163" width="90" height="20" font="4"><b>Size:</b>  7,544 pts </text>
<text top="53" left="305" width="131" height="20" font="4"><b>Inclusion criteria:</b>  Pts </text>
<text top="70" left="305" width="129" height="20" font="5">enrolled in PLATO with </text>
<text top="87" left="305" width="41" height="20" font="5">STEMI </text>
<text top="104" left="305" width="3" height="20" font="5"> </text>
<text top="122" left="305" width="162" height="20" font="4"><b>Exclusion criteria:</b> Same as </text>
<text top="139" left="305" width="76" height="20" font="5">PLATO study </text>
<text top="53" left="481" width="136" height="20" font="4"><b>Intervention:</b> Ticagrelor </text>
<text top="70" left="481" width="7" height="20" font="5">  </text>
<text top="87" left="481" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="104" left="481" width="66" height="20" font="5">Clopidogrel<b> </b></text>
<text top="54" left="636" width="201" height="20" font="4"><b>1</b>°<b> endpoint:</b>  MACE (CV death, MI, </text>
<text top="71" left="636" width="33" height="20" font="5">CVA) </text>
<text top="90" left="636" width="7" height="18" font="5">•</text>
<text top="90" left="643" width="193" height="20" font="5">9.4% with ticagrelor vs. 10.8% with </text>
<text top="107" left="636" width="172" height="20" font="5">clopdiogrel;  HR: 0.87; 95% CI: </text>
<text top="124" left="636" width="103" height="20" font="5">0.75–1.01; p=0.07 </text>
<text top="141" left="636" width="3" height="20" font="5"> </text>
<text top="158" left="636" width="3" height="20" font="5"> </text>
<text top="175" left="636" width="198" height="20" font="4"><b>Safety endpoint: major bleeding</b>   </text>
<text top="195" left="636" width="7" height="18" font="5">•</text>
<text top="194" left="643" width="177" height="20" font="5"> No difference in major bleeding </text>
<text top="211" left="636" width="108" height="20" font="5">(HR: 0.98; p=0.76). </text>
<text top="228" left="636" width="3" height="20" font="5"> </text>
<text top="246" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="55" left="852" width="7" height="18" font="5">•</text>
<text top="54" left="859" width="237" height="20" font="5"> 72% of pts with STEMI underwent primary </text>
<text top="71" left="852" width="24" height="20" font="5">PCI </text>
<text top="90" left="852" width="7" height="18" font="5">•</text>
<text top="90" left="859" width="200" height="20" font="5"> Definite stent thrombosis lower with </text>
<text top="107" left="852" width="162" height="20" font="5">ticagrelor (HR: 0.66; p=0.03). </text>
<text top="126" left="852" width="7" height="18" font="5">•</text>
<text top="125" left="859" width="234" height="20" font="5"> Risk of stroke higher with ticagrelor (1.7% </text>
<text top="142" left="852" width="218" height="20" font="5">vs. 1.0%; HR: 1.63; 95% CI: 1.07–2.48; </text>
<text top="159" left="852" width="49" height="20" font="5">p=0.02). </text>
<text top="177" left="852" width="3" height="20" font="5"> </text>
<text top="194" left="852" width="3" height="20" font="5"> </text>
<text top="211" left="852" width="3" height="20" font="5"> </text>
<text top="312" left="54" width="45" height="20" font="4"><b>PLATO </b></text>
<text top="329" left="54" width="81" height="20" font="5">Wallentin L, et </text>
<text top="346" left="54" width="20" height="20" font="5">al.,<b> </b></text>
<text top="363" left="54" width="31" height="20" font="5">2009 </text>
<text top="381" left="54" width="25" height="20" font="5">(35) </text>
<text top="398" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19717846">19717846</a></text>
<text top="398" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19717846"> </a></text>
<text top="312" left="163" width="100" height="20" font="4"><b>Aim:</b> To compare </text>
<text top="329" left="163" width="78" height="20" font="5">ticagrelor and </text>
<text top="346" left="163" width="121" height="20" font="5">clopidogrel in pts with </text>
<text top="363" left="163" width="29" height="20" font="5">ACS </text>
<text top="380" left="163" width="3" height="20" font="5"> </text>
<text top="398" left="163" width="103" height="20" font="4"><b>Study type:</b> RCT, </text>
<text top="415" left="163" width="115" height="20" font="5">double-blind, double-</text>
<text top="432" left="163" width="83" height="20" font="5">dummy design </text>
<text top="449" left="163" width="3" height="20" font="5"> </text>
<text top="467" left="163" width="93" height="20" font="4"><b>Size:</b> 18,624 pts </text>
<text top="312" left="305" width="138" height="20" font="4"><b>Inclusion criteria:</b>  ACS </text>
<text top="329" left="305" width="147" height="20" font="5">with symptom onset within </text>
<text top="346" left="305" width="27" height="20" font="5">24 h </text>
<text top="363" left="305" width="3" height="20" font="5"> </text>
<text top="380" left="305" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="398" left="305" width="158" height="20" font="5">Fibrinolytic therapy within 24 </text>
<text top="415" left="305" width="162" height="20" font="5">h, oral anticoagulant therapy, </text>
<text top="432" left="305" width="93" height="20" font="5">increased risk of </text>
<text top="449" left="305" width="141" height="20" font="5">bradycardia, concomitant </text>
<text top="467" left="305" width="118" height="20" font="5">therapy with a strong </text>
<text top="484" left="305" width="121" height="20" font="5">cytochrome P-450 3A </text>
<text top="501" left="305" width="105" height="20" font="5">inhibitor or inducer </text>
<text top="312" left="481" width="85" height="20" font="4"><b>Intervention:</b>   </text>
<text top="329" left="481" width="124" height="20" font="5">Ticagrelor (90 mg bid) </text>
<text top="346" left="481" width="56" height="20" font="5">(n=9,333) </text>
<text top="363" left="481" width="7" height="20" font="5">  </text>
<text top="380" left="481" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="398" left="481" width="131" height="20" font="5">Clopidogrel (75 mg qD) </text>
<text top="415" left="481" width="70" height="20" font="5">(n=9,291)  <b>   </b></text>
<text top="313" left="636" width="200" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Vascular death, MI or </text>
<text top="330" left="636" width="29" height="20" font="5">CVA </text>
<text top="349" left="636" width="7" height="18" font="5">•</text>
<text top="348" left="643" width="172" height="20" font="5"> 9.8% with ticagrelor vs. 11.7% </text>
<text top="366" left="636" width="195" height="20" font="5">with clopidogrel (HR: 0.84; 95% CI: </text>
<text top="383" left="636" width="110" height="20" font="5">0.77–0.92; p&lt;0.001 </text>
<text top="400" left="636" width="3" height="20" font="5"> </text>
<text top="418" left="636" width="191" height="20" font="4"><b>1</b>°<b>  Safety endpoint: </b>Trial-defined </text>
<text top="436" left="636" width="84" height="20" font="5">major bleeding<b> </b></text>
<text top="454" left="636" width="188" height="20" font="5"> • 11.6% with ticagrelor vs. 11.2% </text>
<text top="471" left="636" width="138" height="20" font="5">with clopidogrel (p=0.43) </text>
<text top="489" left="636" width="7" height="20" font="5">  </text>
<text top="506" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="314" left="852" width="7" height="18" font="5">•</text>
<text top="313" left="859" width="136" height="20" font="5"> All pts treated with ASA </text>
<text top="332" left="852" width="7" height="18" font="5">•</text>
<text top="331" left="859" width="204" height="20" font="5"> Study included both NSTE-ACS and </text>
<text top="348" left="852" width="225" height="20" font="5">STEMI pts, with treatment either med Rx </text>
<text top="366" left="852" width="215" height="20" font="5">alone or med Rx plus revascularization </text>
<text top="385" left="852" width="7" height="18" font="5">•</text>
<text top="384" left="859" width="225" height="20" font="5"> Ticagrelor associated with higher rate of </text>
<text top="401" left="852" width="211" height="20" font="5">non–CABG related bleeding (4.5% vs. </text>
<text top="418" left="852" width="76" height="20" font="5">3.8%, p=0.03 </text>
<text top="438" left="852" width="7" height="18" font="5">•</text>
<text top="437" left="859" width="236" height="20" font="5"> Stent thrombosis rate lower with ticagrelor </text>
<text top="454" left="852" width="223" height="20" font="5">(1.3% vs. 1.9%, HR: 0.67; 95% CI: 0.50–</text>
<text top="471" left="852" width="83" height="20" font="5">0.91; p=0.009) </text>
<text top="489" left="852" width="3" height="20" font="5"> </text>
<text top="506" left="852" width="3" height="20" font="5"> </text>
<text top="528" left="54" width="95" height="20" font="4"><b>TRITON-TIMI 38 </b></text>
<text top="545" left="54" width="87" height="20" font="5">Montalescot, et </text>
<text top="562" left="54" width="20" height="20" font="5">al., </text>
<text top="579" left="54" width="31" height="20" font="5">2009 </text>
<text top="597" left="54" width="25" height="20" font="5">(25) </text>
<text top="614" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19249633">19249633</a></text>
<text top="614" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19249633"> </a></text>
<text top="631" left="54" width="3" height="20" font="5"> </text>
<text top="528" left="163" width="84" height="20" font="4"><b>Aim:</b> To asses </text>
<text top="545" left="163" width="74" height="20" font="5">prasugrel vs. </text>
<text top="562" left="163" width="96" height="20" font="5">clopidogrel in pts </text>
<text top="579" left="163" width="107" height="20" font="5">undergoing PCI for </text>
<text top="597" left="163" width="101" height="20" font="5">STEMI enrolled in </text>
<text top="614" left="163" width="95" height="20" font="5">TRITON-TIMI 38 </text>
<text top="631" left="163" width="3" height="20" font="5"> </text>
<text top="648" left="163" width="114" height="20" font="4"><b>Study type:</b> Double-</text>
<text top="665" left="163" width="58" height="20" font="5">blind RCT </text>
<text top="683" left="163" width="3" height="20" font="5"> </text>
<text top="700" left="163" width="86" height="20" font="4"><b>Size:</b> 3,534 pts </text>
<text top="528" left="305" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="545" left="305" width="148" height="20" font="5">undergoing PCI for STEMI </text>
<text top="562" left="305" width="3" height="20" font="5"> </text>
<text top="579" left="305" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="596" left="305" width="147" height="20" font="5">Increased risk of bleeding, </text>
<text top="614" left="305" width="143" height="20" font="5">anemia, recent fibrinolytic </text>
<text top="631" left="305" width="142" height="20" font="5">administration, need from </text>
<text top="648" left="305" width="153" height="20" font="5">chronic oral anticoagulants, </text>
<text top="665" left="305" width="120" height="20" font="5">cardiogenic shock, or </text>
<text top="683" left="305" width="135" height="20" font="5">thienopyridine treatment </text>
<text top="700" left="305" width="157" height="20" font="5">within 5 d of randomization.  </text>
<text top="528" left="481" width="134" height="20" font="4"><b>Intervention:</b> Prasugrel </text>
<text top="545" left="481" width="60" height="20" font="5">(n=1,769)  </text>
<text top="562" left="481" width="7" height="20" font="5">  </text>
<text top="579" left="481" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="596" left="481" width="122" height="20" font="5">Clopidogrel (n=1,765)<b> </b></text>
<text top="529" left="636" width="202" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV death, nonfatal MI, </text>
<text top="546" left="636" width="142" height="20" font="5">nonfatal stroke at 15 mo.  </text>
<text top="565" left="636" width="11" height="18" font="5">• </text>
<text top="564" left="645" width="175" height="20" font="5">10.0% with prasugrel vs. 12.4% </text>
<text top="582" left="645" width="176" height="20" font="5">with clopidogrel (HR: 0.79; 95% </text>
<text top="599" left="645" width="140" height="20" font="5">CI: 0.65–0.97; p=0.0221) </text>
<text top="616" left="636" width="3" height="20" font="5"> </text>
<text top="633" left="636" width="107" height="20" font="4"><b>Safety endpoint:</b>   </text>
<text top="652" left="636" width="7" height="18" font="5">•</text>
<text top="652" left="643" width="169" height="20" font="5"> No significant different in non–</text>
<text top="669" left="636" width="192" height="20" font="5">CABG related TIMI major bleeding </text>
<text top="686" left="636" width="93" height="20" font="5">at 30 d or 15 mo<b> </b></text>
<text top="530" left="852" width="7" height="18" font="5">•</text>
<text top="529" left="859" width="235" height="20" font="5"> Secondary endpoint of CV death, nonfatal </text>
<text top="546" left="852" width="231" height="20" font="5">MI or TVR at 30 d 6.5% with prasugrel vs. </text>
<text top="563" left="852" width="226" height="20" font="5">9.5% with clopidogrel (HR: 0.75; 95% CI: </text>
<text top="580" left="852" width="121" height="20" font="5">0.59–0.96; p=0.0205) </text>
<text top="598" left="852" width="3" height="20" font="5"> </text>
<text top="615" left="852" width="3" height="20" font="5"> </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">17 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="49" height="20" font="4"><b>TRITON </b></text>
<text top="70" left="54" width="78" height="20" font="5">Wiviott SD, et </text>
<text top="87" left="54" width="20" height="20" font="5">al., </text>
<text top="104" left="54" width="31" height="20" font="5">2007 </text>
<text top="122" left="54" width="25" height="20" font="5">(26) </text>
<text top="139" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17982182">17982182</a></text>
<text top="139" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17982182"> </a></text>
<text top="53" left="163" width="100" height="20" font="4"><b>Aim:</b> To compare </text>
<text top="70" left="163" width="80" height="20" font="5">prasugrel with </text>
<text top="87" left="163" width="121" height="20" font="5">clopidogrel in pts with </text>
<text top="104" left="163" width="106" height="20" font="5">ACS scheduled for </text>
<text top="122" left="163" width="24" height="20" font="5">PCI </text>
<text top="139" left="163" width="3" height="20" font="5"> </text>
<text top="156" left="163" width="103" height="20" font="4"><b>Study type:</b> RCT, </text>
<text top="173" left="163" width="115" height="20" font="5">double-blind, double-</text>
<text top="190" left="163" width="83" height="20" font="5">dummy design </text>
<text top="208" left="163" width="3" height="20" font="5"> </text>
<text top="225" left="163" width="93" height="20" font="4"><b>Size:</b> 13,608 pts </text>
<text top="53" left="305" width="138" height="20" font="4"><b>Inclusion criteria:</b>  ACS </text>
<text top="70" left="305" width="149" height="20" font="5">(NSTE-ACS or STEMI) pts </text>
<text top="87" left="305" width="136" height="20" font="5">undergoing planned PCI </text>
<text top="104" left="305" width="3" height="20" font="5"> </text>
<text top="122" left="305" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="139" left="305" width="147" height="20" font="5">Increased risk of bleeding, </text>
<text top="156" left="305" width="148" height="20" font="5">anemia, thrombocytopenia </text>
<text top="53" left="481" width="141" height="20" font="4"><b>Intervention:</b>   Prasugrel </text>
<text top="70" left="481" width="121" height="20" font="5">(10 mg qD) (n=6,813) </text>
<text top="87" left="481" width="7" height="20" font="5">  </text>
<text top="104" left="481" width="81" height="20" font="4"><b>Comparator:</b>  </text>
<text top="122" left="481" width="131" height="20" font="5">Clopidogrel (75 mg qD) </text>
<text top="139" left="481" width="60" height="20" font="5">(n=6,795)<b>  </b></text>
<text top="54" left="636" width="183" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV death, MI, CVA </text>
<text top="73" left="636" width="7" height="18" font="5">•</text>
<text top="72" left="643" width="172" height="20" font="5"> 9.9% with prasugrel vs. 12.1% </text>
<text top="89" left="636" width="195" height="20" font="5">with clopidogrel (HR: 0.81; 95% CI: </text>
<text top="107" left="636" width="114" height="20" font="5">0.73–0.90; p&lt;0.001) </text>
<text top="124" left="636" width="3" height="20" font="5"> </text>
<text top="142" left="636" width="187" height="20" font="4"><b>1</b>°<b>  Safety endpoint: </b>Non–CABG </text>
<text top="159" left="636" width="153" height="20" font="5">related TIMI major bleeding<b> </b></text>
<text top="179" left="636" width="7" height="18" font="5">•</text>
<text top="178" left="643" width="191" height="20" font="5"> 2.4% with prasugrel vs. 1.8% with </text>
<text top="195" left="636" width="203" height="20" font="5">clopidogrel (HR: 1.32; CI: 1.03–1.68; </text>
<text top="212" left="636" width="46" height="20" font="5">p=0.03) </text>
<text top="229" left="636" width="3" height="20" font="5"> </text>
<text top="247" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="55" left="852" width="7" height="18" font="5">•</text>
<text top="54" left="859" width="237" height="20" font="5"> Stent thrombosis rate lower with prasugrel </text>
<text top="71" left="852" width="142" height="20" font="5">(1.1% vs. 2.4%, p=0.001) </text>
<text top="90" left="852" width="7" height="18" font="5">•</text>
<text top="90" left="859" width="205" height="20" font="5"> Life-threatening bleeding higher with </text>
<text top="107" left="852" width="190" height="20" font="5">prasugrel (1.4% vs. 0.9%, p=0.01) </text>
<text top="126" left="852" width="7" height="18" font="5">•</text>
<text top="125" left="859" width="202" height="20" font="5"> Fatal bleeding higher with prasugrel </text>
<text top="142" left="852" width="142" height="20" font="5">(0.4% vs. 0.1%, p=0.002) </text>
<text top="161" left="852" width="7" height="18" font="5">•</text>
<text top="161" left="859" width="212" height="20" font="5"> Increased rate of ICH in those treated </text>
<text top="178" left="852" width="203" height="20" font="5">with prasugrel with Hx of CVA or TIA </text>
<text top="197" left="852" width="7" height="18" font="5">•</text>
<text top="196" left="859" width="219" height="20" font="5"> Increased risk of bleeding in those with </text>
<text top="213" left="852" width="224" height="20" font="5">Hx CVA or TIA, elderly (≥75 y) and body </text>
<text top="231" left="852" width="80" height="20" font="5">weight &lt;60 kg </text>
<text top="265" left="54" width="1083" height="20" font="5">ACS indicates acute coronary syndrome; ASA, aspirin; bid, two times per day; CABG, coronary artery bypass graft; CI, confidence interval; CVA, cerebrovascular accident; CV, cardiovascular; DAPT, </text>
<text top="282" left="54" width="1064" height="20" font="5">dual antiplatelet therapy; HR, hazard ratio; Hx, history; MACE; major adverse cardiac events; MI, myocardial infarction; NSTE-ACS, non–ST-elevation acute coronary syndrome; NSTEMI, non–ST-</text>
<text top="299" left="54" width="1058" height="20" font="5">elevation myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; RR, relative risk; Rx, prescription; TIA, transient ischemic attack; TIMI, Thrombolysis In </text>
<text top="316" left="54" width="793" height="20" font="5">Myocardial Infarction; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction;  and TVR, target-vessel revascularization. </text>
<text top="339" left="54" width="5" height="15" font="11"><b> </b></text>
<text top="373" left="54" width="899" height="24" font="2"><b>Data Supplement 6.  Studies and Comparisons of Short-Term or Chronic Aspirin Dose in Patients With Coronary Artery Disease </b></text>
<text top="402" left="84" width="38" height="20" font="4"><b>Study </b></text>
<text top="420" left="72" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="437" left="78" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="454" left="56" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="402" left="196" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="420" left="201" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="437" left="195" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="402" left="341" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="402" left="496" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="420" left="514" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="437" left="496" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="454" left="517" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="402" left="715" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="420" left="699" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="437" left="701" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="454" left="744" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="404" left="915" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="421" left="949" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="438" left="956" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="472" left="54" width="78" height="20" font="4"><b>TRANSLATE-</b></text>
<text top="489" left="54" width="29" height="20" font="4"><b>ACS </b></text>
<text top="506" left="54" width="77" height="20" font="5">Xian Y, et al., </text>
<text top="524" left="54" width="31" height="20" font="5">2015 </text>
<text top="541" left="54" width="25" height="20" font="5">(36) </text>
<text top="558" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25995313">25995313</a></text>
<text top="558" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25995313"> </a></text>
<text top="472" left="163" width="149" height="20" font="4"><b>Aim:</b> Compare outcome of </text>
<text top="489" left="163" width="138" height="20" font="5">pts in TRANSLATE-ACS </text>
<text top="506" left="163" width="124" height="20" font="5">treated with high-dose </text>
<text top="524" left="163" width="141" height="20" font="5">(325 mg) or low-dose (81 </text>
<text top="541" left="163" width="53" height="20" font="5">mg) ASA </text>
<text top="558" left="163" width="3" height="20" font="5"> </text>
<text top="575" left="163" width="133" height="20" font="4"><b>Study type:</b> Analysis of </text>
<text top="593" left="163" width="137" height="20" font="5">data in the TRANSLATE-</text>
<text top="610" left="163" width="138" height="20" font="5">ACS observational study </text>
<text top="627" left="163" width="3" height="20" font="5"> </text>
<text top="644" left="163" width="93" height="20" font="4"><b>Size:</b> 10,213 pts </text>
<text top="472" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="489" left="325" width="137" height="20" font="5">enrolled in TRANSLATE-</text>
<text top="506" left="325" width="29" height="20" font="5">ACS </text>
<text top="524" left="325" width="3" height="20" font="5"> </text>
<text top="541" left="325" width="131" height="20" font="4"><b>Exclusion criteria:</b> Pts </text>
<text top="558" left="325" width="140" height="20" font="5">died in-hospital, were not </text>
<text top="575" left="325" width="123" height="20" font="5">discharged on ASA or </text>
<text top="593" left="325" width="103" height="20" font="5">were missing ASA </text>
<text top="610" left="325" width="127" height="20" font="5">dosing information, did </text>
<text top="627" left="325" width="99" height="20" font="5">not undergo stent </text>
<text top="644" left="325" width="128" height="20" font="5">implantation, or did not </text>
<text top="661" left="325" width="106" height="20" font="5">complete follow-up </text>
<text top="472" left="481" width="136" height="20" font="4"><b>Intervention:</b> ASA dose </text>
<text top="489" left="481" width="96" height="20" font="5">(nonrandomized) </text>
<text top="506" left="481" width="7" height="20" font="5">  </text>
<text top="524" left="481" width="131" height="20" font="4"><b>Comparator:</b> Higher or </text>
<text top="541" left="481" width="94" height="20" font="5">lower ASA dose <b> </b></text>
<text top="473" left="636" width="118" height="20" font="4"><b>1</b>°<b> endpoint:</b> MACE  </text>
<text top="492" left="636" width="7" height="18" font="5">•</text>
<text top="492" left="643" width="241" height="20" font="5"> MACE not statistically significantly different </text>
<text top="509" left="636" width="146" height="20" font="5">between treatment groups </text>
<text top="528" left="636" width="7" height="18" font="5">•</text>
<text top="527" left="643" width="245" height="20" font="5"> 8.2% with high dose vs. 9.2% with low-dose </text>
<text top="544" left="636" width="222" height="20" font="5">(adjusted HR: 0.99; 95% CI: 0.85–1.17). </text>
<text top="562" left="636" width="3" height="20" font="5"> </text>
<text top="579" left="636" width="199" height="20" font="4"><b>Safety endpoint:</b>  bleeding (BARC) </text>
<text top="598" left="636" width="7" height="18" font="5">•</text>
<text top="597" left="643" width="241" height="20" font="5"> BARC (1-5) bleeding higher with high-dose </text>
<text top="614" left="636" width="236" height="20" font="5">ASA (unadjusted 24.2% with high-dose vs. </text>
<text top="632" left="636" width="260" height="20" font="5">22.7% with low-dose;  adjusted HR: 1.19;  95% </text>
<text top="649" left="636" width="78" height="20" font="5">CI:1.06–1.33) </text>
<text top="474" left="913" width="7" height="18" font="5">•</text>
<text top="473" left="919" width="167" height="20" font="5"> High-dose ASA was 325 mg;  </text>
<text top="490" left="913" width="144" height="20" font="5">low-dose ASA was 81 mg </text>
<text top="508" left="913" width="3" height="20" font="5"> </text>
<text top="525" left="913" width="3" height="20" font="5"> </text>
<text top="681" left="54" width="64" height="20" font="4"><b>CURRENT-</b></text>
<text top="698" left="54" width="52" height="20" font="4"><b>OASIS 7 </b></text>
<text top="716" left="54" width="95" height="20" font="5">Mehta SR, et al., </text>
<text top="733" left="54" width="31" height="20" font="5">2010 </text>
<text top="750" left="54" width="25" height="20" font="5">(37) </text>
<text top="767" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20817281">20817281</a></text>
<text top="767" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20817281"> </a></text>
<text top="681" left="163" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="698" left="163" width="119" height="20" font="5">efficacy and safety of </text>
<text top="716" left="163" width="141" height="20" font="5">standard vs. double-dose </text>
<text top="733" left="163" width="131" height="20" font="5">clopidogrel and of high- </text>
<text top="750" left="163" width="132" height="20" font="5">vs. low-dose ASA in pts </text>
<text top="767" left="163" width="146" height="20" font="5">with ACS undergoing PCI  </text>
<text top="681" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="698" left="325" width="113" height="20" font="5">with ACS (STEMI or </text>
<text top="716" left="325" width="137" height="20" font="5">non–STEMI) undergoing </text>
<text top="733" left="325" width="24" height="20" font="5">PCI </text>
<text top="750" left="325" width="3" height="20" font="5"> </text>
<text top="767" left="325" width="110" height="20" font="4"><b>Exclusion criteria: </b></text>
<text top="681" left="481" width="118" height="20" font="4"><b>Intervention 1: </b>High-</text>
<text top="698" left="481" width="139" height="20" font="5">dose ASA (300-325 mg)  </text>
<text top="716" left="481" width="7" height="20" font="5">  </text>
<text top="733" left="481" width="115" height="20" font="4"><b>Intervention 1: </b>Low-</text>
<text top="750" left="481" width="132" height="20" font="5">dose ASA (75-100 mg)  </text>
<text top="767" left="481" width="3" height="20" font="4"><b> </b></text>
<text top="683" left="636" width="247" height="20" font="4"><b>1</b>°<b> endpoint:</b> CV death, MI, or stroke at 30 d </text>
<text top="702" left="636" width="7" height="18" font="5">•</text>
<text top="701" left="643" width="244" height="20" font="5"> 4.1% with high-dose ASA vs. 4.2% with low-</text>
<text top="718" left="636" width="226" height="20" font="5">dose ASA (HR: 0.98; 95% CI: 0.84–1.13; </text>
<text top="735" left="636" width="46" height="20" font="5">p=0.76) </text>
<text top="752" left="636" width="3" height="20" font="5"> </text>
<text top="770" left="636" width="187" height="20" font="4"><b>Safety endpoint:</b>  Major bleeding </text>
<text top="681" left="913" width="3" height="20" font="5"> </text>
<text top="698" left="913" width="3" height="20" font="5"> </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="12" size="10" family="Times" color="#000000"/>
<text top="789" left="1117" width="20" height="21" font="0">18 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="3" height="20" font="5"> </text>
<text top="70" left="54" width="3" height="20" font="5"> </text>
<text top="53" left="163" width="3" height="20" font="5"> </text>
<text top="70" left="163" width="143" height="20" font="4"><b>Study type:</b> Randomized </text>
<text top="87" left="163" width="139" height="20" font="5">factorial trial.  Analysis of </text>
<text top="104" left="163" width="148" height="20" font="5">pts in CURRENT-OASIS 7 </text>
<text top="122" left="163" width="89" height="20" font="5">undergoing PCI </text>
<text top="139" left="163" width="3" height="20" font="5"> </text>
<text top="156" left="163" width="96" height="20" font="4"><b>Size:</b> 17,260 pts  </text>
<text top="53" left="325" width="94" height="20" font="5">Increased risk of </text>
<text top="70" left="325" width="100" height="20" font="5">bleeding or active </text>
<text top="87" left="325" width="50" height="20" font="5">bleeding </text>
<text top="55" left="636" width="7" height="18" font="5">•</text>
<text top="54" left="643" width="244" height="20" font="5"> 1.5% with high-dose ASA vs. 1.3% with low-</text>
<text top="71" left="636" width="226" height="20" font="5">dose ASA (HR: 1.18; 95% CI: 0.92–1.53; </text>
<text top="88" left="636" width="46" height="20" font="5">p=0.20) </text>
<text top="106" left="636" width="3" height="20" font="5"> </text>
<text top="123" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="174" left="54" width="63" height="20" font="4"><b>PCI-CURE </b></text>
<text top="191" left="54" width="85" height="20" font="5">Jolly SS, et al., </text>
<text top="208" left="54" width="31" height="20" font="5">2009 </text>
<text top="226" left="54" width="25" height="20" font="5">(38) </text>
<text top="243" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18819961">18819961</a></text>
<text top="243" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18819961"> </a></text>
<text top="174" left="163" width="139" height="20" font="4"><b>Aim:</b> Evaluate the safety </text>
<text top="191" left="163" width="139" height="20" font="5">of different doses of ASA </text>
<text top="208" left="163" width="128" height="20" font="5">after PCI in PCI-CURE </text>
<text top="226" left="163" width="3" height="20" font="5"> </text>
<text top="243" left="163" width="122" height="20" font="4"><b>Study type:</b> Post hoc </text>
<text top="260" left="163" width="124" height="20" font="5">analysis of PCI-CURE </text>
<text top="277" left="163" width="3" height="20" font="5"> </text>
<text top="294" left="163" width="86" height="20" font="4"><b>Size:</b> 2,658 pts </text>
<text top="174" left="325" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="191" left="325" width="136" height="20" font="5">NSTE-ACS pts in CURE </text>
<text top="208" left="325" width="111" height="20" font="5">who underwent PCI </text>
<text top="226" left="325" width="109" height="20" font="5">(PCI-CURE cohort) </text>
<text top="243" left="325" width="3" height="20" font="5"> </text>
<text top="260" left="325" width="137" height="20" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="174" left="481" width="136" height="20" font="4"><b>Intervention:</b> ASA dose </text>
<text top="191" left="481" width="96" height="20" font="5">(nonrandomized) </text>
<text top="208" left="481" width="7" height="20" font="5">  </text>
<text top="226" left="481" width="131" height="20" font="4"><b>Comparator:</b> Higher or </text>
<text top="243" left="481" width="94" height="20" font="5">lower ASA dose  </text>
<text top="260" left="481" width="3" height="20" font="4"><b> </b></text>
<text top="175" left="636" width="100" height="20" font="4"><b>1</b>°<b> endpoint:</b> N/A </text>
<text top="192" left="636" width="3" height="20" font="5"> </text>
<text top="209" left="636" width="252" height="20" font="4"><b>Safety endpoint:</b>  Major bleeding at 30 d and </text>
<text top="227" left="636" width="128" height="20" font="5">long term (mean 8 mo) </text>
<text top="246" left="636" width="7" height="18" font="5">•</text>
<text top="245" left="643" width="258" height="20" font="5"> Major bleeding increased with high-dose ASA  </text>
<text top="264" left="636" width="7" height="18" font="5">•</text>
<text top="264" left="643" width="228" height="20" font="5"> 1.9% with low-dose, 1.5% with moderate </text>
<text top="281" left="636" width="172" height="20" font="5">dose, and 3.9% with high-dose </text>
<text top="300" left="636" width="7" height="18" font="5">•</text>
<text top="299" left="643" width="227" height="20" font="5"> For high vs. low-dose HR: 2.05 (95% CI: </text>
<text top="316" left="636" width="114" height="20" font="5">1.20–3.50; p=0.009) </text>
<text top="176" left="913" width="7" height="18" font="5">•</text>
<text top="175" left="919" width="165" height="20" font="5"> ASA doses were categorized </text>
<text top="192" left="913" width="133" height="20" font="5">as low-dose (≤100 mg), </text>
<text top="209" left="913" width="169" height="20" font="5">moderate dose (101–199 mg), </text>
<text top="227" left="913" width="145" height="20" font="5">and high-dose (≥200 mg   </text>
<text top="246" left="913" width="7" height="18" font="5">•</text>
<text top="245" left="919" width="153" height="20" font="5"> Net adverse clinical events </text>
<text top="262" left="913" width="137" height="20" font="5">(death, MI, stroke, major </text>
<text top="280" left="913" width="98" height="20" font="5">bleeding) favored </text>
<text top="297" left="913" width="169" height="20" font="5">Low-dose over high-dose ASA </text>
<text top="314" left="913" width="180" height="20" font="5">(8.4% vs. 11.0%; HR: 1.31; 95% </text>
<text top="331" left="913" width="136" height="20" font="5">CI: 1.00–1.73; p=0.056). </text>
<text top="349" left="54" width="73" height="20" font="4"><b>CHARISMA  </b></text>
<text top="366" left="54" width="92" height="20" font="5">Steinhubl, et al., </text>
<text top="384" left="54" width="31" height="20" font="5">2009 </text>
<text top="401" left="54" width="25" height="20" font="5">(39) </text>
<text top="418" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19293071">19293071</a></text>
<text top="418" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19293071"> </a></text>
<text top="349" left="163" width="113" height="20" font="4"><b>Aim:</b> Assess MACE </text>
<text top="366" left="163" width="125" height="20" font="5">based on ASA dose in </text>
<text top="384" left="163" width="68" height="20" font="5">CHARISMA </text>
<text top="401" left="163" width="3" height="20" font="5"> </text>
<text top="418" left="163" width="122" height="20" font="4"><b>Study type:</b> Post hoc </text>
<text top="435" left="163" width="128" height="20" font="5">observational analyses </text>
<text top="452" left="163" width="3" height="20" font="5"> </text>
<text top="470" left="163" width="93" height="20" font="4"><b>Size:</b> 15,595 pts </text>
<text top="349" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="366" left="325" width="128" height="20" font="5">enrolled in CHARISMA </text>
<text top="384" left="325" width="3" height="20" font="5"> </text>
<text top="401" left="325" width="137" height="20" font="4"><b>Exclusion criteria:</b> N/A  </text>
<text top="349" left="481" width="136" height="20" font="4"><b>Intervention:</b> ASA dose </text>
<text top="366" left="481" width="96" height="20" font="5">(nonrandomized) </text>
<text top="384" left="481" width="7" height="20" font="5">  </text>
<text top="401" left="481" width="131" height="20" font="4"><b>Comparator:</b> Higher or </text>
<text top="418" left="481" width="94" height="20" font="5">lower ASA dose  </text>
<text top="435" left="481" width="3" height="20" font="4"><b> </b></text>
<text top="350" left="636" width="237" height="20" font="4"><b>1</b>°<b> endpoint:</b> MACE MI, CVA or CV death) </text>
<text top="369" left="636" width="7" height="18" font="5">•</text>
<text top="369" left="643" width="228" height="20" font="5"> The hazard the same regardless of dose </text>
<text top="388" left="636" width="7" height="18" font="5">•</text>
<text top="387" left="643" width="237" height="20" font="5"> Adjusted HR: 0.95, 95% CI: 0.80–1.13, for </text>
<text top="404" left="636" width="115" height="20" font="5">100 mg vs. &lt;100 mg </text>
<text top="423" left="636" width="7" height="18" font="5">•</text>
<text top="423" left="643" width="230" height="20" font="5"> Adjusted HR: 1.0; 95% CI: 0.85–1.18; for </text>
<text top="440" left="636" width="126" height="20" font="5">&gt;100 mg vs. &lt;100 mg. </text>
<text top="457" left="636" width="3" height="20" font="5"> </text>
<text top="474" left="636" width="245" height="20" font="4"><b>Safety endpoint:</b>  Severe or life-threatening </text>
<text top="492" left="636" width="50" height="20" font="5">bleeding </text>
<text top="511" left="636" width="7" height="18" font="5">•</text>
<text top="510" left="643" width="190" height="20" font="5"> Hazard similar regardless of dose </text>
<text top="529" left="636" width="7" height="18" font="5">•</text>
<text top="528" left="643" width="237" height="20" font="5"> Adjusted HR: 0.85; 95% CI: 0.57–1.26, for </text>
<text top="546" left="636" width="115" height="20" font="5">100 mg vs. &lt;100 mg </text>
<text top="565" left="636" width="7" height="18" font="5">•</text>
<text top="564" left="643" width="247" height="20" font="5"> Adjusted HR: 1.05; 95% CI: 0.74–1.48, for &gt; </text>
<text top="581" left="636" width="119" height="20" font="5">100 mg vs. &lt;100 mg. </text>
<text top="351" left="913" width="7" height="18" font="5">•</text>
<text top="350" left="919" width="165" height="20" font="5"> ASA doses were categorized </text>
<text top="368" left="913" width="169" height="20" font="5">as &lt;100 mg (75 mg or 81 mg), </text>
<text top="385" left="913" width="170" height="20" font="5">100 mg or&gt;100 mg (150 mg or </text>
<text top="402" left="913" width="55" height="20" font="5">162 mg)   </text>
<text top="421" left="913" width="7" height="18" font="5">•</text>
<text top="420" left="919" width="115" height="20" font="5"> In pts also receiving </text>
<text top="438" left="913" width="159" height="20" font="5">clopidogrel, daily ASA doses </text>
<text top="455" left="913" width="130" height="20" font="5">&gt;100 mg seemed to be </text>
<text top="472" left="913" width="150" height="20" font="5">nonstatistically significantly </text>
<text top="489" left="913" width="180" height="20" font="5">associated with reduced efficacy </text>
<text top="507" left="913" width="159" height="20" font="5">(adjusted HR: 1.16; CI: 0.93–</text>
<text top="524" left="913" width="147" height="20" font="5">1.44]) and increased harm </text>
<text top="541" left="913" width="159" height="20" font="5">(adjusted HR: 1.30; CI: 0.83–</text>
<text top="558" left="913" width="38" height="20" font="5">2.04]). </text>
<text top="575" left="913" width="3" height="20" font="5"> </text>
<text top="599" left="54" width="96" height="20" font="5">Patrono C, et al., </text>
<text top="616" left="54" width="31" height="20" font="5">2008 </text>
<text top="633" left="54" width="25" height="20" font="5">(40) </text>
<text top="655" left="54" width="57" height="12" font="9"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18574266">18574266</a></text>
<text top="655" left="111" width="4" height="12" font="12"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18574266"> </a></text>
<text top="665" left="54" width="3" height="20" font="5"> </text>
<text top="683" left="54" width="3" height="20" font="5"> </text>
<text top="599" left="163" width="149" height="20" font="4"><b>Aim:</b> Comparison of OR in </text>
<text top="616" left="163" width="114" height="20" font="5">vascular events with </text>
<text top="633" left="163" width="112" height="20" font="5">different ASA doses </text>
<text top="651" left="163" width="3" height="20" font="5"> </text>
<text top="668" left="163" width="114" height="20" font="4"><b>Study type:</b> Indirect </text>
<text top="685" left="163" width="145" height="20" font="5">comparison of ASA doses </text>
<text top="702" left="163" width="139" height="20" font="5">reducing vascular events </text>
<text top="720" left="163" width="145" height="20" font="5">in high-risk pts;  data from </text>
<text top="737" left="163" width="94" height="20" font="5">prior studies and </text>
<text top="754" left="163" width="68" height="20" font="5">publications </text>
<text top="599" left="325" width="109" height="20" font="4"><b>Inclusion criteria:</b>  </text>
<text top="616" left="325" width="126" height="20" font="5">Studies of ASA in high-</text>
<text top="633" left="325" width="42" height="20" font="5">risk pts </text>
<text top="651" left="325" width="3" height="20" font="5"> </text>
<text top="668" left="325" width="137" height="20" font="4"><b>Exclusion criteria:</b>  N/A </text>
<text top="599" left="481" width="128" height="20" font="4"><b>Intervention:</b> Different </text>
<text top="616" left="481" width="109" height="20" font="5">ASA dosing ranges </text>
<text top="633" left="481" width="7" height="20" font="5">  </text>
<text top="651" left="481" width="3" height="20" font="4"><b> </b></text>
<text top="600" left="636" width="228" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Odds reduction in vascular </text>
<text top="617" left="636" width="40" height="20" font="5">events </text>
<text top="637" left="636" width="7" height="18" font="5">•</text>
<text top="636" left="643" width="168" height="20" font="5"> 500–1,500 mg/d: OR: 19±3% </text>
<text top="655" left="636" width="7" height="18" font="5">•</text>
<text top="654" left="643" width="164" height="20" font="5"> 160–325 mg/d:  OR: 26±3%  </text>
<text top="673" left="636" width="7" height="18" font="5">•</text>
<text top="673" left="643" width="154" height="20" font="5"> 75–150 mg/d:  OR: 32±6% </text>
<text top="692" left="636" width="7" height="18" font="5">•</text>
<text top="691" left="643" width="134" height="20" font="5"> &lt;75 mg/d:  OR: 13±8% </text>
<text top="708" left="636" width="3" height="20" font="5"> </text>
<text top="725" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="601" left="913" width="7" height="18" font="5">•</text>
<text top="600" left="919" width="27" height="20" font="5"> N/A </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">19 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="163" width="3" height="20" font="5"> </text>
<text top="70" left="163" width="130" height="20" font="4"><b>Size: </b>68 trials; &gt;50,000 </text>
<text top="87" left="163" width="20" height="20" font="5">pts </text>
<text top="105" left="54" width="84" height="20" font="5">Serebruany, et </text>
<text top="122" left="54" width="20" height="20" font="5">al., </text>
<text top="139" left="54" width="31" height="20" font="5">2005 </text>
<text top="157" left="54" width="25" height="20" font="5">(41) </text>
<text top="174" left="54" width="55" height="20" font="6"><a href="file://share1/divisions/SQ/Clinical%20Policy%20&amp;%20Documents/Guidelines/2016%20DAPT%20Focused%20Update/Current%20Draft/Data%20Supplement/15877994">15877994</a></text>
<text top="174" left="109" width="3" height="20" font="4"><a href="file://share1/divisions/SQ/Clinical%20Policy%20&amp;%20Documents/Guidelines/2016%20DAPT%20Focused%20Update/Current%20Draft/Data%20Supplement/15877994"><b> </b></a></text>
<text top="105" left="163" width="143" height="20" font="4"><b>Aim:</b> To compare the risk </text>
<text top="122" left="163" width="114" height="20" font="5">of bleeding with low, </text>
<text top="139" left="163" width="143" height="20" font="5">moderate and high-doses </text>
<text top="157" left="163" width="42" height="20" font="5">of ASA </text>
<text top="174" left="163" width="3" height="20" font="5"> </text>
<text top="191" left="163" width="141" height="20" font="4"><b>Study type:</b>   Systematic </text>
<text top="208" left="163" width="112" height="20" font="5">overview of 31 trials </text>
<text top="226" left="163" width="3" height="20" font="5"> </text>
<text top="243" left="163" width="100" height="20" font="4"><b>Size:</b> 192,036 pts </text>
<text top="105" left="325" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="122" left="325" width="133" height="20" font="5">Clinical trials with follow-</text>
<text top="139" left="325" width="31" height="20" font="5">up of </text>
<text top="157" left="325" width="130" height="20" font="5">≥1 mo and contained a </text>
<text top="174" left="325" width="123" height="20" font="5">detailed description of </text>
<text top="191" left="325" width="72" height="20" font="5">hemorrhagic </text>
<text top="208" left="325" width="101" height="20" font="5">complications, pts </text>
<text top="226" left="325" width="130" height="20" font="5">characteristics, therapy </text>
<text top="243" left="325" width="141" height="20" font="5">duration and concomitant </text>
<text top="260" left="325" width="74" height="20" font="5">agents used. </text>
<text top="277" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="294" left="325" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="312" left="325" width="112" height="20" font="5">Studies not meeting </text>
<text top="329" left="325" width="77" height="20" font="5">above criteria </text>
<text top="105" left="481" width="136" height="20" font="4"><b>Intervention:</b> ASA dose </text>
<text top="122" left="481" width="96" height="20" font="5">(nonrandomized) </text>
<text top="139" left="481" width="7" height="20" font="5">  </text>
<text top="157" left="481" width="131" height="20" font="4"><b>Comparator:</b> Higher or </text>
<text top="174" left="481" width="94" height="20" font="5">lower ASA dose  </text>
<text top="191" left="481" width="3" height="20" font="5"> </text>
<text top="208" left="481" width="10" height="20" font="4"><b>   </b></text>
<text top="106" left="636" width="215" height="20" font="4"><b>1</b>°<b> endpoint:</b> None specifically defined </text>
<text top="123" left="636" width="3" height="20" font="5"> </text>
<text top="141" left="636" width="242" height="20" font="5">Major bleeding event rates (most commonly </text>
<text top="158" left="636" width="85" height="20" font="5">TIMI bleeding): </text>
<text top="177" left="636" width="7" height="18" font="5">•</text>
<text top="176" left="643" width="242" height="20" font="5"> 1.56% with low-dose; 1.54% with moderate </text>
<text top="193" left="636" width="238" height="20" font="5">dose;  2.29% with high-dose;  p=0.0001 for </text>
<text top="211" left="636" width="210" height="20" font="5">comparison of low-dose vs. high-dose </text>
<text top="228" left="636" width="3" height="20" font="5"> </text>
<text top="245" left="636" width="148" height="20" font="5">Total bleeding event rates: </text>
<text top="264" left="636" width="7" height="18" font="5">•</text>
<text top="264" left="643" width="252" height="20" font="5"> 3.72% with low-dose;  11.31% with moderate </text>
<text top="281" left="636" width="231" height="20" font="5">dose;  9.8% with high- dose; p=0.0001 for </text>
<text top="298" left="636" width="255" height="20" font="5">comparisons of low-dose with either moderate </text>
<text top="315" left="636" width="72" height="20" font="5">or high-dose </text>
<text top="107" left="913" width="7" height="18" font="5">•</text>
<text top="106" left="919" width="148" height="20" font="5"> Low-dose ASA defined as </text>
<text top="123" left="913" width="173" height="20" font="5">&lt;100 mg;  moderate-dose ASA </text>
<text top="141" left="913" width="164" height="20" font="5">100–200 mg;  high-dose ASA </text>
<text top="158" left="913" width="52" height="20" font="5">&gt;200 mg </text>
<text top="175" left="913" width="3" height="20" font="5"> </text>
<text top="192" left="913" width="3" height="20" font="5"> </text>
<text top="210" left="913" width="3" height="20" font="5"> </text>
<text top="347" left="54" width="42" height="20" font="4"><b>CURE  </b></text>
<text top="364" left="54" width="76" height="20" font="5">Peters, et al., </text>
<text top="381" left="54" width="31" height="20" font="5">2003 </text>
<text top="399" left="54" width="25" height="20" font="5">(42) </text>
<text top="416" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14504182">14504182</a></text>
<text top="416" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14504182"> </a></text>
<text top="347" left="163" width="148" height="20" font="4"><b>Aim:</b> To study the benefits </text>
<text top="364" left="163" width="107" height="20" font="5">and risks of adding </text>
<text top="381" left="163" width="124" height="20" font="5">clopidogrel to different </text>
<text top="399" left="163" width="111" height="20" font="5">doses of ASA in the </text>
<text top="416" left="163" width="69" height="20" font="5">treatment of </text>
<text top="433" left="163" width="74" height="20" font="5">pts with ACS </text>
<text top="450" left="163" width="3" height="20" font="5"> </text>
<text top="467" left="163" width="122" height="20" font="4"><b>Study type:</b> Post hoc </text>
<text top="485" left="163" width="120" height="20" font="5">analysis of the CURE </text>
<text top="502" left="163" width="33" height="20" font="5">study </text>
<text top="519" left="163" width="3" height="20" font="5"> </text>
<text top="536" left="163" width="93" height="20" font="4"><b>Size:</b> 12,562 pts </text>
<text top="553" left="163" width="3" height="20" font="5"> </text>
<text top="347" left="325" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="364" left="325" width="138" height="20" font="5">with NSTE-ACS enrolled </text>
<text top="381" left="325" width="105" height="20" font="5">in the CURE study </text>
<text top="398" left="325" width="3" height="20" font="5"> </text>
<text top="416" left="325" width="3" height="20" font="5"> </text>
<text top="347" left="481" width="139" height="20" font="4"><b>Intervention:</b>  ASA dose </text>
<text top="364" left="481" width="96" height="20" font="5">(nonrandomized) </text>
<text top="381" left="481" width="7" height="20" font="5">  </text>
<text top="398" left="481" width="131" height="20" font="4"><b>Comparator:</b> Higher or </text>
<text top="416" left="481" width="101" height="20" font="5">lower ASA dose <b>   </b></text>
<text top="348" left="636" width="118" height="20" font="4"><b>1</b>°<b> endpoint:</b>  MACE </text>
<text top="367" left="636" width="7" height="18" font="5">•</text>
<text top="366" left="643" width="233" height="20" font="5"> Impact of clopidogrel in preventing MACE </text>
<text top="384" left="636" width="243" height="20" font="5">was not significantly heterogeneous by ASA </text>
<text top="401" left="636" width="30" height="20" font="5">dose </text>
<text top="418" left="636" width="247" height="20" font="5">-high-dose group, 9.8% vs. 13.6%; RR: 0.71; </text>
<text top="435" left="636" width="103" height="20" font="5">95% 95% CI: 0.59 </text>
<text top="453" left="636" width="261" height="20" font="5">-medium-dose group, 9.5% vs. 9.8%; RR: 0.97; </text>
<text top="470" left="636" width="105" height="20" font="5">95% CI: 0.77–1.22 </text>
<text top="487" left="636" width="146" height="20" font="5">-low-dose group, 8.6% vs. </text>
<text top="504" left="636" width="202" height="20" font="5">10.5%; RR: 0.81; 95% CI: 0.68–0.97 </text>
<text top="521" left="636" width="3" height="20" font="5"> </text>
<text top="539" left="636" width="191" height="20" font="4"><b>Safety endpoint:</b>  Major bleeding  </text>
<text top="558" left="636" width="7" height="18" font="5">•</text>
<text top="557" left="643" width="181" height="20" font="5"> The incidence of major bleeding </text>
<text top="574" left="636" width="135" height="20" font="5">complications increased </text>
<text top="591" left="636" width="250" height="20" font="5">significantly with increasing ASA dose both in </text>
<text top="609" left="636" width="259" height="20" font="5">the placebo (1.9%, 2.8%, 3.7%; p=0.0001) and </text>
<text top="626" left="636" width="251" height="20" font="5">the clopidogrel (3.0%, 3.4%, 4.9%; p=0.0009) </text>
<text top="643" left="636" width="41" height="20" font="5">groups<b> </b></text>
<text top="349" left="913" width="7" height="18" font="5">•</text>
<text top="348" left="919" width="132" height="20" font="5"> Incidence of MACE not </text>
<text top="365" left="913" width="171" height="20" font="5">heterogeneous in pts receiving </text>
<text top="382" left="913" width="167" height="20" font="5">ASA alone when examined by </text>
<text top="400" left="913" width="176" height="20" font="5">dose (highest and medium ASA </text>
<text top="417" left="913" width="175" height="20" font="5">dose groups compared with the </text>
<text top="434" left="913" width="166" height="20" font="5">low-dose group: adjusted OR, </text>
<text top="451" left="913" width="178" height="20" font="5">1.0 (95% CI: 0.82–1.23) and 1.2 </text>
<text top="469" left="913" width="117" height="20" font="5">(95% CI: 1.08–1.51), </text>
<text top="486" left="913" width="68" height="20" font="5">respectively </text>
<text top="503" left="913" width="3" height="20" font="5"> </text>
<text top="520" left="913" width="3" height="20" font="5"> </text>
<text top="661" left="54" width="82" height="20" font="5">Antithrombotic </text>
<text top="678" left="54" width="48" height="20" font="5">Trialists’ </text>
<text top="695" left="54" width="79" height="20" font="5">Collaboration, </text>
<text top="713" left="54" width="31" height="20" font="5">2002 </text>
<text top="730" left="54" width="25" height="20" font="5">(43) </text>
<text top="747" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11786451">11786451</a></text>
<text top="747" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11786451"> </a></text>
<text top="661" left="163" width="127" height="20" font="4"><b>Aim:</b> To determine the </text>
<text top="678" left="163" width="116" height="20" font="5">effects of antiplatelet </text>
<text top="695" left="163" width="119" height="20" font="5">therapy among pts at </text>
<text top="713" left="163" width="118" height="20" font="5">high-risk of occlusive </text>
<text top="730" left="163" width="92" height="20" font="5">vascular events. </text>
<text top="747" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="764" left="163" width="146" height="20" font="4"><b>Study type:</b> Collaborative </text>
<text top="661" left="325" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="678" left="325" width="132" height="20" font="5">Randomized trials of an </text>
<text top="695" left="325" width="130" height="20" font="5">antiplatelet regimen vs. </text>
<text top="713" left="325" width="127" height="20" font="5">control or one regimen </text>
<text top="730" left="325" width="119" height="20" font="5">vs. another regimen   </text>
<text top="747" left="325" width="3" height="20" font="5"> </text>
<text top="764" left="325" width="3" height="20" font="5"> </text>
<text top="661" left="481" width="106" height="20" font="4"><b>Intervention:</b> ASA </text>
<text top="678" left="481" width="7" height="20" font="5">  </text>
<text top="695" left="481" width="135" height="20" font="4"><b>Comparator:</b> Control or </text>
<text top="713" left="481" width="46" height="20" font="5">placebo<b> </b></text>
<text top="662" left="636" width="248" height="20" font="4"><b>1</b>°<b> endpoint:</b> Series vascular event (nonfatal </text>
<text top="679" left="636" width="196" height="20" font="5">MI, nonfatal stroke, vascular death) </text>
<text top="699" left="636" width="7" height="18" font="5">•</text>
<text top="698" left="643" width="252" height="20" font="5"> The proportional reduction in vascular events </text>
<text top="715" left="636" width="247" height="20" font="5">was 19% (3%) with 500–1500 mg daily, 26% </text>
<text top="732" left="636" width="55" height="20" font="5">(3%) with </text>
<text top="749" left="636" width="255" height="20" font="5">160–325 mg daily, and 32% (6%) with 75–150 </text>
<text top="767" left="636" width="249" height="20" font="5">mg daily; parentheses denote standard error. </text>
<text top="663" left="913" width="7" height="18" font="5">•</text>
<text top="662" left="920" width="27" height="20" font="4"><b> </b>N/A </text>
<text top="679" left="913" width="3" height="20" font="5"> </text>
<text top="697" left="913" width="3" height="20" font="5"> </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">20 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="163" width="83" height="20" font="5">meta-analyses </text>
<text top="70" left="163" width="3" height="20" font="5"> </text>
<text top="87" left="163" width="118" height="20" font="4"><b>Size:</b> 135,000 pts for </text>
<text top="104" left="163" width="87" height="20" font="5">comparisons of </text>
<text top="122" left="163" width="126" height="20" font="5">antiplatelet therapy vs. </text>
<text top="139" left="163" width="143" height="20" font="5">control and 77,000 pts for </text>
<text top="156" left="163" width="135" height="20" font="5">comparisons of different </text>
<text top="173" left="163" width="120" height="20" font="5">antiplatelet regimens  </text>
<text top="53" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="191" left="54" width="77" height="20" font="5">Lorenz RL, et </text>
<text top="208" left="54" width="20" height="20" font="5">al., </text>
<text top="226" left="54" width="31" height="20" font="5">1984 </text>
<text top="243" left="54" width="25" height="20" font="5">(44) </text>
<text top="260" left="54" width="48" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6144975">6144975</a></text>
<text top="260" left="102" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6144975"><b> </b></a></text>
<text top="277" left="54" width="3" height="20" font="5"> </text>
<text top="191" left="163" width="149" height="20" font="4"><b>Aim: </b>To study the effect of </text>
<text top="208" left="163" width="136" height="20" font="5">ASA in the prevention of </text>
<text top="226" left="163" width="122" height="20" font="5">aortocoronary bypass </text>
<text top="243" left="163" width="55" height="20" font="5">occlusion </text>
<text top="260" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="277" left="163" width="141" height="20" font="4"><b>Study type: </b>Prospective, </text>
<text top="294" left="163" width="98" height="20" font="5">double blind RCT<b> </b></text>
<text top="312" left="163" width="3" height="20" font="4"><b> </b></text>
<text top="329" left="163" width="69" height="20" font="4"><b>Size: </b>60 pts </text>
<text top="191" left="325" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="208" left="325" width="65" height="20" font="5">undergoing </text>
<text top="226" left="325" width="122" height="20" font="5">aortocoronary bypass<b> </b></text>
<text top="243" left="325" width="3" height="20" font="4"><b> </b></text>
<text top="260" left="325" width="113" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="277" left="325" width="71" height="20" font="5">Peptic ulcer, </text>
<text top="294" left="325" width="124" height="20" font="5">anticoagulant therapy, </text>
<text top="312" left="325" width="51" height="20" font="5">acute MI<b> </b></text>
<text top="191" left="481" width="136" height="20" font="4"><b>Intervention: </b>100 mg of </text>
<text top="208" left="481" width="130" height="20" font="5">ASA once daily (n=29)<b>  </b></text>
<text top="226" left="481" width="7" height="20" font="4"><b>  </b></text>
<text top="243" left="481" width="125" height="20" font="4"><b>Comparator: </b>Placebo </text>
<text top="260" left="481" width="39" height="20" font="5">(n=31)<b> </b></text>
<text top="192" left="636" width="213" height="20" font="4"><b>1</b>°<b> endpoint:  </b>Grafts occluded at 4 mo </text>
<text top="209" left="636" width="127" height="20" font="5">angiographic follow-up<b> </b></text>
<text top="229" left="636" width="7" height="18" font="5">•</text>
<text top="228" left="643" width="235" height="20" font="4"><b> </b>4/40 (10%) with ASA vs. 17/53 (32%) with </text>
<text top="245" left="636" width="110" height="20" font="5">placebo (2p=0.012)<b> </b></text>
<text top="262" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="280" left="636" width="127" height="20" font="4"><b>Safety endpoint:  </b>N/A<b> </b></text>
<text top="297" left="636" width="3" height="20" font="4"><b> </b></text>
<text top="193" left="913" width="7" height="18" font="5">•</text>
<text top="192" left="920" width="164" height="20" font="4"><b> </b>100 mg/d dose of ASA found </text>
<text top="209" left="913" width="147" height="20" font="5">to effectively block platelet </text>
<text top="227" left="913" width="154" height="20" font="5">thromboxane formation and </text>
<text top="244" left="913" width="134" height="20" font="5">thromboxane-supported </text>
<text top="261" left="913" width="135" height="20" font="5">aggregation on collagen </text>
<text top="278" left="913" width="3" height="20" font="4"><b> </b></text>
<text top="296" left="913" width="3" height="20" font="4"><b> </b></text>
<text top="313" left="913" width="3" height="20" font="4"><b> </b></text>
<text top="347" left="54" width="1045" height="20" font="5">ACS indicates acute coronary syndrome; ASA, aspirin; CI, confidence interval; CVA, cerebrovascular accident; CV, cardiovascular;  HR, hazard ratio; MACE; major adverse cardiac events; MI, </text>
<text top="367" left="54" width="1064" height="20" font="5">myocardial infarction; N/A, not available; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; OR, odds ratio; RCT, randomized controlled trials; and </text>
<text top="386" left="54" width="94" height="20" font="5">RR, relative risk. </text>
<text top="424" left="54" width="915" height="24" font="2"><b>Data Supplement 7.  RCTs Comparing Antiplatelet Therapy With Anticoagulant Therapy in Patients Undergoing Coronary Stenting </b></text>
<text top="449" left="80" width="38" height="20" font="4"><b>Study </b></text>
<text top="466" left="68" width="61" height="20" font="4"><b>Acronym; </b></text>
<text top="483" left="75" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="500" left="84" width="30" height="20" font="4"><b>Year </b></text>
<text top="518" left="68" width="62" height="20" font="4"><b>Published </b></text>
<text top="449" left="191" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="466" left="196" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="483" left="190" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="449" left="350" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="449" left="519" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="466" left="537" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="483" left="520" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="500" left="541" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="449" left="732" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="466" left="716" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="483" left="718" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="500" left="761" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="450" left="942" width="134" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint  </b></text>
<text top="467" left="983" width="48" height="20" font="4"><b>(if any); </b></text>
<text top="484" left="952" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="501" left="959" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="535" left="54" width="45" height="20" font="4"><b>STARS </b></text>
<text top="553" left="54" width="90" height="20" font="5">Leon MB, et al., </text>
<text top="570" left="54" width="31" height="20" font="5">1998 </text>
<text top="587" left="54" width="25" height="20" font="5">(45) </text>
<text top="604" left="54" width="48" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9834303">9834303</a></text>
<text top="604" left="102" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9834303"><b> </b></a></text>
<text top="622" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="535" left="157" width="131" height="20" font="4"><b>Aim:  </b>To compared the </text>
<text top="553" left="157" width="150" height="20" font="5">efficacy and safety of three </text>
<text top="570" left="157" width="85" height="20" font="5">antithrombotic- </text>
<text top="587" left="157" width="126" height="20" font="5">drug regimens — ASA </text>
<text top="604" left="157" width="65" height="20" font="5">alone, ASA </text>
<text top="622" left="157" width="150" height="20" font="5">and warfarin, and ASA and </text>
<text top="639" left="157" width="102" height="20" font="5">ticlopidine — after </text>
<text top="656" left="157" width="98" height="20" font="5">coronary stenting </text>
<text top="673" left="157" width="38" height="20" font="5">(BMS)<b> </b></text>
<text top="690" left="157" width="3" height="20" font="4"><b> </b></text>
<text top="708" left="157" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="725" left="157" width="3" height="20" font="4"><b> </b></text>
<text top="742" left="157" width="86" height="20" font="4"><b>Size: </b>1,653 pts<b> </b></text>
<text top="535" left="322" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="553" left="322" width="126" height="20" font="5">undergoing successful </text>
<text top="570" left="322" width="151" height="20" font="5">coronary stent implantation<b> </b></text>
<text top="587" left="322" width="3" height="20" font="4"><b> </b></text>
<text top="604" left="322" width="137" height="20" font="4"><b>Exclusion criteria:  </b>Left </text>
<text top="622" left="322" width="154" height="20" font="5">main or bifurcation stenting, </text>
<text top="639" left="322" width="131" height="20" font="5">AMI, bleeding diathesis<b> </b></text>
<text top="535" left="501" width="120" height="20" font="4"><b>Intervention 1:  </b>ASA </text>
<text top="553" left="501" width="33" height="20" font="5">alone<b> </b></text>
<text top="570" left="501" width="3" height="20" font="4"><b> </b></text>
<text top="587" left="501" width="130" height="20" font="4"><b>Intervention 2:  </b>ASA + </text>
<text top="604" left="501" width="47" height="20" font="5">warfarin<b> </b></text>
<text top="622" left="501" width="3" height="20" font="4"><b> </b></text>
<text top="639" left="501" width="130" height="20" font="4"><b>Intervention 3:  </b>ASA + </text>
<text top="656" left="501" width="58" height="20" font="5">ticlopidine<b> </b></text>
<text top="673" left="501" width="3" height="20" font="4"><b> </b></text>
<text top="690" left="501" width="3" height="20" font="4"><b> </b></text>
<text top="708" left="501" width="7" height="20" font="4"><b>  </b></text>
<text top="725" left="501" width="3" height="20" font="4"><b> </b></text>
<text top="537" left="663" width="145" height="20" font="4"><b>1</b>°<b> endpoint:</b> Death, TLR, </text>
<text top="554" left="663" width="236" height="20" font="5">Angiographically-evident thrombosis, or MI </text>
<text top="571" left="663" width="62" height="20" font="5">within 30 d </text>
<text top="590" left="663" width="7" height="18" font="5">•</text>
<text top="590" left="670" width="224" height="20" font="5"> 3.6% with ASA alone;  2.7% with ASA + </text>
<text top="607" left="663" width="208" height="20" font="5">warfarin;  0.5% with ASA + ticlopidine </text>
<text top="624" left="663" width="197" height="20" font="5">(p=0.001 for the comparison of all 3 </text>
<text top="641" left="663" width="49" height="20" font="5">groups). </text>
<text top="658" left="663" width="3" height="20" font="5"> </text>
<text top="676" left="663" width="231" height="20" font="4"><b>Safety endpoint:</b> bleeding complications  </text>
<text top="695" left="663" width="7" height="18" font="5">•</text>
<text top="694" left="670" width="224" height="20" font="5"> 1.8% with ASA alone;  6.2% with ASA + </text>
<text top="711" left="663" width="208" height="20" font="5">warfarin;  5.5% with ASA + ticlopidine </text>
<text top="728" left="663" width="242" height="20" font="5">(p&lt;0.001 for the comparison of all 3 groups) </text>
<text top="537" left="919" width="7" height="18" font="5">•</text>
<text top="537" left="926" width="143" height="20" font="4"><b> </b>Compared to ASA alone, </text>
<text top="554" left="919" width="145" height="20" font="5">ASA + ticlopidine reduced </text>
<text top="571" left="919" width="164" height="20" font="5">incidence of primary endpoint </text>
<text top="588" left="919" width="143" height="20" font="5">(RR: 0.15;  CI: 0.05–0.43; </text>
<text top="606" left="919" width="48" height="20" font="5">p&lt;0.001<b> </b></text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">21 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="80" height="20" font="5">Schomig A, et </text>
<text top="70" left="54" width="20" height="20" font="5">al., </text>
<text top="87" left="54" width="31" height="20" font="5">1996 </text>
<text top="104" left="54" width="25" height="20" font="5">(46) </text>
<text top="122" left="54" width="48" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8598866">8598866</a></text>
<text top="122" left="102" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8598866"> </a></text>
<text top="53" left="157" width="103" height="20" font="4"><b>Aim:  </b>To compare </text>
<text top="70" left="157" width="132" height="20" font="5">antiplatelet therapy with </text>
<text top="87" left="157" width="149" height="20" font="5">conventional anticoagulant </text>
<text top="104" left="157" width="127" height="20" font="5">therapy with respect to </text>
<text top="122" left="157" width="152" height="20" font="5">clinical outcomes 30 d after </text>
<text top="139" left="157" width="133" height="20" font="5">coronary-artery stenting </text>
<text top="156" left="157" width="38" height="20" font="5">(BMS) </text>
<text top="173" left="157" width="3" height="20" font="4"><b> </b></text>
<text top="190" left="157" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="208" left="157" width="3" height="20" font="4"><b> </b></text>
<text top="225" left="157" width="76" height="20" font="4"><b>Size: </b>517 pts<b> </b></text>
<text top="53" left="322" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="70" left="322" width="146" height="20" font="5">undergoing coronary stent </text>
<text top="87" left="322" width="108" height="20" font="5">implantation (BMS)<b> </b></text>
<text top="104" left="322" width="3" height="20" font="4"><b> </b></text>
<text top="122" left="322" width="145" height="20" font="4"><b>Exclusion criteria:  </b>Stent </text>
<text top="139" left="322" width="159" height="20" font="5">placed as a bridge to CABG, </text>
<text top="156" left="322" width="154" height="20" font="5">cardiogenic shock, need for </text>
<text top="173" left="322" width="124" height="20" font="5">mechanical ventilation<b> </b></text>
<text top="53" left="501" width="117" height="20" font="4"><b>Intervention: </b>ASA + </text>
<text top="70" left="501" width="125" height="20" font="5">ticlopidine (antiplatelet </text>
<text top="87" left="501" width="49" height="20" font="5">therapy)<b> </b></text>
<text top="104" left="501" width="7" height="20" font="4"><b>  </b></text>
<text top="122" left="501" width="84" height="20" font="4"><b>Comparator:   </b></text>
<text top="139" left="501" width="121" height="20" font="5">anticoagulant therapy </text>
<text top="156" left="501" width="119" height="20" font="5">(intravenous heparin, </text>
<text top="173" left="501" width="120" height="20" font="5">phenprocoumon, and </text>
<text top="190" left="501" width="32" height="20" font="5">ASA)<b> </b></text>
<text top="54" left="663" width="229" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Primary cardiac endpoint a </text>
<text top="71" left="663" width="204" height="20" font="5">composite of CV death, MI, CABG or </text>
<text top="88" left="663" width="121" height="20" font="5">repeated angioplasty. </text>
<text top="108" left="663" width="7" height="18" font="5">•</text>
<text top="107" left="670" width="218" height="20" font="5"> 1.6% with antiplatelet therapy vs. 6.2% </text>
<text top="124" left="663" width="156" height="20" font="5">with anticoagulation therapy </text>
<text top="141" left="663" width="169" height="20" font="5">(RR: 0.25; 95% CI: 0.06–0.77) </text>
<text top="158" left="663" width="3" height="20" font="5"> </text>
<text top="175" left="663" width="198" height="20" font="4"><b>Safety endpoint: </b>Bleeding events   </text>
<text top="195" left="663" width="7" height="18" font="5">•</text>
<text top="194" left="670" width="233" height="20" font="5"> 0% with antiplatelet therapy vs. 6.5% with </text>
<text top="211" left="663" width="232" height="20" font="5">anticoagulant therapy RR: 0.00;  p&lt;0.001) </text>
<text top="228" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="55" left="919" width="7" height="18" font="5">•</text>
<text top="54" left="926" width="27" height="20" font="4"><b> </b>N/A<b> </b></text>
<text top="246" left="54" width="1060" height="20" font="5">ASA indicates aspirin; BMS, bare metal stent; CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular;  HR, hazard ratio; MI, myocardial infarction; N/A, not available; OR, </text>
<text top="266" left="54" width="566" height="20" font="5">odds ratio; RCT, randomized controlled trial; RR, relative risk;  and TLR, target-lesion revascularization. </text>
<text top="286" left="54" width="4" height="24" font="2"><b> </b></text>
<text top="327" left="54" width="574" height="24" font="2"><b>Data Supplement 8.  Nonrandomized Studies of DAPT Duration After BMS or DES </b></text>
<text top="352" left="60" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="369" left="86" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="387" left="63" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="352" left="207" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="369" left="212" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="387" left="206" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="352" left="361" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="352" left="533" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="369" left="551" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="387" left="534" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="404" left="554" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="352" left="719" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="369" left="702" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="387" left="705" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="404" left="747" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="353" left="884" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="371" left="918" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="388" left="926" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="422" left="54" width="83" height="20" font="5">Brar SS, et al., </text>
<text top="439" left="54" width="31" height="20" font="5">2008 </text>
<text top="456" left="54" width="25" height="20" font="5">(47) </text>
<text top="473" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18534267">18534267</a></text>
<text top="473" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18534267"> </a></text>
<text top="491" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="508" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="422" left="178" width="139" height="20" font="4"><b>Aim: </b>To asses long term </text>
<text top="439" left="178" width="122" height="20" font="5">clinical outcomes with </text>
<text top="456" left="178" width="137" height="20" font="5">BMS or DES by duration </text>
<text top="473" left="178" width="132" height="20" font="5">of clopidogrel use in pts </text>
<text top="491" left="178" width="48" height="20" font="5">with DM </text>
<text top="508" left="178" width="3" height="20" font="4"><b> </b></text>
<text top="525" left="178" width="70" height="20" font="4"><b>Study type: </b></text>
<text top="542" left="178" width="82" height="20" font="5">Retrospective, </text>
<text top="559" left="178" width="87" height="20" font="5">observational<b>    </b></text>
<text top="577" left="178" width="3" height="20" font="4"><b> </b></text>
<text top="594" left="178" width="76" height="20" font="4"><b>Size: </b>749 pts<b> </b></text>
<text top="422" left="332" width="152" height="20" font="4"><b>Inclusion criteria: </b>Pts with </text>
<text top="439" left="332" width="139" height="20" font="5">DM who underwent stent </text>
<text top="456" left="332" width="159" height="20" font="5">implantation with either BMS </text>
<text top="473" left="332" width="46" height="20" font="5">or DES<b>  </b></text>
<text top="491" left="332" width="3" height="20" font="4"><b> </b></text>
<text top="508" left="332" width="157" height="20" font="4"><b>Exclusion criteria: </b>Pts with </text>
<text top="525" left="332" width="165" height="20" font="5">CABG, pts who received both </text>
<text top="542" left="332" width="141" height="20" font="5">a BMS and DES, pts with </text>
<text top="559" left="332" width="152" height="20" font="5">valvular disease, nonhealth </text>
<text top="577" left="332" width="81" height="20" font="5">plan members<b> </b></text>
<text top="422" left="514" width="147" height="20" font="4"><b>Intervention:  </b>Clopidogrel </text>
<text top="439" left="514" width="38" height="20" font="5">&gt;6 mo<b> </b></text>
<text top="456" left="514" width="7" height="20" font="4"><b>  </b></text>
<text top="473" left="514" width="100" height="20" font="4"><b>Comparator:  </b>No </text>
<text top="491" left="514" width="108" height="20" font="5">clopidogrel &gt;6 mo<b>   </b></text>
<text top="423" left="676" width="188" height="20" font="4"><b>1</b>°<b> endpoint: </b>All-cause death and </text>
<text top="440" left="676" width="64" height="20" font="5">nonfatal MI<b> </b></text>
<text top="459" left="676" width="7" height="18" font="5">•</text>
<text top="459" left="683" width="168" height="20" font="4"><b> </b>3.2% with &gt;9 mo clopidogrel;  </text>
<text top="476" left="676" width="167" height="20" font="5">9.4% with 6–9 mo clopidogrel; </text>
<text top="493" left="676" width="188" height="20" font="5">and 16.5% with &lt;6 mo clopidogrel </text>
<text top="510" left="676" width="56" height="20" font="5">(p&lt;0.001)<b> </b></text>
<text top="527" left="676" width="3" height="20" font="4"><b> </b></text>
<text top="545" left="676" width="3" height="20" font="4"><b> </b></text>
<text top="562" left="676" width="3" height="20" font="4"><b> </b></text>
<text top="424" left="879" width="7" height="18" font="5">•</text>
<text top="423" left="886" width="141" height="20" font="4"><b> </b>For pts treated with DES </text>
<text top="440" left="879" width="183" height="20" font="5">adjusted HR: 0.48; 95% CI: 0.16–</text>
<text top="457" left="879" width="132" height="20" font="5">1.47; p=0.48) for &gt;6 mo </text>
<text top="475" left="879" width="179" height="20" font="5">clopidogrel vs. no clopidogrel &gt;6 </text>
<text top="492" left="879" width="21" height="20" font="5">mo<b> </b></text>
<text top="509" left="879" width="3" height="20" font="4"><b> </b></text>
<text top="526" left="879" width="3" height="20" font="4"><b> </b></text>
<text top="543" left="879" width="3" height="20" font="4"><b> </b></text>
<text top="612" left="54" width="97" height="20" font="5">Eisenstein, et al., </text>
<text top="629" left="54" width="31" height="20" font="5">2007 </text>
<text top="646" left="54" width="25" height="20" font="5">(48) </text>
<text top="663" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17148711">17148711</a></text>
<text top="663" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17148711"> </a></text>
<text top="612" left="178" width="98" height="20" font="4"><b>Aim:  </b>Assess the </text>
<text top="629" left="178" width="115" height="20" font="5">association between </text>
<text top="646" left="178" width="137" height="20" font="5">clopidogrel use and long-</text>
<text top="663" left="178" width="68" height="20" font="5">term clinical </text>
<text top="681" left="178" width="90" height="20" font="5">outcomes of pts </text>
<text top="698" left="178" width="135" height="20" font="5">receiving DES and BMS </text>
<text top="715" left="178" width="3" height="20" font="4"><b> </b></text>
<text top="732" left="178" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="749" left="178" width="116" height="20" font="5">Observational study<b>  </b></text>
<text top="767" left="178" width="3" height="20" font="4"><b> </b></text>
<text top="612" left="332" width="106" height="20" font="4"><b>Inclusion criteria:</b> </text>
<text top="629" left="332" width="156" height="20" font="5">Consecutive pts treated at 1 </text>
<text top="646" left="332" width="165" height="20" font="5">institution undergoing BMS or </text>
<text top="663" left="332" width="32" height="20" font="5">DES <b> </b></text>
<text top="681" left="332" width="3" height="20" font="4"><b> </b></text>
<text top="612" left="514" width="148" height="20" font="4"><b>Comparators:</b> Duration of </text>
<text top="629" left="514" width="135" height="20" font="5">self-reported clopidogrel </text>
<text top="646" left="514" width="33" height="20" font="5">use   <b> </b></text>
<text top="613" left="676" width="189" height="20" font="4"><b>1</b>°<b> endpoints in DES-treated pts </b></text>
<text top="630" left="676" width="122" height="20" font="4"><b>at 24 mo follow-up:</b>   </text>
<text top="649" left="676" width="7" height="18" font="5">•</text>
<text top="649" left="683" width="175" height="20" font="5"> Death: 2.% with clopidogrel vs. </text>
<text top="666" left="676" width="137" height="20" font="5">5.3% without clopidogrel </text>
<text top="683" left="676" width="166" height="20" font="5">(difference -3.3%; CI: -6.3% –-</text>
<text top="700" left="676" width="80" height="20" font="5">0.3%; p=0.03) </text>
<text top="719" left="676" width="7" height="18" font="5">•</text>
<text top="719" left="683" width="131" height="20" font="5"> Death or MI: 3.1% with </text>
<text top="736" left="676" width="156" height="20" font="5">clopidogrel vs. 7.2% without </text>
<text top="753" left="676" width="163" height="20" font="5">clopidogrel (difference -4.1%; </text>
<text top="614" left="879" width="7" height="18" font="5">•</text>
<text top="613" left="886" width="156" height="20" font="5"> Results based on landmark </text>
<text top="630" left="879" width="178" height="20" font="5">analysis of those event-free at 6 </text>
<text top="647" left="879" width="179" height="20" font="5">or 12 mo follow-up (6 mo results </text>
<text top="665" left="879" width="119" height="20" font="5">included in this table)<b> </b></text>
<text top="682" left="879" width="3" height="20" font="4"><b> </b></text>
<text top="699" left="879" width="3" height="20" font="4"><b> </b></text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="13" size="12" family="Times" color="#ff0000"/>
<text top="789" left="1117" width="20" height="21" font="0">22 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="178" width="130" height="20" font="4"><b>Size:  </b>4,666 pts;  3,165 </text>
<text top="70" left="178" width="117" height="20" font="5">BMS and 1,501 DES<b> </b></text>
<text top="53" left="676" width="177" height="20" font="5">95% CI: -7.6% – -0.6%; p=0.02) </text>
<text top="70" left="676" width="3" height="20" font="4"><b> </b></text>
<text top="93" left="54" width="1074" height="20" font="5">ASA indicates aspirin; BMS, bare metal stent; CABG, coronary artery bypass graft; CI confidence interval; DES, drug-eluting stent; DM, diabetes mellitus; HR, hazard ratio; MI, myocardial infarction; </text>
<text top="113" left="54" width="490" height="20" font="5">N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="138" left="54" width="5" height="15" font="11"><b> </b></text>
<text top="169" left="54" width="593" height="24" font="2"><b>Data Supplement 9.  Randomized Studies of 1 Versus 12 Months of DAPT After BMS </b></text>
<text top="194" left="60" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="211" left="86" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="229" left="63" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="194" left="202" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="211" left="207" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="229" left="201" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="194" left="350" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="194" left="519" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="211" left="537" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="229" left="520" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="246" left="541" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="194" left="699" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="211" left="682" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="229" left="685" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="246" left="727" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="196" left="871" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="213" left="905" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="230" left="912" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="264" left="54" width="92" height="20" font="5">Steinhubl SR, et </text>
<text top="281" left="54" width="20" height="20" font="5">al., </text>
<text top="298" left="54" width="31" height="20" font="5">2002 </text>
<text top="316" left="54" width="25" height="20" font="5">(49) </text>
<text top="333" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12435254">12435254</a></text>
<text top="333" left="109" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12435254"><b> </b></a></text>
<text top="264" left="178" width="119" height="20" font="4"><b>Aim:</b> To evaluate the </text>
<text top="281" left="178" width="131" height="20" font="5">benefit of long-term (12 </text>
<text top="298" left="178" width="105" height="20" font="5">mo) treatment with </text>
<text top="316" left="178" width="126" height="20" font="5">clopidogrel (in addition </text>
<text top="333" left="178" width="130" height="20" font="5">to ASA) after PCI in pts </text>
<text top="350" left="178" width="97" height="20" font="5">treated with BMS<b> </b></text>
<text top="367" left="178" width="3" height="20" font="4"><b> </b></text>
<text top="384" left="178" width="99" height="20" font="4"><b>Study type: </b>RCT<b> </b></text>
<text top="402" left="178" width="3" height="20" font="4"><b> </b></text>
<text top="419" left="178" width="86" height="20" font="4"><b>Size: </b>2,116 pts<b> </b></text>
<text top="264" left="322" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="281" left="322" width="135" height="20" font="5">referred for planned PCI<b> </b></text>
<text top="298" left="322" width="3" height="20" font="4"><b> </b></text>
<text top="316" left="322" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="333" left="322" width="112" height="20" font="5">Contraindications to </text>
<text top="350" left="322" width="158" height="20" font="5">antiplatelet or antithrombotic </text>
<text top="367" left="322" width="130" height="20" font="5">therapy, recent STEMI, </text>
<text top="384" left="322" width="102" height="20" font="5">recent use of GPI, </text>
<text top="402" left="322" width="150" height="20" font="5">clopidogrel, or thrombolytic </text>
<text top="419" left="322" width="44" height="20" font="5">therapy<b> </b></text>
<text top="264" left="501" width="117" height="20" font="4"><b>Intervention: </b>ASA + </text>
<text top="281" left="501" width="63" height="20" font="5">clopidogrel </text>
<text top="298" left="501" width="7" height="20" font="4"><b>  </b></text>
<text top="316" left="501" width="116" height="20" font="4"><b>Comparator: </b>ASA + </text>
<text top="333" left="501" width="60" height="20" font="5">placebo    <b> </b></text>
<text top="265" left="663" width="165" height="20" font="4"><b>1</b>°<b> endpoint:</b> 1 y incidence of </text>
<text top="282" left="663" width="153" height="20" font="5">MACE (death, MI or stroke) </text>
<text top="301" left="663" width="7" height="18" font="5">•</text>
<text top="301" left="670" width="133" height="20" font="5"> RRR: 26.9% (CI: 3.9%–</text>
<text top="318" left="663" width="87" height="20" font="5">44.4%; p=0.02) </text>
<text top="335" left="663" width="3" height="20" font="5"> </text>
<text top="352" left="663" width="3" height="20" font="5"> </text>
<text top="370" left="663" width="137" height="20" font="4"><b>Safety endpoint:</b>  Major </text>
<text top="387" left="663" width="50" height="20" font="5">bleeding </text>
<text top="406" left="663" width="7" height="18" font="5">•</text>
<text top="405" left="670" width="147" height="20" font="5"> 8.8% with DAPT vs. 6.7% </text>
<text top="422" left="663" width="103" height="20" font="5">with ASA (p=0.07)<b> </b></text>
<text top="266" left="852" width="7" height="18" font="5">•</text>
<text top="265" left="859" width="194" height="20" font="4"><b> </b>All study pts treated with DAPT for </text>
<text top="282" left="852" width="71" height="20" font="5">the first 28 d<b> </b></text>
<text top="301" left="852" width="7" height="18" font="5">•</text>
<text top="301" left="859" width="178" height="20" font="4"><b> </b>Absolute risk reduction 3% with </text>
<text top="318" left="852" width="36" height="20" font="5">DAPT<b> </b></text>
<text top="335" left="852" width="3" height="20" font="4"><b> </b></text>
<text top="447" left="54" width="1041" height="20" font="5">ASA indicates aspirin; BMS, bare metal stent; CI, indicates confidence interval; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DM, diabetes mellitus; HR, hazard ratio; MACE, major </text>
<text top="467" left="54" width="1055" height="20" font="5">adverse cardiac events; MI, myocardial infarction; N/A, not available; OR, odds ratio; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; RR, relative risk; and STEMI, ST-</text>
<text top="486" left="54" width="169" height="20" font="5">elevation myocardial infarction.</text>
<text top="486" left="223" width="3" height="20" font="13"> </text>
<text top="511" left="54" width="5" height="15" font="11"><b> </b></text>
<text top="543" left="54" width="563" height="24" font="2"><b>Data Supplement 10.  Studies and Meta-Analyses Comparing Graft Patency Post</b></text>
<text top="546" left="617" width="7" height="20" font="4"><b>–</b></text>
<text top="543" left="624" width="514" height="24" font="2"><b>CABG in Patients Treated With Either Antiplatelet Monotherapy or DAPT  </b></text>
<text top="568" left="62" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="585" left="87" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="602" left="65" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="568" left="222" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="585" left="227" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="602" left="221" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="568" left="381" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="568" left="533" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="585" left="551" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="602" left="533" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="619" left="554" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="568" left="716" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="585" left="699" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="602" left="701" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="619" left="744" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="569" left="891" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="586" left="925" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="603" left="933" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="640" left="54" width="113" height="20" font="4"><b>Randomized Trials </b></text>
<text top="661" left="54" width="117" height="20" font="5">Mannacio VA, et al.,  </text>
<text top="678" left="54" width="31" height="20" font="5">2012 </text>
<text top="695" left="54" width="25" height="20" font="5">(50) </text>
<text top="712" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22942294">22942294</a></text>
<text top="712" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22942294"> </a></text>
<text top="730" left="54" width="3" height="20" font="5"> </text>
<text top="661" left="181" width="127" height="20" font="4"><b>Aim: </b>To determine the </text>
<text top="678" left="181" width="143" height="20" font="5">individual variability in the </text>
<text top="695" left="181" width="134" height="20" font="5">response to ASA and/or </text>
<text top="712" left="181" width="159" height="20" font="5">clopidogrel and its impact on </text>
<text top="730" left="181" width="155" height="20" font="5">graft patency after off-pump </text>
<text top="747" left="181" width="38" height="20" font="5">CABG<b> </b></text>
<text top="764" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="661" left="359" width="109" height="20" font="4"><b>Inclusion criteria:  </b></text>
<text top="678" left="359" width="156" height="20" font="5">Consecutive pts undergoing </text>
<text top="695" left="359" width="90" height="20" font="5">off-pump CABG<b> </b></text>
<text top="712" left="359" width="3" height="20" font="4"><b> </b></text>
<text top="730" left="359" width="113" height="20" font="4"><b>Exclusion criteria:  </b></text>
<text top="747" left="359" width="103" height="20" font="5">Additional surgical </text>
<text top="764" left="359" width="133" height="20" font="5">procedures, emergency </text>
<text top="661" left="528" width="116" height="20" font="4"><b>Intervention: </b>ASA +<b> </b></text>
<text top="678" left="528" width="63" height="20" font="5">clopidogrel<b> </b></text>
<text top="695" left="528" width="7" height="20" font="4"><b>  </b></text>
<text top="712" left="528" width="122" height="20" font="4"><b>Comparator:  </b>ASA<b>     </b></text>
<text top="662" left="663" width="207" height="20" font="4"><b>1</b>°<b> endpoint:  </b>Platelet resistance and </text>
<text top="679" left="663" width="52" height="20" font="5">inhibition<b> </b></text>
<text top="698" left="663" width="7" height="18" font="5">•</text>
<text top="698" left="670" width="197" height="20" font="5"> In the ASA group 32.6% were ASA </text>
<text top="715" left="663" width="202" height="20" font="5">resistant and, in the ASA-clopidogrel </text>
<text top="732" left="663" width="158" height="20" font="5">group, 12.6% were ASA and </text>
<text top="749" left="663" width="116" height="20" font="5">clopidogrel resistant. </text>
<text top="766" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="663" left="886" width="7" height="18" font="5">•</text>
<text top="662" left="892" width="159" height="20" font="5"> Secondary endpoint of SVG </text>
<text top="679" left="886" width="150" height="20" font="5">graft occlusion at 12 mo as </text>
<text top="696" left="886" width="163" height="20" font="5">assessed by CTA:  7.4% with </text>
<text top="714" left="886" width="147" height="20" font="5">DAPT vs. 13.1% with ASA </text>
<text top="731" left="886" width="49" height="20" font="5">(p=0.04) </text>
<text top="748" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="765" left="886" width="3" height="20" font="4"><b> </b></text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">23 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="181" width="149" height="20" font="4"><b>Study type: </b>Single  center </text>
<text top="70" left="181" width="29" height="20" font="5">RCT<b> </b></text>
<text top="87" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="104" left="181" width="76" height="20" font="4"><b>Size: </b>300 pts<b> </b></text>
<text top="53" left="359" width="150" height="20" font="5">operations, active bleeding </text>
<text top="70" left="359" width="116" height="20" font="5">or bleeding diathesis<b> </b></text>
<text top="53" left="663" width="187" height="20" font="4"><b>Safety endpoint:  </b>Major bleeding<b> </b></text>
<text top="72" left="663" width="7" height="18" font="5">•</text>
<text top="71" left="670" width="200" height="20" font="4"><b> </b>1.3% with DAPT vs. 1.3% with ASA </text>
<text top="88" left="663" width="49" height="20" font="5">(p=1.00)<b> </b></text>
<text top="106" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="53" left="886" width="3" height="20" font="5"> </text>
<text top="123" left="54" width="87" height="20" font="5">Sun JCJ, et al., </text>
<text top="141" left="54" width="31" height="20" font="5">2010 </text>
<text top="158" left="54" width="25" height="20" font="5">(51) </text>
<text top="175" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21146675">21146675</a></text>
<text top="175" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21146675"> </a></text>
<text top="123" left="181" width="158" height="20" font="4"><b>Aim:</b> Assess graft patency 1 </text>
<text top="141" left="181" width="161" height="20" font="5">mo after CABG in pts treated </text>
<text top="158" left="181" width="101" height="20" font="5">with ASA alone or </text>
<text top="175" left="181" width="95" height="20" font="5">ASA+clopidogrel </text>
<text top="192" left="181" width="3" height="20" font="5"> </text>
<text top="209" left="181" width="161" height="20" font="4"><b>Study type:</b> RCT, pilot study </text>
<text top="227" left="181" width="3" height="20" font="5"> </text>
<text top="244" left="181" width="147" height="20" font="4"><b>Size:</b> 100 pts (79 of whom </text>
<text top="261" left="181" width="146" height="20" font="5">underwent follow-up CTA) </text>
<text top="123" left="359" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="141" left="359" width="155" height="20" font="5">undergoing on-pump CABG </text>
<text top="158" left="359" width="152" height="20" font="5">treated with ≥1 free bypass </text>
<text top="175" left="359" width="28" height="20" font="5">graft </text>
<text top="192" left="359" width="3" height="20" font="5"> </text>
<text top="209" left="359" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="227" left="359" width="74" height="20" font="5">Indication for </text>
<text top="244" left="359" width="152" height="20" font="5">anticoagulation, Hx of GI or </text>
<text top="261" left="359" width="114" height="20" font="5">intracranial bleeding </text>
<text top="123" left="528" width="82" height="20" font="4"><b>Intervention:</b>  </text>
<text top="141" left="528" width="95" height="20" font="5">ASA+clopidogrel </text>
<text top="158" left="528" width="7" height="20" font="5">  </text>
<text top="175" left="528" width="112" height="20" font="4"><b>Comparator:</b> ASA+ </text>
<text top="192" left="528" width="46" height="20" font="5">placebo<b> </b></text>
<text top="125" left="663" width="206" height="20" font="4"><b>1</b>°<b> endpoint:</b> Proportion of pts with ≥ </text>
<text top="142" left="663" width="203" height="20" font="5">occluded grafts at 1 mo as assessed </text>
<text top="159" left="663" width="44" height="20" font="5">by CTA </text>
<text top="178" left="663" width="7" height="18" font="5">•</text>
<text top="178" left="670" width="181" height="20" font="5"> 17.5% with ASA+clopidogrel vs. </text>
<text top="195" left="663" width="201" height="20" font="5">23.1% with ASA+placebo (RR: 0.95; </text>
<text top="212" left="663" width="154" height="20" font="5">95% CI: 0.80–1.14; p=0.54) </text>
<text top="229" left="663" width="3" height="20" font="5"> </text>
<text top="246" left="663" width="184" height="20" font="4"><b>Safety endpoint:</b> Major bleeding </text>
<text top="263" left="663" width="72" height="20" font="5">complication </text>
<text top="283" left="663" width="7" height="18" font="5">•</text>
<text top="282" left="670" width="174" height="20" font="5"> 6.1% with ASA+clopidogrel vs. </text>
<text top="299" left="663" width="185" height="20" font="5">6.0% with ASA+placebo (p=1.00)<b> </b></text>
<text top="123" left="886" width="24" height="20" font="5">N/A </text>
<text top="141" left="886" width="3" height="20" font="5"> </text>
<text top="158" left="886" width="3" height="20" font="5"> </text>
<text top="317" left="54" width="68" height="20" font="4"><b>CASCADE  </b></text>
<text top="334" left="54" width="79" height="20" font="5">Kulik A, et al., </text>
<text top="352" left="54" width="34" height="20" font="5">2010  </text>
<text top="369" left="54" width="25" height="20" font="5">(52) </text>
<text top="386" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21135365">21135365</a></text>
<text top="386" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21135365"> </a></text>
<text top="317" left="181" width="143" height="20" font="4"><b>Aim:</b> Assess if addition of </text>
<text top="334" left="181" width="132" height="20" font="5">clopidogrel to ASA after </text>
<text top="352" left="181" width="155" height="20" font="5">CABG inhibits SVG disease </text>
<text top="369" left="181" width="154" height="20" font="5">at 1 y as assessed by IVUS </text>
<text top="386" left="181" width="3" height="20" font="5"> </text>
<text top="403" left="181" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="420" left="181" width="3" height="20" font="5"> </text>
<text top="438" left="181" width="158" height="20" font="4"><b>Size:</b> 113 pts (92 underwent </text>
<text top="455" left="181" width="89" height="20" font="5">follow-up IVUS) </text>
<text top="317" left="359" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="334" left="359" width="72" height="20" font="5">undergoing 1</text>
<text top="336" left="431" width="6" height="13" font="7">st</text>
<text top="334" left="437" width="68" height="20" font="5"> time CABG </text>
<text top="352" left="359" width="150" height="20" font="5">treated with at least 2 SVG </text>
<text top="369" left="359" width="139" height="20" font="5">with or without the use of </text>
<text top="386" left="359" width="137" height="20" font="5">cardiopulmonary bypass </text>
<text top="403" left="359" width="3" height="20" font="5"> </text>
<text top="420" left="359" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="438" left="359" width="152" height="20" font="5">Concomitant valve surgery, </text>
<text top="455" left="359" width="73" height="20" font="5">need for oral </text>
<text top="472" left="359" width="86" height="20" font="5">anticoagulation </text>
<text top="317" left="528" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="334" left="528" width="83" height="20" font="5">Clopidogrel (in </text>
<text top="352" left="528" width="92" height="20" font="5">addition to ASA) </text>
<text top="369" left="528" width="7" height="20" font="5">  </text>
<text top="386" left="528" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="403" left="528" width="111" height="20" font="5">Placebo (in addition </text>
<text top="420" left="528" width="46" height="20" font="5">to ASA)<b> </b></text>
<text top="318" left="663" width="206" height="20" font="4"><b>1</b>°<b> endpoint:</b> Mean SVG intimal area </text>
<text top="335" left="663" width="127" height="20" font="5">per pts at 1 y follow-up </text>
<text top="355" left="663" width="7" height="18" font="5">•</text>
<text top="354" left="670" width="44" height="20" font="5"> 4.1 mm</text>
<text top="356" left="714" width="4" height="13" font="7">2</text>
<text top="354" left="719" width="131" height="20" font="5"> with clopidogrel vs. 4.5 </text>
<text top="371" left="663" width="20" height="20" font="5">mm</text>
<text top="373" left="683" width="4" height="13" font="7">2</text>
<text top="371" left="688" width="125" height="20" font="5"> with placebo (p=0.90) </text>
<text top="388" left="663" width="3" height="20" font="5"> </text>
<text top="406" left="663" width="184" height="20" font="4"><b>Safety endpoint:</b> Major bleeding </text>
<text top="425" left="663" width="7" height="18" font="5">•</text>
<text top="424" left="670" width="189" height="20" font="5"> 1.8% with clopidogrel vs. 0% with </text>
<text top="441" left="663" width="96" height="20" font="5">placebo (p=0.50) </text>
<text top="458" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="319" left="886" width="7" height="18" font="5">•</text>
<text top="318" left="892" width="179" height="20" font="5"> Overall 1 y graft patency 95.2% </text>
<text top="335" left="886" width="171" height="20" font="5">with clopidogrel vs. 95.5% with </text>
<text top="353" left="886" width="96" height="20" font="5">placebo (p=0.90) </text>
<text top="372" left="886" width="7" height="18" font="5">•</text>
<text top="371" left="892" width="163" height="20" font="5"> 1 y SVG patency 94.3% with </text>
<text top="388" left="886" width="145" height="20" font="5">clopidogrel vs. 95.5% with </text>
<text top="406" left="886" width="96" height="20" font="5">placebo (p=0.90) </text>
<text top="423" left="886" width="3" height="20" font="5"> </text>
<text top="440" left="886" width="3" height="20" font="5"> </text>
<text top="457" left="886" width="3" height="20" font="5"> </text>
<text top="490" left="54" width="77" height="20" font="5">Gao G, et al., </text>
<text top="507" left="54" width="34" height="20" font="5">2010  </text>
<text top="524" left="54" width="25" height="20" font="5">(53) </text>
<text top="542" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21050973">21050973</a></text>
<text top="542" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21050973"> </a></text>
<text top="490" left="181" width="132" height="20" font="4"><b>Aim:</b> Assess 3 mo graft </text>
<text top="507" left="181" width="159" height="20" font="5">patency after CABG in those </text>
<text top="524" left="181" width="124" height="20" font="5">treated with or without </text>
<text top="542" left="181" width="140" height="20" font="5">clopidogrel (in addition to </text>
<text top="559" left="181" width="81" height="20" font="5">baseline ASA) </text>
<text top="576" left="181" width="3" height="20" font="5"> </text>
<text top="593" left="181" width="149" height="20" font="4"><b>Study type:</b> Single center, </text>
<text top="610" left="181" width="29" height="20" font="5">RCT </text>
<text top="628" left="181" width="3" height="20" font="5"> </text>
<text top="645" left="181" width="165" height="20" font="4"><b>Size:</b> 249 pts (244 underwent </text>
<text top="662" left="181" width="32" height="20" font="5">CTA) </text>
<text top="490" left="359" width="127" height="20" font="4"><b>Inclusion criteria:</b> Pts </text>
<text top="507" left="359" width="152" height="20" font="5">referred for isolated CABG, </text>
<text top="524" left="359" width="82" height="20" font="5">with or without </text>
<text top="542" left="359" width="137" height="20" font="5">cardiopulmonary bypass </text>
<text top="559" left="359" width="3" height="20" font="5"> </text>
<text top="576" left="359" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="593" left="359" width="109" height="20" font="5">Thrombocytopenia, </text>
<text top="610" left="359" width="91" height="20" font="5">previous CABG, </text>
<text top="628" left="359" width="146" height="20" font="5">concomitant valve surgery </text>
<text top="645" left="359" width="125" height="20" font="5">or aneurysm resection </text>
<text top="490" left="528" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="507" left="528" width="112" height="20" font="5">Clopidogrel (n=113) </text>
<text top="524" left="528" width="7" height="20" font="5">  </text>
<text top="542" left="528" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="559" left="528" width="116" height="20" font="5">clopiodogrel (n=111)<b> </b></text>
<text top="491" left="663" width="204" height="20" font="4"><b>1</b>°<b> endpoint:</b> SVG graft patency at 3 </text>
<text top="508" left="663" width="128" height="20" font="5">mo (assessed by CTA) </text>
<text top="528" left="663" width="7" height="18" font="5">•</text>
<text top="527" left="670" width="187" height="20" font="5"> 91.6% with clopidogrel vs. 85.7% </text>
<text top="544" left="663" width="205" height="20" font="5">without clopidogrel (RR: 1.7; 95% CI: </text>
<text top="561" left="663" width="100" height="20" font="5">1.0–2.9; p=0.043) </text>
<text top="578" left="663" width="3" height="20" font="5"> </text>
<text top="596" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="492" left="886" width="7" height="18" font="5">•</text>
<text top="491" left="892" width="155" height="20" font="5"> In the multivariate analysis, </text>
<text top="508" left="886" width="164" height="20" font="5">combined antiplatelet therapy </text>
<text top="526" left="886" width="80" height="20" font="5">independently </text>
<text top="545" left="886" width="7" height="18" font="5">•</text>
<text top="544" left="892" width="179" height="20" font="5"> Increased venous graft patency </text>
<text top="561" left="886" width="161" height="20" font="5">(RR: 1.996; CI: 1.015–3.922; </text>
<text top="578" left="886" width="56" height="20" font="5">p=0.045). </text>
<text top="596" left="886" width="3" height="20" font="5"> </text>
<text top="613" left="886" width="3" height="20" font="5"> </text>
<text top="680" left="54" width="69" height="20" font="5">Gao C, et al </text>
<text top="697" left="54" width="31" height="20" font="5">2009 </text>
<text top="714" left="54" width="25" height="20" font="5">(54) </text>
<text top="732" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19559191">19559191</a></text>
<text top="732" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19559191"> </a></text>
<text top="680" left="181" width="149" height="20" font="4"><b>Aim:</b>  Assess 1 and 12 mo </text>
<text top="697" left="181" width="142" height="20" font="5">SVG patency after CABG </text>
<text top="714" left="181" width="156" height="20" font="5">with either clopidogrel alone </text>
<text top="732" left="181" width="109" height="20" font="5">or clopidogrel+ASA </text>
<text top="749" left="181" width="3" height="20" font="5"> </text>
<text top="766" left="181" width="99" height="20" font="4"><b>Study type:</b> RCT </text>
<text top="680" left="359" width="152" height="20" font="4"><b>Inclusion criteria:</b> Elective </text>
<text top="697" left="359" width="38" height="20" font="5">CABG </text>
<text top="714" left="359" width="3" height="20" font="5"> </text>
<text top="732" left="359" width="113" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="749" left="359" width="109" height="20" font="5">Thrombocytopenia, </text>
<text top="766" left="359" width="146" height="20" font="5">concomitant valve surgery </text>
<text top="680" left="528" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="697" left="528" width="104" height="20" font="5">Clopidogrel + ASA </text>
<text top="714" left="528" width="39" height="20" font="5">(n=95) </text>
<text top="732" left="528" width="3" height="20" font="5"> </text>
<text top="749" left="528" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="766" left="528" width="99" height="20" font="5">Clopidogrel alone </text>
<text top="681" left="663" width="203" height="20" font="4"><b>1</b>°<b> endpoint:</b> SVG patency rates (as </text>
<text top="698" left="663" width="104" height="20" font="5">assessed by CTA) </text>
<text top="718" left="663" width="7" height="18" font="5">•</text>
<text top="717" left="670" width="189" height="20" font="5"> 1 mo: 98.2% with clopdigrel+ASA </text>
<text top="734" left="663" width="179" height="20" font="5">vs. 98.1% with clopidogrel alone </text>
<text top="751" left="663" width="49" height="20" font="5">(p=0.73) </text>
<text top="770" left="663" width="7" height="18" font="5">•</text>
<text top="770" left="670" width="203" height="20" font="5"> 12 mo: 96.3% with clopiodgrel+ASA </text>
<text top="682" left="886" width="7" height="18" font="5">•</text>
<text top="681" left="892" width="139" height="20" font="5"> All pts underwent CABG </text>
<text top="698" left="886" width="148" height="20" font="5">performed by one surgeon </text>
<text top="718" left="886" width="7" height="18" font="5">•</text>
<text top="717" left="892" width="154" height="20" font="5"> Treatment assignment was </text>
<text top="734" left="886" width="123" height="20" font="5">alternated every wk in </text>
<text top="751" left="886" width="139" height="20" font="5">consecutively treated pts </text>
<text top="770" left="886" width="7" height="18" font="5">•</text>
<text top="770" left="892" width="143" height="20" font="5"> Report states no obvious </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">24 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="181" width="3" height="20" font="5"> </text>
<text top="70" left="181" width="76" height="20" font="4"><b>Size:</b> 197 pts </text>
<text top="53" left="359" width="125" height="20" font="5">or aneurysm resection </text>
<text top="53" left="528" width="49" height="20" font="5">(n=102)  </text>
<text top="70" left="528" width="3" height="20" font="4"><b> </b></text>
<text top="53" left="663" width="179" height="20" font="5">vs. 93.5% with clopidogrel alone </text>
<text top="70" left="663" width="49" height="20" font="5">(p=0.25) </text>
<text top="53" left="886" width="146" height="20" font="5">bleeding events in any pts </text>
<text top="96" left="54" width="144" height="20" font="4"><b>Nonrandomized Studies </b></text>
<text top="122" left="54" width="52" height="20" font="4"><b>ROOBY  </b></text>
<text top="139" left="54" width="101" height="20" font="5">Ebrahimi R, et al., </text>
<text top="156" left="54" width="31" height="20" font="5">2014 </text>
<text top="173" left="54" width="25" height="20" font="5">(55) </text>
<text top="191" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24206971">24206971</a></text>
<text top="191" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24206971"> </a></text>
<text top="122" left="181" width="140" height="20" font="4"><b>Aim:</b> Evaluate the role of </text>
<text top="139" left="181" width="165" height="20" font="5">clopidogrel use post CABG to </text>
<text top="156" left="181" width="154" height="20" font="5">improve graft patency when </text>
<text top="173" left="181" width="127" height="20" font="5">added to ASA therapy. </text>
<text top="191" left="181" width="3" height="20" font="5"> </text>
<text top="208" left="181" width="122" height="20" font="4"><b>Study type:</b> Post hoc </text>
<text top="225" left="181" width="135" height="20" font="5">substudy analysis of the </text>
<text top="242" left="181" width="71" height="20" font="5">ROOBY trial </text>
<text top="259" left="181" width="3" height="20" font="5"> </text>
<text top="277" left="181" width="146" height="20" font="4"><b>Size:</b> 2,203 pts enrolled in </text>
<text top="294" left="181" width="136" height="20" font="5">trial;  953 pts included in </text>
<text top="311" left="181" width="51" height="20" font="5">analysis  </text>
<text top="122" left="359" width="153" height="20" font="4"><b>Inclusion criteria: </b>Pts who </text>
<text top="139" left="359" width="111" height="20" font="5">were enrolled in the </text>
<text top="156" left="359" width="150" height="20" font="5">ROOBY trial with complete </text>
<text top="173" left="359" width="154" height="20" font="5">data on clopidogrel use and </text>
<text top="191" left="359" width="146" height="20" font="5">with 1 y angiographic data </text>
<text top="208" left="359" width="3" height="20" font="5"> </text>
<text top="225" left="359" width="130" height="20" font="4"><b>Exclusion criteria (for </b></text>
<text top="242" left="359" width="130" height="20" font="4"><b>substudy): </b>No data on </text>
<text top="259" left="359" width="126" height="20" font="5">clopidogrel use, no 1 y </text>
<text top="277" left="359" width="127" height="20" font="5">angiographic follow-up </text>
<text top="122" left="528" width="78" height="20" font="4"><b>Intervention:</b> </text>
<text top="139" left="528" width="102" height="20" font="5">Clopidogrel use at </text>
<text top="156" left="528" width="57" height="20" font="5">discharge </text>
<text top="173" left="528" width="96" height="20" font="5">(nonrandomized) </text>
<text top="191" left="528" width="46" height="20" font="5">(n=345) </text>
<text top="208" left="528" width="7" height="20" font="5">  </text>
<text top="225" left="528" width="96" height="20" font="4"><b>Comparator:</b> No </text>
<text top="242" left="528" width="100" height="20" font="5">clopidogrel use at </text>
<text top="259" left="528" width="103" height="20" font="5">discharge (n=608)<b> </b></text>
<text top="123" left="663" width="201" height="20" font="4"><b>1</b>°<b> endpoint:</b> 1 y graft patency rates </text>
<text top="140" left="663" width="85" height="20" font="5">at angiography </text>
<text top="159" left="663" width="7" height="18" font="5">•</text>
<text top="159" left="670" width="181" height="20" font="5"> 86.5% with clopiogrel vs. 85.3% </text>
<text top="176" left="663" width="155" height="20" font="5">without clopidogrel (p=0.43) </text>
<text top="193" left="663" width="3" height="20" font="5"> </text>
<text top="210" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="124" left="886" width="7" height="18" font="5">•</text>
<text top="123" left="892" width="179" height="20" font="5"> No significant difference in graft </text>
<text top="140" left="886" width="153" height="20" font="5">patency found in those who </text>
<text top="157" left="886" width="185" height="20" font="5">underwent on-pump CABG nor in </text>
<text top="174" left="886" width="172" height="20" font="5">those who underwent off-pump </text>
<text top="192" left="886" width="38" height="20" font="5">CABG </text>
<text top="209" left="886" width="3" height="20" font="5"> </text>
<text top="226" left="886" width="3" height="20" font="5"> </text>
<text top="243" left="886" width="3" height="20" font="5"> </text>
<text top="329" left="54" width="93" height="20" font="5">Ibrahim K, et al., </text>
<text top="346" left="54" width="31" height="20" font="5">2006 </text>
<text top="363" left="54" width="25" height="20" font="5">(56) </text>
<text top="381" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17060036">17060036</a></text>
<text top="381" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17060036"> </a></text>
<text top="398" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="329" left="181" width="156" height="20" font="4"><b>Aim:  </b>To evaluate the effect </text>
<text top="346" left="181" width="141" height="20" font="5">of clopidogrel on midterm </text>
<text top="363" left="181" width="143" height="20" font="5">graft patency following off-</text>
<text top="381" left="181" width="85" height="20" font="5">pump coronary </text>
<text top="398" left="181" width="140" height="20" font="5">revascularization surgery<b> </b></text>
<text top="415" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="432" left="181" width="146" height="20" font="4"><b>Study type: </b>Single center </text>
<text top="449" left="181" width="161" height="20" font="5">study in which the first 36 pts </text>
<text top="467" left="181" width="158" height="20" font="5">were treated with ASA alone </text>
<text top="484" left="181" width="141" height="20" font="5">then the next 58 pts were </text>
<text top="501" left="181" width="105" height="20" font="5">treated with ASA + </text>
<text top="518" left="181" width="63" height="20" font="5">clopidogrel<b> </b></text>
<text top="535" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="553" left="181" width="126" height="20" font="4"><b>Size: </b>94 consecutively </text>
<text top="570" left="181" width="163" height="20" font="5">treated pts; 62 pts underwent </text>
<text top="587" left="181" width="127" height="20" font="5">angiographic follow-up<b> </b></text>
<text top="329" left="359" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="346" left="359" width="155" height="20" font="5">undergoing off-pump CABG<b> </b></text>
<text top="363" left="359" width="3" height="20" font="4"><b> </b></text>
<text top="381" left="359" width="3" height="20" font="4"><b> </b></text>
<text top="329" left="528" width="120" height="20" font="4"><b>Intervention: </b> ASA + </text>
<text top="346" left="528" width="63" height="20" font="5">clopidogrel<b> </b></text>
<text top="363" left="528" width="7" height="20" font="4"><b>  </b></text>
<text top="381" left="528" width="77" height="20" font="4"><b>Comparator: </b></text>
<text top="398" left="528" width="64" height="20" font="5">Antiplatelet </text>
<text top="415" left="528" width="89" height="20" font="5">monotherapy<b>     </b></text>
<text top="330" left="663" width="206" height="20" font="4"><b>1</b>°<b> endpoint: </b>Overall graft patency at </text>
<text top="347" left="663" width="157" height="20" font="5">6 mo angiographic follow-up </text>
<text top="366" left="663" width="7" height="18" font="5">•</text>
<text top="366" left="670" width="201" height="20" font="5"> 42/45 (93%) with ASA + clopidogrel </text>
<text top="383" left="663" width="176" height="20" font="5">vs. 31/37 (84%) with ASA alone </text>
<text top="400" left="663" width="43" height="20" font="5">(p=NS) </text>
<text top="417" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="435" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="331" left="886" width="7" height="18" font="5">•</text>
<text top="330" left="893" width="159" height="20" font="4"><b> </b>LIMA patency:  28/29 (96%) </text>
<text top="347" left="886" width="176" height="20" font="5">with DAPT vs. 23/35 (92%) with </text>
<text top="364" left="886" width="71" height="20" font="5">ASA (p=NS) </text>
<text top="384" left="886" width="7" height="18" font="5">•</text>
<text top="383" left="892" width="182" height="20" font="5"> SVG patency:  14/16 (87%) with </text>
<text top="400" left="886" width="172" height="20" font="5">DAPT vs. 7/11 (66%) with ASA </text>
<text top="417" left="886" width="43" height="20" font="5">(p=NS) </text>
<text top="435" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="452" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="469" left="886" width="3" height="20" font="5"> </text>
<text top="611" left="54" width="248" height="20" font="4"><b>Meta-Analyses and Systematic Overviews </b></text>
<text top="634" left="54" width="83" height="20" font="5">Deo SV, et al., </text>
<text top="651" left="54" width="38" height="20" font="5">2013<b>   </b></text>
<text top="668" left="54" width="25" height="20" font="5">(57) </text>
<text top="686" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23488578">23488578</a></text>
<text top="686" left="109" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23488578"><b> </b></a></text>
<text top="634" left="181" width="127" height="20" font="4"><b>Aim: </b>Assess effects of </text>
<text top="651" left="181" width="140" height="20" font="5">clopidogrel (in addition to </text>
<text top="668" left="181" width="98" height="20" font="5">ASA) after CABG<b> </b></text>
<text top="686" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="703" left="181" width="150" height="20" font="4"><b>Study type: </b>Meta-analysis<b> </b></text>
<text top="720" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="737" left="181" width="105" height="20" font="4"><b>Size: </b>5 RCT and 6 </text>
<text top="755" left="181" width="163" height="20" font="5">observations studies;  25,728 </text>
<text top="634" left="359" width="150" height="20" font="4"><b>Inclusion criteria: </b>Studies </text>
<text top="651" left="359" width="153" height="20" font="5">of isolated CABG, on-pump </text>
<text top="668" left="359" width="66" height="20" font="5">or off-pump<b> </b></text>
<text top="686" left="359" width="3" height="20" font="4"><b> </b></text>
<text top="703" left="359" width="3" height="20" font="4"><b> </b></text>
<text top="634" left="528" width="78" height="20" font="4"><b>Intervention: </b></text>
<text top="651" left="528" width="83" height="20" font="5">Clopidogrel (in </text>
<text top="668" left="528" width="92" height="20" font="5">addition to ASA)<b> </b></text>
<text top="686" left="528" width="7" height="20" font="4"><b>  </b></text>
<text top="703" left="528" width="105" height="20" font="4"><b>Comparator:</b> ASA </text>
<text top="720" left="528" width="33" height="20" font="5">alone<b> </b></text>
<text top="635" left="663" width="171" height="20" font="4"><b>1</b>°<b> endpoint:  </b>SVG patency as </text>
<text top="652" left="663" width="209" height="20" font="5">assessed by coronary angiography or </text>
<text top="670" left="663" width="163" height="20" font="5">CT angiography in the 5 RCT<b> </b></text>
<text top="689" left="663" width="7" height="18" font="5">•</text>
<text top="688" left="670" width="197" height="20" font="4"><b> </b>Early SVG occlusion rates reduced </text>
<text top="705" left="663" width="199" height="20" font="5">with DAPT (RR: 0.59; 95% CI: 0.43–</text>
<text top="723" left="663" width="80" height="20" font="5">0.82; p=0.02).<b> </b></text>
<text top="740" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="636" left="886" width="7" height="18" font="5">•</text>
<text top="635" left="893" width="133" height="20" font="4"><b> </b>Trend towards a higher </text>
<text top="652" left="886" width="153" height="20" font="5">incidence of major bleeding </text>
<text top="670" left="886" width="174" height="20" font="5">episodes with DAPT (RR: 1.17; </text>
<text top="687" left="886" width="84" height="20" font="5">CI: 1.00–1.37;  </text>
<text top="704" left="886" width="46" height="20" font="5">p=0.05) </text>
<text top="721" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="739" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="756" left="886" width="3" height="20" font="4"><b> </b></text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">25 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="181" width="20" height="20" font="5">pts<b> </b></text>
<text top="80" left="54" width="111" height="20" font="5">Nocerino AG, et al., </text>
<text top="97" left="54" width="31" height="20" font="5">2013 </text>
<text top="114" left="54" width="25" height="20" font="5">(58) </text>
<text top="131" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24035160">24035160</a></text>
<text top="131" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24035160"> </a></text>
<text top="149" left="54" width="7" height="20" font="5">  </text>
<text top="80" left="181" width="161" height="20" font="4"><b>Aim:</b>  Assess whether DAPT </text>
<text top="97" left="181" width="137" height="20" font="5">is superior to antiplatelet </text>
<text top="114" left="181" width="164" height="20" font="5">monotherapy to improve graft </text>
<text top="131" left="181" width="143" height="20" font="5">patency early after CABG </text>
<text top="149" left="181" width="3" height="20" font="5"> </text>
<text top="166" left="181" width="163" height="20" font="4"><b>Study type:</b> Meta-analysis of </text>
<text top="183" left="181" width="42" height="20" font="5">5 RCT  </text>
<text top="200" left="181" width="3" height="20" font="5"> </text>
<text top="217" left="181" width="148" height="20" font="4"><b>Size:</b> 958 pts; 2,919 grafts </text>
<text top="80" left="359" width="148" height="20" font="4"><b>Inclusion criteria:</b> RCT of </text>
<text top="97" left="359" width="144" height="20" font="5">single vs. dual antiplatelet </text>
<text top="114" left="359" width="98" height="20" font="5">therapy for ≥30 d </text>
<text top="131" left="359" width="3" height="20" font="5"> </text>
<text top="149" left="359" width="110" height="20" font="4"><b>Exclusion criteria:</b> </text>
<text top="166" left="359" width="133" height="20" font="5">Nonrandomized studies </text>
<text top="80" left="528" width="114" height="20" font="4"><b>Intervention:</b> DAPT </text>
<text top="97" left="528" width="7" height="20" font="5">  </text>
<text top="114" left="528" width="77" height="20" font="4"><b>Comparator:</b> </text>
<text top="131" left="528" width="64" height="20" font="5">Antiplatelet </text>
<text top="149" left="528" width="79" height="20" font="5">monotherapy<b>  </b></text>
<text top="81" left="663" width="196" height="20" font="4"><b>1</b>°<b> endpoint:</b>  Overall graft patency </text>
<text top="100" left="663" width="7" height="18" font="5">•</text>
<text top="99" left="670" width="174" height="20" font="5"> Early graft occlusion 5.0% with </text>
<text top="116" left="663" width="187" height="20" font="5">DAPT vs. 7.7% with monotherapy </text>
<text top="134" left="663" width="56" height="20" font="5">(p=0.005) </text>
<text top="153" left="663" width="7" height="18" font="5">•</text>
<text top="152" left="670" width="183" height="20" font="5"> OR=1.59 for graft occlusion with </text>
<text top="169" left="663" width="182" height="20" font="5">monotherapy (95% CI: 1.16–2.1) </text>
<text top="186" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="82" left="886" width="7" height="18" font="5">•</text>
<text top="81" left="892" width="157" height="20" font="5"> Follow-up in studies ranged </text>
<text top="98" left="886" width="100" height="20" font="5">from 3 d to 12 mo </text>
<text top="117" left="886" width="7" height="18" font="5">•</text>
<text top="117" left="892" width="163" height="20" font="5"> For SVG only, monotherapy, </text>
<text top="134" left="886" width="144" height="20" font="5">when compared to DAPT, </text>
<text top="151" left="886" width="172" height="20" font="5">associated with increased graft </text>
<text top="168" left="886" width="172" height="20" font="5">loss rate (10.8% vs. 6.6%; OR: </text>
<text top="185" left="886" width="76" height="20" font="5">1.70; p=0.03) </text>
<text top="204" left="886" width="7" height="18" font="5">•</text>
<text top="204" left="892" width="148" height="20" font="5"> No significant reduction in </text>
<text top="221" left="886" width="185" height="20" font="5">arterial graft occlusion with DAPT </text>
<text top="238" left="886" width="34" height="20" font="5">found </text>
<text top="271" left="54" width="97" height="20" font="5">de Leon N, et al., </text>
<text top="289" left="54" width="34" height="20" font="5">2012  </text>
<text top="306" left="54" width="25" height="20" font="5">(59) </text>
<text top="323" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22570427">22570427</a></text>
<text top="323" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22570427"> </a></text>
<text top="271" left="181" width="158" height="20" font="4"><b>Aim:</b>  Evaluate the evidence </text>
<text top="289" left="181" width="122" height="20" font="5">for DAPT post–CABG </text>
<text top="306" left="181" width="3" height="20" font="5"> </text>
<text top="323" left="181" width="141" height="20" font="4"><b>Study type:</b>   Systematic </text>
<text top="340" left="181" width="52" height="20" font="5">overview </text>
<text top="357" left="181" width="3" height="20" font="5"> </text>
<text top="375" left="181" width="134" height="20" font="4"><b>Size:</b>  4 RCT evaluating </text>
<text top="392" left="181" width="146" height="20" font="5">surrogate endpoints and 9 </text>
<text top="409" left="181" width="142" height="20" font="5">studies evaluating clinical </text>
<text top="426" left="181" width="57" height="20" font="5">endpoints </text>
<text top="271" left="359" width="136" height="20" font="4"><b>Inclusion criteria:</b> Peer-</text>
<text top="289" left="359" width="119" height="20" font="5">reviewed studies that </text>
<text top="306" left="359" width="121" height="20" font="5">evaluated DAPT after </text>
<text top="323" left="359" width="38" height="20" font="5">CABG </text>
<text top="340" left="359" width="7" height="20" font="5">  </text>
<text top="271" left="528" width="114" height="20" font="4"><b>Intervention:</b> DAPT </text>
<text top="289" left="528" width="66" height="20" font="5">after CABG </text>
<text top="306" left="528" width="7" height="20" font="5">  </text>
<text top="323" left="528" width="87" height="20" font="4"><b>Comparator:</b>  <b>  </b></text>
<text top="340" left="528" width="64" height="20" font="5">Antiplatelet </text>
<text top="357" left="528" width="75" height="20" font="5">monotherapy<b> </b></text>
<text top="271" left="663" width="152" height="20" font="4"><b>Primary relevant finding:</b>  </text>
<text top="291" left="663" width="7" height="18" font="5">•</text>
<text top="290" left="670" width="197" height="20" font="5"> 3 clinical trials assessing surrogate </text>
<text top="307" left="663" width="196" height="20" font="5">end points failed to demonstrate an </text>
<text top="324" left="663" width="187" height="20" font="5">improvement in graft patency with </text>
<text top="341" left="663" width="202" height="20" font="5">DAPT use, while 1 clinical trial found </text>
<text top="359" left="663" width="158" height="20" font="5">an increase in graft patency. </text>
<text top="376" left="663" width="3" height="20" font="5"> </text>
<text top="393" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="273" left="886" width="7" height="18" font="5">•</text>
<text top="273" left="893" width="27" height="20" font="4"><b> </b>N/A </text>
<text top="444" left="54" width="1068" height="20" font="5">ASA indicates aspirin; CABG, coronary artery bypass graft; CI, confidence interval; CTA, computed tomography angiography; DAPT, dual antiplatelet therapy; GI, gastrointestinal; HR, hazard ratio; </text>
<text top="464" left="54" width="911" height="20" font="5">Hx, history; N/A, not available; LIMA, left internal mammary artery; OR, odds ratio; RCT, randomized controlled trials; RR, relative risk; and SVG, saphenous vein graft. </text>
<text top="489" left="54" width="5" height="15" font="11"><b> </b></text>
<text top="523" left="54" width="393" height="24" font="2"><b>Data Supplement 11.  Studies Comparing Outcome Post</b></text>
<text top="526" left="447" width="7" height="20" font="4"><b>–</b></text>
<text top="523" left="454" width="388" height="24" font="2"><b>CABG in Patients Treated With Either Aspirin or DAPT  </b></text>
<text top="548" left="62" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="565" left="87" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="583" left="65" width="92" height="20" font="4"><b>Year Published </b></text>
<text top="548" left="209" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="565" left="213" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="583" left="207" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="548" left="356" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="548" left="521" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="565" left="539" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="583" left="521" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="600" left="542" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="548" left="716" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="565" left="699" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="583" left="701" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="600" left="744" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="550" left="891" width="179" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="567" left="925" width="111" height="20" font="4"><b>Study Limitations; </b></text>
<text top="584" left="933" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="618" left="54" width="93" height="20" font="5">Sorenson, et al., </text>
<text top="635" left="54" width="31" height="20" font="5">2001 </text>
<text top="652" left="54" width="25" height="20" font="5">(60) </text>
<text top="669" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21371637">21371637</a></text>
<text top="669" left="109" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21371637"><b> </b></a></text>
<text top="687" left="54" width="3" height="20" font="5"> </text>
<text top="618" left="181" width="126" height="20" font="4"><b>Aim: </b>To study efficacy </text>
<text top="635" left="181" width="124" height="20" font="5">of post–op clopidogrel </text>
<text top="652" left="181" width="131" height="20" font="5">treatment in pts with MI </text>
<text top="669" left="181" width="107" height="20" font="5">undergoing CABG <b> </b></text>
<text top="687" left="181" width="3" height="20" font="5"> </text>
<text top="704" left="181" width="119" height="20" font="4"><b>Study type: </b>Registry </text>
<text top="721" left="181" width="33" height="20" font="5">study<b> </b></text>
<text top="738" left="181" width="3" height="20" font="5"> </text>
<text top="755" left="181" width="86" height="20" font="4"><b>Size: </b>3,545 pts<b> </b></text>
<text top="618" left="332" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="635" left="332" width="118" height="20" font="5">surviving &gt; 30 d after </text>
<text top="652" left="332" width="156" height="20" font="5">CABG, pts observed 18 mo. </text>
<text top="669" left="332" width="66" height="20" font="5">after CABG<b> </b></text>
<text top="687" left="332" width="3" height="20" font="5"> </text>
<text top="704" left="332" width="148" height="20" font="4"><b>Exclusion criteria: </b>Those </text>
<text top="721" left="332" width="156" height="20" font="5">not meeting above inclusion </text>
<text top="738" left="332" width="40" height="20" font="5">criteria<b> </b></text>
<text top="618" left="504" width="144" height="20" font="4"><b>Intervention: </b>Clopidogrel </text>
<text top="635" left="504" width="46" height="20" font="5">(n=957)<b> </b></text>
<text top="652" left="504" width="3" height="20" font="5"> </text>
<text top="669" left="504" width="96" height="20" font="4"><b>Comparator: </b>No </text>
<text top="687" left="504" width="123" height="20" font="5">clopidogrel ( n=2,588)<b> </b></text>
<text top="619" left="663" width="199" height="20" font="4"><b>1</b>°<b> endpoint:  </b>Death or recurrent MI </text>
<text top="638" left="663" width="7" height="18" font="5">•</text>
<text top="638" left="670" width="170" height="20" font="5">4.1% with clopidogrel vs. 7.8% </text>
<text top="655" left="663" width="193" height="20" font="5">without clopidogrel (HR: 0.59; 95% </text>
<text top="672" left="663" width="140" height="20" font="5">CI: 0.42–0.85; p=0.0003)<b> </b></text>
<text top="691" left="663" width="7" height="18" font="5">•</text>
<text top="690" left="670" width="184" height="20" font="5">By propensity score (total n=945) </text>
<text top="707" left="663" width="170" height="20" font="5">4.0% with clopidogrel vs. 6.0% </text>
<text top="725" left="663" width="193" height="20" font="5">without clopidogrel (HR: 0.67; 95% </text>
<text top="742" left="663" width="126" height="20" font="5">CI: 0.44–1.00; p=0.05)<b> </b></text>
<text top="619" left="886" width="38" height="20" font="4"><b> </b>•<b> </b>N/A<b> </b></text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">26 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="139" left="54" width="83" height="20" font="5">Kim DH, et al., </text>
<text top="156" left="54" width="31" height="20" font="5">2009 </text>
<text top="173" left="54" width="25" height="20" font="5">(61) </text>
<text top="191" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19931667">19931667</a></text>
<text top="191" left="109" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19931667"><b> </b></a></text>
<text top="208" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="225" left="54" width="3" height="20" font="4"><b> </b></text>
<text top="139" left="181" width="107" height="20" font="4"><b>Aim: </b>To determine </text>
<text top="156" left="181" width="128" height="20" font="5">benefit and risk of ASA </text>
<text top="173" left="181" width="120" height="20" font="5">+ clopidogrel use (vs. </text>
<text top="191" left="181" width="66" height="20" font="5">ASA alone) </text>
<text top="208" left="181" width="137" height="20" font="5">postoperatively following </text>
<text top="225" left="181" width="118" height="20" font="5">on-pump or off-pump </text>
<text top="242" left="181" width="42" height="20" font="5">CABG. </text>
<text top="260" left="181" width="7" height="20" font="4"><b>  </b></text>
<text top="277" left="181" width="74" height="20" font="4"><b>Study type:  </b></text>
<text top="294" left="181" width="79" height="20" font="5">Observational </text>
<text top="311" left="181" width="7" height="20" font="4"><b>  </b></text>
<text top="328" left="181" width="107" height="20" font="4"><b>Size: </b>15,067 pts  <b>   </b></text>
<text top="139" left="332" width="127" height="20" font="4"><b>Inclusion criteria: </b>Pts </text>
<text top="156" left="332" width="158" height="20" font="5">undergoing CABG treated in </text>
<text top="173" left="332" width="135" height="20" font="5">the early post–operative </text>
<text top="191" left="332" width="105" height="20" font="5">period with ASA or </text>
<text top="208" left="332" width="102" height="20" font="5">clopidogrel + ASA </text>
<text top="225" left="332" width="3" height="20" font="4"><b> </b></text>
<text top="242" left="332" width="154" height="20" font="4"><b>Exclusion criteria:  </b>Pre-op </text>
<text top="260" left="332" width="98" height="20" font="5">and  late post–op </text>
<text top="277" left="332" width="148" height="20" font="5">clopidogrel use, prolonged </text>
<text top="294" left="332" width="152" height="20" font="5">hospitalization &gt;1wk before </text>
<text top="311" left="332" width="156" height="20" font="5">surgery, valvular procedure, </text>
<text top="328" left="332" width="70" height="20" font="5">warfarin use<b> </b></text>
<text top="139" left="504" width="117" height="20" font="4"><b>Intervention: </b>ASA + </text>
<text top="156" left="504" width="133" height="20" font="5">clopidogrel (n=3,268)<b>     </b></text>
<text top="173" left="504" width="7" height="20" font="4"><b>  </b></text>
<text top="191" left="504" width="105" height="20" font="4"><b>Comparator:</b> ASA </text>
<text top="208" left="504" width="63" height="20" font="5">(n=11,799)<b> </b></text>
<text top="140" left="663" width="189" height="20" font="4"><b>1</b>°<b> endpoint:  </b>In-hospital mortality </text>
<text top="159" left="663" width="7" height="18" font="5">•</text>
<text top="159" left="670" width="186" height="20" font="5"> 0.95% with DAPT vs. 1.78% with </text>
<text top="176" left="663" width="185" height="20" font="5">ASA (adjusted OR: 0.50; 95% CI: </text>
<text top="193" left="663" width="62" height="20" font="5">0.25–0.99) </text>
<text top="210" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="227" left="663" width="209" height="20" font="4"><b>Safety endpoint: </b>in-hospital bleeding </text>
<text top="245" left="663" width="40" height="20" font="5">events </text>
<text top="264" left="663" width="7" height="18" font="5">•</text>
<text top="263" left="670" width="186" height="20" font="5"> 4.19% with DAPT vs. 5.17% with </text>
<text top="280" left="663" width="185" height="20" font="5">ASA (adjusted OR: 0.70; 95% CI: </text>
<text top="297" left="663" width="66" height="20" font="5">0.51–0.97)  </text>
<text top="141" left="886" width="7" height="18" font="5">•</text>
<text top="140" left="893" width="160" height="20" font="4"><b> </b>Adjusted HR: 0.83 (CI: 0.61–</text>
<text top="157" left="886" width="109" height="20" font="5">1.12) for in-hospital </text>
<text top="175" left="886" width="187" height="20" font="5">mortality or 30 d readmission with </text>
<text top="192" left="886" width="136" height="20" font="5">DAPT compared to ASA </text>
<text top="209" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="226" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="244" left="886" width="3" height="20" font="5"> </text>
<text top="346" left="54" width="38" height="20" font="4"><b>CURE </b></text>
<text top="364" left="54" width="84" height="20" font="5">Fox KA, et al.,  </text>
<text top="381" left="54" width="31" height="20" font="5">2004 </text>
<text top="398" left="54" width="25" height="20" font="5">(32) </text>
<text top="415" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15313956">15313956</a></text>
<text top="415" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15313956"> </a></text>
<text top="432" left="54" width="3" height="20" font="5"> </text>
<text top="346" left="181" width="137" height="20" font="4"><b>Aim:</b> To assess benefits </text>
<text top="364" left="181" width="120" height="20" font="5">and risks of ASA plus </text>
<text top="381" left="181" width="96" height="20" font="5">clopidogrel in pts </text>
<text top="398" left="181" width="121" height="20" font="5">undergoing CABG for </text>
<text top="415" left="181" width="66" height="20" font="5">NSTE-ACS </text>
<text top="432" left="181" width="3" height="20" font="4"><b> </b></text>
<text top="450" left="181" width="122" height="20" font="4"><b>Study type: </b>Post hoc </text>
<text top="467" left="181" width="116" height="20" font="5">subgroup analysis of </text>
<text top="484" left="181" width="77" height="20" font="5">CURE;<b>  </b>RCT  </text>
<text top="501" left="181" width="10" height="20" font="4"><b>   </b></text>
<text top="518" left="181" width="127" height="20" font="4"><b>Size: </b>12,562 pts entire </text>
<text top="536" left="181" width="131" height="20" font="5">study population; 1,061 </text>
<text top="553" left="181" width="126" height="20" font="5">pts underwent CABG<b>   </b></text>
<text top="346" left="332" width="113" height="20" font="4"><b>Inclusion criteria:   </b></text>
<text top="364" left="332" width="138" height="20" font="5">NSTE-ACS within &lt;24 h  </text>
<text top="381" left="332" width="3" height="20" font="4"><b> </b></text>
<text top="398" left="332" width="117" height="20" font="4"><b>Exclusion criteria:   </b></text>
<text top="415" left="332" width="146" height="20" font="5">NYHA class IV HF, PCI or </text>
<text top="432" left="332" width="83" height="20" font="5">CABG &lt;3 mo,  </text>
<text top="450" left="332" width="103" height="20" font="5">contraindication to </text>
<text top="467" left="332" width="93" height="20" font="5">antiplatelets and </text>
<text top="484" left="332" width="90" height="20" font="5">antithrombotics, </text>
<text top="501" left="332" width="142" height="20" font="5">hemorrhagic or IC stroke, </text>
<text top="518" left="332" width="141" height="20" font="5">severe thrombocytopenia </text>
<text top="536" left="332" width="3" height="20" font="4"><b> </b></text>
<text top="346" left="504" width="144" height="20" font="4"><b>Intervention: </b>Clopidogrel </text>
<text top="364" left="504" width="42" height="20" font="5">+ ASA  </text>
<text top="381" left="504" width="3" height="20" font="4"><b> </b></text>
<text top="398" left="504" width="7" height="20" font="4"><b>  </b></text>
<text top="415" left="504" width="91" height="20" font="4"><b>Comparator:     </b></text>
<text top="432" left="504" width="90" height="20" font="5">Placebo + ASA <b> </b></text>
<text top="348" left="663" width="198" height="20" font="4"><b>1</b>°<b> endpoint:  MACE (</b>CV death, MI </text>
<text top="365" left="663" width="55" height="20" font="5">or stroke) </text>
<text top="384" left="663" width="7" height="18" font="5">•</text>
<text top="383" left="670" width="200" height="20" font="4"><b> </b>14.5% with DAPT % vs. 16.2% with </text>
<text top="400" left="663" width="197" height="20" font="5">ASA (RR: 0.89; 95% CI: 0.71–1.11) </text>
<text top="417" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="435" left="663" width="3" height="20" font="4"><b> </b></text>
<text top="348" left="886" width="7" height="18" font="5">•</text>
<text top="348" left="893" width="165" height="20" font="4"><b> </b>Benefits of DAPT with CABG </text>
<text top="365" left="886" width="172" height="20" font="5">were deemed “consistent” (test </text>
<text top="382" left="886" width="185" height="20" font="5">for interaction among strata 0.53) </text>
<text top="399" left="886" width="125" height="20" font="5">with the benefits in pts </text>
<text top="416" left="886" width="186" height="20" font="5">undergoing PCI (9.6% with DAPT </text>
<text top="434" left="886" width="189" height="20" font="5">vs. 13.2% with ASA; RR: 0.72; CI: </text>
<text top="451" left="886" width="174" height="20" font="5">0.47–0.90) and in those treated </text>
<text top="468" left="886" width="185" height="20" font="5">with medical therapy alone (8.1% </text>
<text top="485" left="886" width="175" height="20" font="5">with DAPT vs. 10.0% with ASA; </text>
<text top="502" left="886" width="137" height="20" font="5">RR: 0.80; CI: 0.69–0.92) </text>
<text top="520" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="537" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="554" left="886" width="3" height="20" font="4"><b> </b></text>
<text top="572" left="54" width="1065" height="20" font="5">ASA indicates aspirin; CABG, coronary artery bypass graft; CI, confidence interval; DAPT, dual antiplatelet therapy; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; N/A, not available; </text>
<text top="592" left="54" width="939" height="20" font="5">NSTE-ACS, non–ST-elevation acute coronary syndrome; NYHA, New York Heart Association; OR, odds ratio; PCI, percutaneous coronary intervention and RR, relative risk.</text>
<text top="592" left="993" width="3" height="20" font="13"> </text>
<text top="617" left="54" width="5" height="15" font="11"><b> </b></text>
<text top="651" left="54" width="4" height="21" font="0"> </text>
<text top="648" left="270" width="4" height="24" font="2"><b> </b></text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">27 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="51" left="54" width="507" height="24" font="2"><b>Data Supplement 12. Studies of Timing of Noncardiac Surgery After PCI </b></text>
<text top="76" left="56" width="98" height="20" font="4"><b>Study Acronym; </b></text>
<text top="94" left="82" width="51" height="20" font="4"><b>Author;  </b></text>
<text top="111" left="59" width="96" height="20" font="4"><b>Year Published  </b></text>
<text top="76" left="203" width="83" height="20" font="4"><b>Aim of Study; </b></text>
<text top="94" left="208" width="74" height="20" font="4"><b>Study Type; </b></text>
<text top="111" left="202" width="86" height="20" font="4"><b>Study Size (N) </b></text>
<text top="76" left="381" width="111" height="20" font="4"><b>Patient Population </b></text>
<text top="76" left="563" width="115" height="20" font="4"><b>Study Intervention  </b></text>
<text top="94" left="581" width="79" height="20" font="4"><b>(# patients) /  </b></text>
<text top="111" left="564" width="114" height="20" font="4"><b>Study Comparator  </b></text>
<text top="128" left="585" width="69" height="20" font="4"><b>(# patients) </b></text>
<text top="76" left="753" width="105" height="20" font="4"><b>Endpoint Results </b></text>
<text top="94" left="736" width="141" height="20" font="4"><b>(Absolute Event Rates,  </b></text>
<text top="111" left="739" width="133" height="20" font="4"><b>P values; OR or RR; &amp; </b></text>
<text top="128" left="781" width="48" height="20" font="4"><b>95% CI) </b></text>
<text top="78" left="935" width="131" height="20" font="4"><b>Relevant  2</b>°<b> Endpoint </b></text>
<text top="95" left="977" width="48" height="20" font="4"><b>(if any); </b></text>
<text top="112" left="945" width="114" height="20" font="4"><b>Study Limitations;  </b></text>
<text top="129" left="953" width="96" height="20" font="4"><b>Adverse Events </b></text>
<text top="147" left="54" width="78" height="20" font="5">Kaluza, et al., </text>
<text top="164" left="54" width="31" height="20" font="5">2000 </text>
<text top="182" left="54" width="25" height="20" font="5">(62) </text>
<text top="199" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10758971?dopt=Citation">10758971</a></text>
<text top="199" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10758971?dopt=Citation"> </a></text>
<text top="216" left="54" width="3" height="20" font="5"> </text>
<text top="147" left="170" width="111" height="20" font="4"><b>Aim:</b> To assess the </text>
<text top="164" left="170" width="140" height="20" font="5">clinical course of pts who </text>
<text top="182" left="170" width="144" height="20" font="5">have undergone coronary </text>
<text top="199" left="170" width="126" height="20" font="5">stent placement &gt;6 wk </text>
<text top="216" left="170" width="102" height="20" font="5">before noncardiac </text>
<text top="233" left="170" width="48" height="20" font="5">surgery. </text>
<text top="251" left="170" width="3" height="20" font="5"> </text>
<text top="268" left="170" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="285" left="170" width="44" height="20" font="5">cohort   </text>
<text top="302" left="170" width="3" height="20" font="5"> </text>
<text top="319" left="170" width="69" height="20" font="4"><b>Size:</b> 40 pts </text>
<text top="147" left="332" width="197" height="20" font="4"><b>Inclusion criteria:</b> Consecutive pts </text>
<text top="164" left="332" width="168" height="20" font="5">who underwent coronary stent </text>
<text top="182" left="332" width="198" height="20" font="5">placement &gt;6 wk before noncardiac </text>
<text top="199" left="332" width="150" height="20" font="5">surgery requiring a general </text>
<text top="216" left="332" width="209" height="20" font="5">anesthesia were included in the study </text>
<text top="233" left="332" width="3" height="20" font="5"> </text>
<text top="251" left="332" width="134" height="20" font="4"><b>Exclusion criteria:</b> N/A </text>
<text top="147" left="555" width="102" height="20" font="4"><b>Intervention:</b> N/A </text>
<text top="164" left="555" width="3" height="20" font="5"> </text>
<text top="182" left="555" width="3" height="20" font="5"> </text>
<text top="199" left="555" width="101" height="20" font="4"><b>Comparator:</b> N/A<b> </b></text>
<text top="216" left="555" width="3" height="20" font="5"> </text>
<text top="233" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="148" left="697" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="168" left="697" width="7" height="18" font="5">•</text>
<text top="167" left="703" width="54" height="20" font="5"> MI: 7 pts </text>
<text top="184" left="697" width="112" height="20" font="5">Major Bleeds: 11pts </text>
<text top="201" left="697" width="56" height="20" font="5">Deaths: 8 </text>
<text top="220" left="697" width="7" height="18" font="5">•</text>
<text top="220" left="703" width="169" height="20" font="5"> All deaths/MI and 8/11 bleeds </text>
<text top="237" left="697" width="198" height="20" font="5">occurred if surgery &lt;14 d from stent </text>
<text top="254" left="697" width="60" height="20" font="5">placement </text>
<text top="271" left="697" width="3" height="20" font="5"> </text>
<text top="289" left="697" width="3" height="20" font="4"><b> </b></text>
<text top="149" left="926" width="7" height="18" font="5">•</text>
<text top="148" left="933" width="142" height="20" font="5"> DAPT not well described </text>
<text top="168" left="926" width="7" height="18" font="5">•</text>
<text top="167" left="933" width="79" height="20" font="5"> Single center </text>
<text top="184" left="926" width="3" height="20" font="5"> </text>
<text top="343" left="54" width="77" height="20" font="5">Wilson, et al., </text>
<text top="360" left="54" width="31" height="20" font="5">2003 </text>
<text top="377" left="54" width="25" height="20" font="5">(63) </text>
<text top="395" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12875757?dopt=Citation">12875757</a></text>
<text top="395" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12875757?dopt=Citation"> </a></text>
<text top="412" left="54" width="3" height="20" font="5"> </text>
<text top="343" left="170" width="127" height="20" font="4"><b>Aim:</b> To determine the </text>
<text top="360" left="170" width="131" height="20" font="5">frequency and timing of </text>
<text top="377" left="170" width="113" height="20" font="5">complications at our </text>
<text top="395" left="170" width="132" height="20" font="5">institution when surgery </text>
<text top="412" left="170" width="130" height="20" font="5">was performed within 2 </text>
<text top="429" left="170" width="116" height="20" font="5">mo of coronary stent </text>
<text top="446" left="170" width="64" height="20" font="5">placement. </text>
<text top="463" left="170" width="3" height="20" font="5"> </text>
<text top="481" left="170" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="498" left="170" width="38" height="20" font="5">cohort </text>
<text top="515" left="170" width="3" height="20" font="5"> </text>
<text top="532" left="170" width="76" height="20" font="4"><b>Size:</b> 207 pts </text>
<text top="343" left="332" width="193" height="20" font="4"><b>Inclusion criteria:</b>  Analysis of the </text>
<text top="360" left="332" width="169" height="20" font="5">PCI database and the General </text>
<text top="377" left="332" width="199" height="20" font="5">Surgery database at Mayo Clinic for </text>
<text top="395" left="332" width="170" height="20" font="5">pts who underwent noncardiac </text>
<text top="412" left="332" width="202" height="20" font="5">surgery within 60 d of coronary stent </text>
<text top="429" left="332" width="176" height="20" font="5">placement. Surgical procedures </text>
<text top="446" left="332" width="196" height="20" font="5">included in this analysis were those </text>
<text top="464" left="332" width="209" height="20" font="5">that required a significant incision and </text>
<text top="481" left="332" width="187" height="20" font="5">had the potential for perioperative </text>
<text top="498" left="332" width="53" height="20" font="5">bleeding. </text>
<text top="515" left="332" width="3" height="20" font="5"> </text>
<text top="532" left="332" width="209" height="20" font="4"><b>Exclusion criteria:</b>  Procedures such </text>
<text top="550" left="332" width="199" height="20" font="5">as joint aspirations, endoscopy, and </text>
<text top="567" left="332" width="210" height="20" font="5">skin biopsies, among others, were not </text>
<text top="584" left="332" width="133" height="20" font="5">included in this analysis </text>
<text top="343" left="555" width="102" height="20" font="4"><b>Intervention:</b> N/A </text>
<text top="360" left="555" width="3" height="20" font="5"> </text>
<text top="377" left="555" width="3" height="20" font="5"> </text>
<text top="395" left="555" width="101" height="20" font="4"><b>Comparator:</b> N/A </text>
<text top="412" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="429" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="344" left="697" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="363" left="697" width="7" height="18" font="5">•</text>
<text top="363" left="703" width="80" height="20" font="5"> MACE: 8/207 </text>
<text top="380" left="697" width="3" height="20" font="5"> </text>
<text top="398" left="697" width="120" height="20" font="4"><b>1</b>°<b>  Safety endpoint:</b> </text>
<text top="417" left="697" width="7" height="18" font="5">•</text>
<text top="417" left="703" width="150" height="20" font="5"> Excessive bleeding: 2/207 </text>
<text top="434" left="697" width="3" height="20" font="5"> </text>
<text top="451" left="697" width="3" height="20" font="4"><b> </b></text>
<text top="345" left="926" width="7" height="18" font="5">•</text>
<text top="344" left="933" width="79" height="20" font="5"> Single center </text>
<text top="361" left="926" width="3" height="20" font="5"> </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">28 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="73" height="20" font="5">Nuttal, et al., </text>
<text top="70" left="54" width="34" height="20" font="5">2008  </text>
<text top="87" left="54" width="25" height="20" font="5">(64) </text>
<text top="104" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18813036?dopt=Citation">18813036</a></text>
<text top="104" left="109" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18813036?dopt=Citation"><b> </b></a></text>
<text top="53" left="170" width="120" height="20" font="4"><b>Aim:</b>  To address the </text>
<text top="70" left="170" width="143" height="20" font="5">hypothesis that the risk of </text>
<text top="87" left="170" width="119" height="20" font="5">MACEs and bleeding </text>
<text top="104" left="170" width="127" height="20" font="5">events is related to the </text>
<text top="122" left="170" width="143" height="20" font="5">time interval between PCI </text>
<text top="139" left="170" width="109" height="20" font="5">with BMS and NCS </text>
<text top="156" left="170" width="3" height="20" font="5"> </text>
<text top="173" left="170" width="149" height="20" font="4"><b>Study type:</b> Retrospective </text>
<text top="190" left="170" width="3" height="20" font="5"> </text>
<text top="208" left="170" width="76" height="20" font="4"><b>Size:</b> 889 pts </text>
<text top="53" left="332" width="189" height="20" font="4"><b>Inclusion criteria:</b> Analysis of pts </text>
<text top="70" left="332" width="199" height="20" font="5">who underwent NCS within 1 y after </text>
<text top="87" left="332" width="160" height="20" font="5">PCI with BMS at Mayo Clinic </text>
<text top="104" left="332" width="181" height="20" font="5">(Rochester, Minnesota) between </text>
<text top="122" left="332" width="180" height="20" font="5">January 1, 1990, and January 1, </text>
<text top="139" left="332" width="192" height="20" font="5">2005. Pts were identified using the </text>
<text top="156" left="332" width="179" height="20" font="5">Mayo Clinic PCI registry and the </text>
<text top="173" left="332" width="172" height="20" font="5">Mayo Clinic Surgical database. </text>
<text top="190" left="332" width="3" height="20" font="5"> </text>
<text top="208" left="332" width="204" height="20" font="4"><b>Exclusion criteria:</b> Pts on long-term </text>
<text top="225" left="332" width="92" height="20" font="5">warfarin therapy </text>
<text top="53" left="555" width="102" height="20" font="4"><b>Intervention:</b> N/A </text>
<text top="70" left="555" width="3" height="20" font="5"> </text>
<text top="87" left="555" width="3" height="20" font="5"> </text>
<text top="104" left="555" width="111" height="20" font="4"><b>Comparator:</b>  N/A<b>   </b></text>
<text top="122" left="555" width="14" height="20" font="5"> <b>   </b></text>
<text top="54" left="697" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="73" left="697" width="7" height="18" font="5">•</text>
<text top="72" left="703" width="209" height="20" font="5"> MACE- 47 (5.2%; 95% CI: 3.8–6.7%) </text>
<text top="91" left="697" width="7" height="18" font="5">•</text>
<text top="91" left="703" width="187" height="20" font="5"> Frequency of MACEs was 10.5% </text>
<text top="108" left="697" width="205" height="20" font="5">(95% CI: 6.7–14.3%) when NCS was </text>
<text top="125" left="697" width="212" height="20" font="5">performed 30 or fewer d after PCI with </text>
<text top="142" left="697" width="209" height="20" font="5">BMS, 3.8% (95% CI: 1.5–6.2%) when </text>
<text top="159" left="697" width="213" height="20" font="5">NCS was 31–90 d after PCI with BMS, </text>
<text top="177" left="697" width="199" height="20" font="5">and 2.8% (95% CI: 1.2–4.5%) when </text>
<text top="194" left="697" width="205" height="20" font="5">NCS was 91 or more d after PCI with </text>
<text top="211" left="697" width="30" height="20" font="5">BMS<b> </b></text>
<text top="55" left="926" width="7" height="18" font="5">•</text>
<text top="54" left="933" width="142" height="20" font="5"> DAPT not well described </text>
<text top="73" left="926" width="7" height="18" font="5">•</text>
<text top="72" left="933" width="79" height="20" font="5"> Single center </text>
<text top="89" left="926" width="3" height="20" font="5"> </text>
<text top="249" left="54" width="95" height="20" font="5">Wijeysundera, et </text>
<text top="266" left="54" width="23" height="20" font="5">al.,  </text>
<text top="283" left="54" width="31" height="20" font="5">2012 </text>
<text top="300" left="54" width="25" height="20" font="5">(65) </text>
<text top="317" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22893606?dopt=Citation">22893606</a></text>
<text top="317" left="109" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22893606?dopt=Citation"><b> </b></a></text>
<text top="335" left="54" width="3" height="20" font="5"> </text>
<text top="249" left="170" width="119" height="20" font="4"><b>Aim:</b> To evaluate the </text>
<text top="266" left="170" width="116" height="20" font="5">outcomes of pts who </text>
<text top="283" left="170" width="106" height="20" font="5">underwent elective </text>
<text top="300" left="170" width="139" height="20" font="5">intermediate- to high-risk </text>
<text top="317" left="170" width="121" height="20" font="5">noncardiac surgery in </text>
<text top="335" left="170" width="122" height="20" font="5">Ontario, Canada after </text>
<text top="352" left="170" width="103" height="20" font="5">stent implantation. </text>
<text top="369" left="170" width="3" height="20" font="5"> </text>
<text top="386" left="170" width="143" height="20" font="4"><b>Study type:</b> A population-</text>
<text top="403" left="170" width="107" height="20" font="5">based cohort study </text>
<text top="421" left="170" width="3" height="20" font="5"> </text>
<text top="438" left="170" width="86" height="20" font="4"><b>Size:</b> 8,116 pts </text>
<text top="249" left="332" width="170" height="20" font="4"><b>Inclusion criteria:</b>  All Ontario </text>
<text top="266" left="332" width="208" height="20" font="5">residents who were ≥40 y, underwent </text>
<text top="283" left="332" width="179" height="20" font="5">any 1 of 16 prespecified elective </text>
<text top="300" left="332" width="209" height="20" font="5">noncardiac surgeries between April 1, </text>
<text top="317" left="332" width="171" height="20" font="5">2003 and March 31, 2009, and </text>
<text top="335" left="332" width="142" height="20" font="5">underwent coronary stent </text>
<text top="352" left="332" width="197" height="20" font="5">implantation within 10 y before their </text>
<text top="369" left="332" width="209" height="20" font="5">index surgery. The included surgeries </text>
<text top="386" left="332" width="181" height="20" font="5">were abdominal aortic aneurysm </text>
<text top="403" left="332" width="171" height="20" font="5">repair, carotid endarterectomy, </text>
<text top="421" left="332" width="200" height="20" font="5">peripheral vascular bypass, total hip </text>
<text top="438" left="332" width="206" height="20" font="5">replacement, total knee replacement, </text>
<text top="455" left="332" width="186" height="20" font="5">large bowel resection, partial liver </text>
<text top="472" left="332" width="167" height="20" font="5">resection, Whipple procedure, </text>
<text top="489" left="332" width="159" height="20" font="5">pneumonectomy, pulmonary </text>
<text top="507" left="332" width="137" height="20" font="5">lobectomy, gastrectomy, </text>
<text top="524" left="332" width="180" height="20" font="5">esophagectomy, total abdominal </text>
<text top="541" left="332" width="204" height="20" font="5">hysterectomy, radical prostatectomy, </text>
<text top="558" left="332" width="170" height="20" font="5">nephrectomy, and cystectomy. </text>
<text top="575" left="332" width="3" height="20" font="5"> </text>
<text top="593" left="332" width="114" height="20" font="4"><b>Exclusion criteria:</b>  </text>
<text top="612" left="332" width="7" height="18" font="5">•</text>
<text top="611" left="339" width="190" height="20" font="5"> Individuals who underwent CABG </text>
<text top="628" left="332" width="187" height="20" font="5">surgery between the preoperative </text>
<text top="645" left="332" width="148" height="20" font="5">PCI and subsequent index </text>
<text top="663" left="332" width="198" height="20" font="5">noncardiac surgery were excluded.  </text>
<text top="682" left="332" width="7" height="18" font="5">•</text>
<text top="681" left="339" width="174" height="20" font="5"> Low-risk ambulatory surgeries  </text>
<text top="249" left="555" width="102" height="20" font="4"><b>Intervention:</b> N/A </text>
<text top="266" left="555" width="3" height="20" font="5"> </text>
<text top="283" left="555" width="3" height="20" font="5"> </text>
<text top="300" left="555" width="3" height="20" font="5"> </text>
<text top="317" left="555" width="105" height="20" font="4"><b>Comparator:</b>  N/A </text>
<text top="335" left="555" width="10" height="20" font="4"><b>   </b></text>
<text top="352" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="250" left="697" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="269" left="697" width="7" height="18" font="5">•</text>
<text top="268" left="703" width="174" height="20" font="5"> Overall risk of 30 d MACE was </text>
<text top="285" left="697" width="168" height="20" font="5">relatively low at 2.1% (n=170), </text>
<text top="302" left="697" width="191" height="20" font="5">whereas the risk of 1 y MACE was </text>
<text top="320" left="697" width="84" height="20" font="5">9.8% (n=798).  </text>
<text top="339" left="697" width="7" height="18" font="5">•</text>
<text top="338" left="703" width="194" height="20" font="5"> The rate of postoperative mortality </text>
<text top="355" left="697" width="199" height="20" font="5">was 1.2% (n=100) at 30 d and 5.2% </text>
<text top="372" left="697" width="83" height="20" font="5">(n=419) at 1 y. </text>
<text top="392" left="697" width="7" height="18" font="5">•</text>
<text top="391" left="703" width="179" height="20" font="5"> BMS: 1-45 d OR: 2.35 (95% CI: </text>
<text top="408" left="697" width="205" height="20" font="5">0.98–5.64); 46–180 d OR: 1.06 (95% </text>
<text top="425" left="697" width="196" height="20" font="5">CI: 0.58–1.92); 181–365 d OR 1.89 </text>
<text top="442" left="697" width="66" height="20" font="5">(1.08–3.32) </text>
<text top="462" left="697" width="7" height="18" font="5">•</text>
<text top="461" left="703" width="185" height="20" font="5"> DES: 1-45 d OR: 11.58 (95% CI: </text>
<text top="478" left="697" width="207" height="20" font="5">4.08-32.80); 46-180 d OR: 1.71 (95% </text>
<text top="495" left="697" width="196" height="20" font="5">CI: 0.73–4.01); 181-365 d OR: 0.64 </text>
<text top="513" left="697" width="114" height="20" font="5">(95% CI: 0.20–2.04) </text>
<text top="530" left="697" width="3" height="20" font="5"> </text>
<text top="547" left="697" width="3" height="20" font="5"> </text>
<text top="564" left="697" width="3" height="20" font="4"><b> </b></text>
<text top="250" left="926" width="7" height="18" font="5">•</text>
<text top="250" left="933" width="138" height="20" font="5"> Administrative database </text>
<text top="267" left="926" width="3" height="20" font="5"> </text>
<text top="699" left="54" width="97" height="20" font="4"><b>EVENT Registry </b></text>
<text top="716" left="54" width="77" height="20" font="5">Berger, et al., </text>
<text top="733" left="54" width="31" height="20" font="5">2010 </text>
<text top="751" left="54" width="25" height="20" font="5">(66) </text>
<text top="768" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20850090?dopt=Citation">20850090</a></text>
<text top="768" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20850090?dopt=Citation"> </a></text>
<text top="699" left="170" width="127" height="20" font="4"><b>Aim:</b> To determine the </text>
<text top="716" left="170" width="135" height="20" font="5">frequency of noncardiac </text>
<text top="733" left="170" width="116" height="20" font="5">surgery and adverse </text>
<text top="751" left="170" width="117" height="20" font="5">postoperative events </text>
<text top="768" left="170" width="133" height="20" font="5">among pts who recently </text>
<text top="699" left="332" width="178" height="20" font="4"><b>Inclusion criteria:</b>  The EVENT </text>
<text top="716" left="332" width="161" height="20" font="5">registry, consecutive pts who </text>
<text top="733" left="332" width="209" height="20" font="5">underwent attempted stent placement </text>
<text top="751" left="332" width="189" height="20" font="5">at 42 hospitals between July 2004 </text>
<text top="768" left="332" width="196" height="20" font="5">and September 2005 were enrolled </text>
<text top="699" left="555" width="125" height="20" font="4"><b>Intervention: </b>Pts who </text>
<text top="716" left="555" width="95" height="20" font="5">underwent major </text>
<text top="733" left="555" width="44" height="20" font="5">surgery </text>
<text top="751" left="555" width="3" height="20" font="5"> </text>
<text top="768" left="555" width="91" height="20" font="4"><b>Comparator:</b>  <b>   </b></text>
<text top="700" left="697" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="719" left="697" width="7" height="18" font="5">•</text>
<text top="719" left="703" width="198" height="20" font="5"> In the 7 d after surgery, 4 pts had a </text>
<text top="736" left="697" width="215" height="20" font="5">cardiac death, myocardial infarction, or </text>
<text top="753" left="697" width="161" height="20" font="5">stent thrombosis (1.9%; 95% </text>
<text top="701" left="926" width="7" height="18" font="5">•</text>
<text top="700" left="933" width="100" height="20" font="5"> DAPT status and </text>
<text top="717" left="926" width="145" height="20" font="5">bleeding endpoint not well </text>
<text top="735" left="926" width="57" height="20" font="5">described </text>
<text top="752" left="926" width="3" height="20" font="5"> </text>
<text top="769" left="926" width="3" height="20" font="5"> </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">29 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="3" height="20" font="5"> </text>
<text top="53" left="170" width="140" height="20" font="5">received a DES following </text>
<text top="70" left="170" width="108" height="20" font="5">noncardiac surgery </text>
<text top="87" left="170" width="3" height="20" font="5"> </text>
<text top="104" left="170" width="119" height="20" font="4"><b>Study type:</b> Registry </text>
<text top="122" left="170" width="3" height="20" font="5"> </text>
<text top="139" left="170" width="76" height="20" font="4"><b>Size:</b> 206 pts </text>
<text top="53" left="332" width="151" height="20" font="5">and followed for 1 y.  Major </text>
<text top="70" left="332" width="187" height="20" font="5">noncardiac surgical procedures in </text>
<text top="87" left="332" width="194" height="20" font="5">which a significant surgical incision </text>
<text top="104" left="332" width="187" height="20" font="5">was required from which bleeding </text>
<text top="122" left="332" width="184" height="20" font="5">would result were included in this </text>
<text top="139" left="332" width="51" height="20" font="5">analysis. </text>
<text top="156" left="332" width="3" height="20" font="5"> </text>
<text top="173" left="332" width="161" height="20" font="4"><b>Exclusion criteria:</b>  Pts who </text>
<text top="190" left="332" width="190" height="20" font="5">underwent CABG or valve surgery </text>
<text top="208" left="332" width="195" height="20" font="5">(n=67), pacemaker and defibrillator </text>
<text top="225" left="332" width="176" height="20" font="5">placement  (n=46), and pts who </text>
<text top="242" left="332" width="183" height="20" font="5">underwent surgery whose nature </text>
<text top="259" left="332" width="205" height="20" font="5">could not be determined (n=50) were </text>
<text top="276" left="332" width="178" height="20" font="5">prospectively excluded from this </text>
<text top="294" left="332" width="194" height="20" font="5">analysis. Pts who underwent minor </text>
<text top="311" left="332" width="199" height="20" font="5">surgical procedures (n=27), such as </text>
<text top="328" left="332" width="186" height="20" font="5">minor dermatological procedures, </text>
<text top="345" left="332" width="160" height="20" font="5">endoscopic procedures, joint </text>
<text top="362" left="332" width="182" height="20" font="5">aspirations, and cataract surgery </text>
<text top="53" left="555" width="87" height="20" font="5">Pts who did not </text>
<text top="70" left="555" width="127" height="20" font="5">undergo major surgery </text>
<text top="87" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="104" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="53" left="697" width="97" height="20" font="5">CI=0.5%–4.9%).  </text>
<text top="72" left="697" width="7" height="18" font="5">•</text>
<text top="71" left="703" width="195" height="20" font="5"> The risk of the composite outcome </text>
<text top="88" left="697" width="175" height="20" font="5">was increased 27-fold in the wk </text>
<text top="106" left="697" width="159" height="20" font="5">following noncardiac surgery </text>
<text top="123" left="697" width="215" height="20" font="5">compared with any other wk after stent </text>
<text top="140" left="697" width="207" height="20" font="5">implantation (HR: 27.3; 95% CI: 10.0–</text>
<text top="157" left="697" width="90" height="20" font="5">74.2; p &lt;0.001). </text>
<text top="174" left="697" width="3" height="20" font="5"> </text>
<text top="192" left="697" width="3" height="20" font="5"> </text>
<text top="209" left="697" width="3" height="20" font="5"> </text>
<text top="226" left="697" width="3" height="20" font="4"><b> </b></text>
<text top="380" left="54" width="41" height="20" font="4"><b>PARIS </b></text>
<text top="398" left="54" width="82" height="20" font="5">Mehran, et al., </text>
<text top="415" left="54" width="34" height="20" font="5">2013  </text>
<text top="432" left="54" width="25" height="20" font="5">(67) </text>
<text top="449" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24004642">24004642</a></text>
<text top="449" left="109" width="3" height="20" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24004642"> </a></text>
<text top="380" left="170" width="127" height="20" font="4"><b>Aim:</b> To determine the </text>
<text top="398" left="170" width="115" height="20" font="5">association between </text>
<text top="415" left="170" width="138" height="20" font="5">different modes of DAPT </text>
<text top="432" left="170" width="79" height="20" font="5">cessation and </text>
<text top="449" left="170" width="133" height="20" font="5">cardiovascular risk after </text>
<text top="467" left="170" width="146" height="20" font="5">PCI in the PARIS Registry </text>
<text top="484" left="170" width="3" height="20" font="5"> </text>
<text top="501" left="170" width="74" height="20" font="4"><b>Study type:</b>  </text>
<text top="518" left="170" width="140" height="20" font="5">Retrospective analysis of </text>
<text top="535" left="170" width="124" height="20" font="5">a prospective registry  </text>
<text top="553" left="170" width="3" height="20" font="5"> </text>
<text top="570" left="170" width="86" height="20" font="4"><b>Size:</b> 5,031 pts </text>
<text top="587" left="170" width="89" height="20" font="5">undergoing PCI </text>
<text top="380" left="332" width="204" height="20" font="4"><b>Inclusion criteria:</b>  Adult pts (≥18 y) </text>
<text top="398" left="332" width="156" height="20" font="5">undergoing successful stent </text>
<text top="415" left="332" width="185" height="20" font="5">implantation in ≥1native coronary </text>
<text top="432" left="332" width="206" height="20" font="5">artery and discharged on DAPT were </text>
<text top="449" left="332" width="121" height="20" font="5">eligible for enrolment. </text>
<text top="467" left="332" width="3" height="20" font="5"> </text>
<text top="484" left="332" width="204" height="20" font="4"><b>Exclusion criteria:</b>  Pts participating </text>
<text top="501" left="332" width="193" height="20" font="5">in an investigational device or drug </text>
<text top="518" left="332" width="169" height="20" font="5">study or with evidence of stent </text>
<text top="535" left="332" width="189" height="20" font="5">thrombosis at the index procedure </text>
<text top="553" left="332" width="86" height="20" font="5">were excluded. </text>
<text top="380" left="555" width="117" height="20" font="4"><b>DAPT Cessation 1:  </b></text>
<text top="398" left="555" width="55" height="20" font="5">physician </text>
<text top="415" left="555" width="82" height="20" font="5">recommended </text>
<text top="432" left="555" width="85" height="20" font="5">discontinuation<b> </b></text>
<text top="449" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="467" left="555" width="117" height="20" font="4"><b>DAPT Cessation 2:  </b></text>
<text top="484" left="555" width="114" height="20" font="5">brief interruption (for </text>
<text top="501" left="555" width="49" height="20" font="5">surgery)<b> </b></text>
<text top="518" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="535" left="555" width="117" height="20" font="4"><b>DAPT Cessation 3:  </b></text>
<text top="553" left="555" width="57" height="20" font="5">disruption </text>
<text top="570" left="555" width="105" height="20" font="5">(noncompliance or </text>
<text top="587" left="555" width="114" height="20" font="5">because of bleeding </text>
<text top="604" left="555" width="3" height="20" font="5"> </text>
<text top="622" left="555" width="3" height="20" font="5"> </text>
<text top="639" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="382" left="697" width="82" height="20" font="4"><b>1</b>°<b> Findings:</b>   </text>
<text top="401" left="697" width="7" height="18" font="5">•</text>
<text top="400" left="703" width="193" height="20" font="5"> Overall incidence DAPT cessation </text>
<text top="417" left="697" width="169" height="20" font="5">57.3% (discontinuation 40.8%; </text>
<text top="435" left="697" width="202" height="20" font="5">interruption 10.5%; disruption 14.4% </text>
<text top="454" left="697" width="7" height="18" font="5">•</text>
<text top="453" left="703" width="200" height="20" font="5"> Compared with those on DAPT, the </text>
<text top="470" left="697" width="165" height="20" font="5">adjusted HR for MACE due to </text>
<text top="487" left="697" width="189" height="20" font="5">discontinuation was 0.63 (95% CI: </text>
<text top="505" left="697" width="202" height="20" font="5">0.46–0.86); for interruption was 1·41 </text>
<text top="522" left="697" width="201" height="20" font="5">(95% CI: 0.94–2.12; p=0·10) and for </text>
<text top="539" left="697" width="192" height="20" font="5">disruption was 1·50 (95% CI: 1.14–</text>
<text top="556" left="697" width="87" height="20" font="5">1.97; p=0.004). </text>
<text top="575" left="697" width="7" height="18" font="5">•</text>
<text top="575" left="703" width="209" height="20" font="5"> Within 7 d, 8–30 d, and more than 30 </text>
<text top="592" left="697" width="206" height="20" font="5">d after disruption, adjusted HRs were </text>
<text top="609" left="697" width="211" height="20" font="5">7·04 (95% CI: 3.31–14.95), 2.17 (95% </text>
<text top="626" left="697" width="129" height="20" font="5">CI: 0.97–4.88), and 1.3 </text>
<text top="643" left="697" width="192" height="20" font="5"> (95% CI: 0.97–1.76), respectively. </text>
<text top="382" left="926" width="7" height="18" font="5">•</text>
<text top="382" left="933" width="27" height="20" font="5"> N/A </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
<text top="789" left="1117" width="20" height="21" font="0">30 </text>
<text top="810" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="843" left="54" width="4" height="21" font="0"> </text>
<text top="843" left="843" width="4" height="21" font="0"> </text>
<text top="53" left="54" width="89" height="20" font="5">Holcomb, et al., </text>
<text top="70" left="54" width="31" height="20" font="5">2015 </text>
<text top="87" left="54" width="25" height="20" font="5">(68) </text>
<text top="104" left="54" width="55" height="20" font="6"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26720292">26720292</a></text>
<text top="104" left="109" width="3" height="20" font="4"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26720292"><b> </b></a></text>
<text top="122" left="54" width="7" height="20" font="4"><b>  </b></text>
<text top="53" left="170" width="149" height="20" font="4"><b>Aim:</b> To better understand </text>
<text top="70" left="170" width="141" height="20" font="5">the factors contributing to </text>
<text top="87" left="170" width="124" height="20" font="5">cardiac risk in pts who </text>
<text top="104" left="170" width="130" height="20" font="5">have undergone recent </text>
<text top="122" left="170" width="89" height="20" font="5">PCI and require </text>
<text top="139" left="170" width="130" height="20" font="5">noncardiac surgery, we </text>
<text top="156" left="170" width="136" height="20" font="5">comparatively examined </text>
<text top="173" left="170" width="137" height="20" font="5">the postoperative MACE </text>
<text top="190" left="170" width="139" height="20" font="5">associated with 3 distinct </text>
<text top="208" left="170" width="105" height="20" font="5">subgroups of stent </text>
<text top="225" left="170" width="116" height="20" font="5">indication: (1) MI; (2) </text>
<text top="242" left="170" width="136" height="20" font="5">unstable angina; and (3) </text>
<text top="259" left="170" width="56" height="20" font="5">non–ACS </text>
<text top="277" left="170" width="99" height="20" font="5">revascularization. </text>
<text top="294" left="170" width="3" height="20" font="5"> </text>
<text top="311" left="170" width="77" height="20" font="4"><b>Study type:</b>   </text>
<text top="328" left="170" width="116" height="20" font="5">Retrospective cohort </text>
<text top="345" left="170" width="3" height="20" font="5"> </text>
<text top="362" left="170" width="93" height="20" font="4"><b>Size:</b> 26,661 pts </text>
<text top="53" left="332" width="168" height="20" font="4"><b>Inclusion criteria:</b> All pts with </text>
<text top="70" left="332" width="197" height="20" font="5">coronary stents implanted in the VA </text>
<text top="87" left="332" width="169" height="20" font="5">between January 1, 2000, and </text>
<text top="104" left="332" width="111" height="20" font="5">December 31, 2010 </text>
<text top="122" left="332" width="3" height="20" font="5"> </text>
<text top="139" left="332" width="205" height="20" font="4"><b>Exclusion criteria:</b> Minor operations </text>
<text top="156" left="332" width="200" height="20" font="5">such as endoscopic procedures and </text>
<text top="173" left="332" width="190" height="20" font="5">minor musculoskeletal procedures </text>
<text top="190" left="332" width="208" height="20" font="5">such as application of a cast and joint </text>
<text top="208" left="332" width="183" height="20" font="5">aspiration. Operations performed </text>
<text top="225" left="332" width="199" height="20" font="5">under local or monitored anesthesia </text>
<text top="242" left="332" width="166" height="20" font="5">were excluded from analyses. </text>
<text top="53" left="555" width="102" height="20" font="4"><b>Intervention:</b> N/A </text>
<text top="70" left="555" width="3" height="20" font="5"> </text>
<text top="87" left="555" width="3" height="20" font="5"> </text>
<text top="104" left="555" width="3" height="20" font="5"> </text>
<text top="122" left="555" width="101" height="20" font="4"><b>Comparator:</b> N/A </text>
<text top="139" left="555" width="7" height="20" font="4"><b>  </b></text>
<text top="156" left="555" width="3" height="20" font="4"><b> </b></text>
<text top="54" left="697" width="83" height="20" font="4"><b>1</b>°<b> endpoint:</b>   </text>
<text top="73" left="697" width="7" height="18" font="5">•</text>
<text top="72" left="703" width="182" height="20" font="5"> Postoperative MACE rates were </text>
<text top="89" left="697" width="190" height="20" font="5">significantly higher in the MI group </text>
<text top="107" left="697" width="194" height="20" font="5">(7.5%) compared with the unstable </text>
<text top="124" left="697" width="200" height="20" font="5">angina (2.7%) and non–ACS (2.6%) </text>
<text top="141" left="697" width="104" height="20" font="5">groups (p&lt;0.001).  </text>
<text top="160" left="697" width="7" height="18" font="5">•</text>
<text top="160" left="703" width="203" height="20" font="5"> When surgery was performed within </text>
<text top="177" left="697" width="204" height="20" font="5">3 mo of PCI, adjusted odds of MACE </text>
<text top="194" left="697" width="185" height="20" font="5">were significantly higher in the MI </text>
<text top="211" left="697" width="195" height="20" font="5">group compared with the non–ACS </text>
<text top="228" left="697" width="208" height="20" font="5">group (OR: 5.25; 95% CI: 4.08–6.75). </text>
<text top="246" left="697" width="215" height="20" font="5">This risk decreased overtime, although </text>
<text top="263" left="697" width="203" height="20" font="5">it remained significantly higher at 12–</text>
<text top="280" left="697" width="197" height="20" font="5">24 mo from PCI (OR: 1.95; 95% CI: </text>
<text top="297" left="697" width="69" height="20" font="5">1.58–2.40).  </text>
<text top="316" left="697" width="7" height="18" font="5">•</text>
<text top="316" left="703" width="196" height="20" font="5">The adjusted odds of MACE for the </text>
<text top="333" left="697" width="208" height="20" font="5">unstable angina group were similar to </text>
<text top="350" left="697" width="196" height="20" font="5">those for the non–ACS group when </text>
<text top="367" left="697" width="195" height="20" font="5">surgery was performed within 3 mo </text>
<text top="384" left="697" width="206" height="20" font="5">(OR: 1.11; CI: 0.80–1.53) or between </text>
<text top="402" left="697" width="189" height="20" font="5">12 and 24 mo (OR: 1.08; CI: 0.86–</text>
<text top="419" left="697" width="153" height="20" font="5">1.37) from stent placement. </text>
<text top="55" left="926" width="7" height="18" font="5">•</text>
<text top="54" left="933" width="118" height="20" font="5"> Primarily older white </text>
<text top="71" left="926" width="36" height="20" font="5">males </text>
<text top="90" left="926" width="7" height="18" font="5">•</text>
<text top="90" left="933" width="121" height="20" font="5"> Unknown medication </text>
<text top="107" left="926" width="48" height="20" font="5">regimen </text>
<text top="126" left="926" width="7" height="18" font="5">•</text>
<text top="125" left="933" width="108" height="20" font="5"> Stent type was not </text>
<text top="142" left="926" width="129" height="20" font="5">significantly associated </text>
<text top="159" left="926" width="139" height="20" font="5">with MACE regardless of </text>
<text top="177" left="926" width="59" height="20" font="5">indication. </text>
<text top="194" left="926" width="3" height="20" font="5"> </text>
<text top="211" left="926" width="3" height="20" font="5"> </text>
<text top="437" left="54" width="1062" height="20" font="5">ACS indicates acute coronary syndrome; BMS, bare metal stent; CABG, coronary artery bypass graft; CI, confidence interval; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; HR, hazard </text>
<text top="457" left="54" width="1041" height="20" font="5">ratio; MACE, major adverse cardiac events; MI, myocardial infarction; N/A, not available; NCS, noncardiac surgery; OR, odds ratio; PCI, percutaneous coronary intervention; RCT, randomized </text>
<text top="477" left="54" width="393" height="20" font="5">controlled trials; RR, relative risk; and VA, US Veterans Affairs Hospital. </text>
<text top="514" left="54" width="1034" height="20" font="5">ARCTIC indicates Assessment by a Double Randomisation of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment </text>
<text top="533" left="54" width="1059" height="20" font="5">Interruption Versus Continuation 1 Year AfterS; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DES-LATE, Optimal Duration of Clopidogrel Therapy With Drug Eluting Stents to Reduce </text>
<text top="553" left="54" width="1043" height="20" font="5">Late Coronary Arterial Thrombotic Events; EXCELLENT, Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; ISAR-SAFE, Intracoronary Stenting and Antithrombotic </text>
<text top="573" left="54" width="1078" height="20" font="5">Regimen: Safety and Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting; ITALIC, Is There A Life for DES After Discontinuation of Clopidogrel; MACCE, major adverse cardiac </text>
<text top="593" left="54" width="1032" height="20" font="5">and cerebrovascular events (death, MI, or stroke); MI, myocardial infarction; OPTIDUAL, Optimal Dual Antiplatelet Therapy; OPTIMIZE, Optimized Duration of Clopidogrel Therapy Following </text>
<text top="612" left="54" width="1068" height="20" font="5">Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice; NACCE, net adverse cardiac and cerebrovascular events (death, MI, stroke or major bleeding); PRODIGY, Prolonging </text>
<text top="632" left="54" width="1055" height="20" font="5">Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia; REAL-LATE, REAL-world patients treated with drug-eluting stent implantation and Late coronary Arterial Thrombotic </text>
<text top="652" left="54" width="1081" height="20" font="5">Events; RESET, Real Safety and Efficacy of 3-month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation; revasc, revascularization; SECURITY, Second Generation </text>
<text top="672" left="54" width="1072" height="20" font="5">Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy; ST, stent thrombosis; TIMI, Thrombolysis In Myocardial Infarction; TVF, target-vessel failure; TVR, </text>
<text top="691" left="54" width="1065" height="20" font="5">target-vessel revascularization; and ZEST-LATE, Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or Paclitaxel-Eluting Stent Implantation for Coronary Lesions-Late coronary Arterial Thrombotic </text>
<text top="711" left="54" width="44" height="20" font="5">Events. </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1059" left="847" width="20" height="21" font="0">31 </text>
<text top="1080" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1113" left="54" width="4" height="21" font="0"> </text>
<text top="1113" left="843" width="4" height="21" font="0"> </text>
<text top="55" left="419" width="84" height="24" font="2"><b>References </b></text>
<text top="89" left="54" width="4" height="13" font="5"> </text>
<text top="89" left="83" width="753" height="13" font="5">1.   Schulz-Schupke S, Byrne RA, ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 </text>
<text top="106" left="108" width="524" height="13" font="5">versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015; </text>
<text top="123" left="54" width="4" height="13" font="5"> </text>
<text top="123" left="83" width="777" height="13" font="5">2.   Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month </text>
<text top="140" left="108" width="635" height="13" font="5">dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086-97. </text>
<text top="158" left="54" width="4" height="13" font="5"> </text>
<text top="158" left="83" width="775" height="13" font="5">3.   Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the </text>
<text top="175" left="108" width="347" height="13" font="5">OPTIMIZE randomized trial. JAMA. 2013;310:2510-22. </text>
<text top="192" left="54" width="4" height="13" font="5"> </text>
<text top="192" left="83" width="770" height="13" font="5">4.   Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal </text>
<text top="209" left="108" width="747" height="13" font="5">Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am </text>
<text top="227" left="108" width="185" height="13" font="5">Coll Cardiol. 2012;60:1340-8. </text>
<text top="244" left="54" width="4" height="13" font="5"> </text>
<text top="244" left="83" width="775" height="13" font="5">5.   Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting </text>
<text top="261" left="108" width="719" height="13" font="5">stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, </text>
<text top="278" left="108" width="298" height="13" font="5">multicenter study. Circulation. 2012;125:505-13. </text>
<text top="296" left="54" width="4" height="13" font="5"> </text>
<text top="296" left="83" width="751" height="13" font="5">6.   Gilard M, Barragan P, Noryani AA, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting </text>
<text top="313" left="108" width="722" height="13" font="5">stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777-86. </text>
<text top="330" left="54" width="4" height="13" font="5"> </text>
<text top="330" left="83" width="784" height="13" font="5">7.   Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: </text>
<text top="347" left="108" width="382" height="13" font="5">a randomized multicenter trial. Circulation. 2012;125:2015-26. </text>
<text top="365" left="54" width="4" height="13" font="5"> </text>
<text top="365" left="83" width="727" height="13" font="5">8.   Helft G, Steg PG, Le FC, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the </text>
<text top="382" left="108" width="299" height="13" font="5">OPTIDUAL randomized trial. Eur Heart J. 2015; </text>
<text top="399" left="54" width="4" height="13" font="5"> </text>
<text top="399" left="83" width="767" height="13" font="5">9.   Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J </text>
<text top="416" left="108" width="153" height="13" font="5">Med. 2014;371:2155-66. </text>
<text top="434" left="54" width="4" height="13" font="5"> </text>
<text top="434" left="76" width="753" height="13" font="5">10.   Collet JP, Silvain J, Barthelemy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation </text>
<text top="451" left="108" width="432" height="13" font="5">(ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577-85. </text>
<text top="468" left="54" width="4" height="13" font="5"> </text>
<text top="468" left="76" width="750" height="13" font="5">11.   Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a </text>
<text top="485" left="108" width="361" height="13" font="5">randomized, controlled trial. Circulation. 2014;129:304-12. </text>
<text top="503" left="54" width="4" height="13" font="5"> </text>
<text top="503" left="76" width="767" height="13" font="5">12.   Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J </text>
<text top="520" left="108" width="153" height="13" font="5">Med. 2010;362:1374-82. </text>
<text top="537" left="54" width="4" height="13" font="5"> </text>
<text top="537" left="76" width="786" height="13" font="5">13.   Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events </text>
<text top="554" left="108" width="757" height="13" font="5">in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart </text>
<text top="572" left="108" width="51" height="13" font="5">J. 2015; </text>
<text top="589" left="54" width="4" height="13" font="5"> </text>
<text top="589" left="76" width="754" height="13" font="5">14.   Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and </text>
<text top="606" left="108" width="242" height="13" font="5">meta-analysis. Lancet. 2015;385:792-8. </text>
<text top="623" left="54" width="4" height="13" font="5"> </text>
<text top="623" left="76" width="750" height="13" font="5">15.   Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent </text>
<text top="641" left="108" width="699" height="13" font="5">implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol. 2015;65:1092-102. </text>
<text top="658" left="54" width="4" height="13" font="5"> </text>
<text top="658" left="76" width="745" height="13" font="5">16.   Giustino G, Baber U, Sartori S, et al. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A </text>
<text top="675" left="108" width="679" height="13" font="5">Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol. 2015;65:1298-310. </text>
<text top="693" left="54" width="4" height="13" font="5"> </text>
<text top="693" left="76" width="739" height="13" font="5">17.   Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary </text>
<text top="710" left="108" width="646" height="13" font="5">intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618. </text>
<text top="727" left="54" width="4" height="13" font="5"> </text>
<text top="727" left="76" width="761" height="13" font="5">18.   Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet </text>
<text top="744" left="108" width="738" height="13" font="5">therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. </text>
<text top="761" left="108" width="118" height="13" font="5">2015;385:2371-82. </text>
<text top="779" left="54" width="4" height="13" font="5"> </text>
<text top="779" left="76" width="770" height="13" font="5">19.   Spencer FA, Prasad M, Vandvik PO, et al. Longer Versus Shorter Duration Dual-Antiplatelet Therapy After Drug-Eluting </text>
<text top="796" left="108" width="498" height="13" font="5">Stent Placement: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; </text>
<text top="813" left="54" width="4" height="13" font="5"> </text>
<text top="813" left="76" width="756" height="13" font="5">20.   Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in </text>
<text top="830" left="108" width="498" height="13" font="5">Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015; </text>
<text top="848" left="54" width="4" height="13" font="5"> </text>
<text top="848" left="76" width="780" height="13" font="5">21.   Bonaca MP, Bhatt DL, Cohen M, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J </text>
<text top="865" left="108" width="73" height="13" font="5">Med. 2015; </text>
<text top="882" left="54" width="4" height="13" font="5"> </text>
<text top="882" left="76" width="685" height="13" font="5">22.   Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without </text>
<text top="899" left="108" width="327" height="13" font="5">revascularization. N Engl J Med. 2012;367:1297-309. </text>
<text top="917" left="54" width="4" height="13" font="5"> </text>
<text top="917" left="76" width="781" height="13" font="5">23.   James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for </text>
<text top="934" left="108" width="756" height="13" font="5">non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. </text>
<text top="951" left="108" width="143" height="13" font="5">BMJ. 2011;342:d3527. </text>
<text top="969" left="54" width="4" height="13" font="5"> </text>
<text top="969" left="76" width="727" height="13" font="5">24.   Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary </text>
<text top="986" left="108" width="716" height="13" font="5">syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient </text>
<text top="1003" left="108" width="463" height="13" font="5">Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131-41. </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1059" left="847" width="20" height="21" font="0">32 </text>
<text top="1080" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1113" left="54" width="4" height="21" font="0"> </text>
<text top="1113" left="843" width="4" height="21" font="0"> </text>
<text top="57" left="54" width="4" height="13" font="5"> </text>
<text top="57" left="76" width="771" height="13" font="5">25.   Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous </text>
<text top="75" left="108" width="753" height="13" font="5">coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. </text>
<text top="92" left="108" width="159" height="13" font="5">Lancet. 2009;373:723-31. </text>
<text top="109" left="54" width="4" height="13" font="5"> </text>
<text top="109" left="76" width="761" height="13" font="5">26.   Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N </text>
<text top="126" left="108" width="195" height="13" font="5">Engl J Med. 2007;357:2001-15. </text>
<text top="144" left="54" width="4" height="13" font="5"> </text>
<text top="144" left="76" width="775" height="13" font="5">27.   Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial </text>
<text top="161" left="108" width="420" height="13" font="5">disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-8. </text>
<text top="178" left="54" width="4" height="13" font="5"> </text>
<text top="178" left="76" width="752" height="13" font="5">28.   Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic </text>
<text top="195" left="108" width="255" height="13" font="5">events. N Engl J Med. 2006;354:1706-17. </text>
<text top="213" left="54" width="4" height="13" font="5"> </text>
<text top="213" left="76" width="775" height="13" font="5">29.   Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: </text>
<text top="230" left="108" width="388" height="13" font="5">randomised placebo-controlled trial. Lancet. 2005;366:1607-21. </text>
<text top="247" left="54" width="4" height="13" font="5"> </text>
<text top="247" left="76" width="786" height="13" font="5">30.   Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in </text>
<text top="264" left="108" width="755" height="13" font="5">patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224-</text>
<text top="282" left="108" width="22" height="13" font="5">32. </text>
<text top="299" left="54" width="4" height="13" font="5"> </text>
<text top="299" left="76" width="747" height="13" font="5">31.   Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial </text>
<text top="316" left="108" width="441" height="13" font="5">infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-89. </text>
<text top="333" left="54" width="4" height="13" font="5"> </text>
<text top="333" left="76" width="772" height="13" font="5">32.   Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing </text>
<text top="351" left="108" width="725" height="13" font="5">surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent </text>
<text top="368" left="108" width="441" height="13" font="5">Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202-8. </text>
<text top="385" left="54" width="4" height="13" font="5"> </text>
<text top="385" left="76" width="760" height="13" font="5">33.   Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes </text>
<text top="402" left="108" width="398" height="13" font="5">without ST-segment elevation. N Engl J Med. 2001;345:494-502. </text>
<text top="420" left="54" width="4" height="13" font="5"> </text>
<text top="420" left="76" width="771" height="13" font="5">34.   Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in </text>
<text top="437" left="108" width="636" height="13" font="5">patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33. </text>
<text top="454" left="54" width="4" height="13" font="5"> </text>
<text top="454" left="76" width="775" height="13" font="5">35.   Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J </text>
<text top="471" left="108" width="153" height="13" font="5">Med. 2009;361:1045-57. </text>
<text top="489" left="54" width="4" height="13" font="5"> </text>
<text top="489" left="76" width="772" height="13" font="5">36.   Xian Y, Wang TY, McCoy LA, et al. The Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial </text>
<text top="506" left="108" width="458" height="13" font="5">Infarction: Insights From the TRANSLATE-ACS Study. Circulation. 2015; </text>
<text top="523" left="54" width="4" height="13" font="5"> </text>
<text top="523" left="76" width="779" height="13" font="5">37.   Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose </text>
<text top="540" left="108" width="759" height="13" font="5">aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a </text>
<text top="558" left="108" width="326" height="13" font="5">randomised factorial trial. Lancet. 2010;376:1233-43. </text>
<text top="575" left="54" width="4" height="13" font="5"> </text>
<text top="575" left="76" width="765" height="13" font="5">38.   Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary </text>
<text top="592" left="108" width="470" height="13" font="5">intervention: insights from the PCI-CURE study. Eur Heart J. 2009;30:900-7. </text>
<text top="609" left="54" width="4" height="13" font="5"> </text>
<text top="609" left="76" width="768" height="13" font="5">39.   Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and </text>
<text top="627" left="108" width="472" height="13" font="5">clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009;150:379-86. </text>
<text top="644" left="54" width="4" height="13" font="5"> </text>
<text top="644" left="76" width="755" height="13" font="5">40.   Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical </text>
<text top="661" left="108" width="382" height="13" font="5">Practice Guidelines (8th Edition). Chest. 2008;133:199S-233S. </text>
<text top="679" left="54" width="4" height="13" font="5"> </text>
<text top="679" left="76" width="780" height="13" font="5">41.   Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in </text>
<text top="696" left="108" width="566" height="13" font="5">192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218-22. </text>
<text top="713" left="54" width="4" height="13" font="5"> </text>
<text top="713" left="76" width="774" height="13" font="5">42.   Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients </text>
<text top="730" left="108" width="747" height="13" font="5">with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) </text>
<text top="747" left="108" width="226" height="13" font="5">study. Circulation. 2003;108:1682-7. </text>
<text top="765" left="54" width="4" height="13" font="5"> </text>
<text top="765" left="76" width="771" height="13" font="5">43.   Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and </text>
<text top="782" left="108" width="306" height="13" font="5">stroke in high risk patients. BMJ. 2002;324:71-86. </text>
<text top="799" left="54" width="4" height="13" font="5"> </text>
<text top="799" left="76" width="749" height="13" font="5">44.   Lorenz RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). </text>
<text top="816" left="108" width="506" height="13" font="5">Effects on platelet aggregation and thromboxane formation. Lancet. 1984;1:1261-4. </text>
<text top="834" left="54" width="4" height="13" font="5"> </text>
<text top="834" left="76" width="762" height="13" font="5">45.   Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery </text>
<text top="851" left="108" width="591" height="13" font="5">stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-71. </text>
<text top="868" left="54" width="4" height="13" font="5"> </text>
<text top="868" left="76" width="755" height="13" font="5">46.   Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the </text>
<text top="886" left="108" width="423" height="13" font="5">placement of coronary-artery stents. N Engl J Med. 1996;334:1084-9. </text>
<text top="903" left="54" width="4" height="13" font="5"> </text>
<text top="903" left="76" width="775" height="13" font="5">47.   Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de </text>
<text top="920" left="108" width="400" height="13" font="5">novo coronary artery lesions. J Am Coll Cardiol. 2008;51:2220-7. </text>
<text top="937" left="54" width="4" height="13" font="5"> </text>
<text top="937" left="76" width="739" height="13" font="5">48.   Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent </text>
<text top="955" left="108" width="243" height="13" font="5">implantation. JAMA. 2007;297:159-68. </text>
<text top="972" left="54" width="4" height="13" font="5"> </text>
<text top="972" left="76" width="748" height="13" font="5">49.   Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous </text>
<text top="989" left="108" width="485" height="13" font="5">coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20. </text>
<text top="1006" left="54" width="4" height="13" font="5"> </text>
<text top="1006" left="76" width="790" height="13" font="5">50.   Mannacio VA, Di TL, Antignan A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary </text>
<text top="1023" left="108" width="699" height="13" font="5">artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump </text>
<text top="1041" left="108" width="332" height="13" font="5">procedures) randomised study. Heart. 2012;98:1710-5. </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1059" left="847" width="20" height="21" font="0">33 </text>
<text top="1080" left="54" width="552" height="17" font="1">© 2016 by the American College of Cardiology Foundation, and the American Heart Association, Inc. </text>
<text top="1113" left="54" width="4" height="21" font="0"> </text>
<text top="1113" left="843" width="4" height="21" font="0"> </text>
<text top="57" left="54" width="4" height="13" font="5"> </text>
<text top="57" left="76" width="753" height="13" font="5">51.   Sun JC, Teoh KH, Lamy A, et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of </text>
<text top="75" left="108" width="745" height="13" font="5">coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass </text>
<text top="92" left="108" width="290" height="13" font="5">Grafting study. Am Heart J. 2010;160:1178-84. </text>
<text top="109" left="54" width="4" height="13" font="5"> </text>
<text top="109" left="76" width="791" height="13" font="5">52.   Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the </text>
<text top="126" left="108" width="622" height="13" font="5">clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation. 2010;122:2680-7. </text>
<text top="144" left="54" width="4" height="13" font="5"> </text>
<text top="144" left="76" width="752" height="13" font="5">53.   Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery </text>
<text top="161" left="108" width="592" height="13" font="5">bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol. 2010;56:1639-43. </text>
<text top="178" left="54" width="4" height="13" font="5"> </text>
<text top="178" left="76" width="761" height="13" font="5">54.   Gao C, Ren C, Li D, et al. Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass </text>
<text top="195" left="108" width="262" height="13" font="5">grafting. Ann Thorac Surg. 2009;88:59-62. </text>
<text top="213" left="54" width="4" height="13" font="5"> </text>
<text top="213" left="76" width="763" height="13" font="5">55.   Ebrahimi R, Bakaeen FG, Uberoi A, et al. Effect of clopidogrel use post coronary artery bypass surgery on graft patency. </text>
<text top="230" left="108" width="207" height="13" font="5">Ann Thorac Surg. 2014;97:15-21. </text>
<text top="247" left="54" width="4" height="13" font="5"> </text>
<text top="247" left="76" width="769" height="13" font="5">56.   Ibrahim K, Tjomsland O, Halvorsen D, et al. Effect of clopidogrel on midterm graft patency following off-pump coronary </text>
<text top="264" left="108" width="397" height="13" font="5">revascularization surgery. Heart Surg Forum. 2006;9:E581-E856. </text>
<text top="282" left="54" width="4" height="13" font="5"> </text>
<text top="282" left="76" width="779" height="13" font="5">57.   Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A </text>
<text top="299" left="108" width="409" height="13" font="5">systematic review and meta-analysis. J Card Surg. 2013;28:109-16. </text>
<text top="316" left="54" width="4" height="13" font="5"> </text>
<text top="316" left="76" width="784" height="13" font="5">58.   Nocerino AG, Achenbach S, Taylor AJ. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of </text>
<text top="333" left="108" width="525" height="13" font="5">bypass conduits after coronary artery bypass grafting. Am J Cardiol. 2013;112:1576-9. </text>
<text top="351" left="54" width="4" height="13" font="5"> </text>
<text top="351" left="76" width="741" height="13" font="5">59.   de LN, Jackevicius CA. Use of aspirin and clopidogrel after coronary artery bypass graft surgery. Ann Pharmacother. </text>
<text top="368" left="108" width="103" height="13" font="5">2012;46:678-87. </text>
<text top="385" left="54" width="4" height="13" font="5"> </text>
<text top="385" left="76" width="762" height="13" font="5">60.   Sorensen R, Abildstrom SZ, Hansen PR, et al. Efficacy of post-operative clopidogrel treatment in patients revascularized </text>
<text top="402" left="108" width="611" height="13" font="5">with coronary artery bypass grafting after myocardial infarction. J Am Coll Cardiol. 2011;57:1202-9. </text>
<text top="420" left="54" width="4" height="13" font="5"> </text>
<text top="420" left="76" width="783" height="13" font="5">61.   Kim DH, Daskalakis C, Silvestry SC, et al. Aspirin and clopidogrel use in the early postoperative period following on-pump </text>
<text top="437" left="108" width="562" height="13" font="5">and off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2009;138:1377-84. </text>
<text top="454" left="54" width="4" height="13" font="5"> </text>
<text top="454" left="76" width="763" height="13" font="5">62.   Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll </text>
<text top="471" left="108" width="163" height="13" font="5">Cardiol. 2000;35:1288-94. </text>
<text top="489" left="54" width="4" height="13" font="5"> </text>
<text top="489" left="76" width="752" height="13" font="5">63.   Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months </text>
<text top="506" left="108" width="395" height="13" font="5">following coronary stenting. J Am Coll Cardiol. 2003;42:234-40. </text>
<text top="523" left="54" width="4" height="13" font="5"> </text>
<text top="523" left="76" width="781" height="13" font="5">64.   Nuttall GA, Brown MJ, Stombaugh JW, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary </text>
<text top="540" left="108" width="292" height="13" font="5">intervention. Anesthesiology. 2008;109:588-95. </text>
<text top="558" left="54" width="4" height="13" font="5"> </text>
<text top="558" left="76" width="789" height="13" font="5">65.   Wijeysundera DN, Wijeysundera HC, Yun L, et al. Risk of elective major noncardiac surgery after coronary stent insertion: a </text>
<text top="575" left="108" width="340" height="13" font="5">population-based study. Circulation. 2012;126:1355-62. </text>
<text top="592" left="54" width="4" height="13" font="5"> </text>
<text top="592" left="76" width="791" height="13" font="5">66.   Berger PB, Kleiman NS, Pencina MJ, et al. Frequency of major noncardiac surgery and subsequent adverse events in the year </text>
<text top="609" left="108" width="704" height="13" font="5">after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) </text>
<text top="627" left="108" width="302" height="13" font="5">Registry. JACC Cardiovasc Interv. 2010;3:920-7. </text>
<text top="644" left="54" width="4" height="13" font="5"> </text>
<text top="644" left="76" width="773" height="13" font="5">67.   Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary </text>
<text top="661" left="108" width="628" height="13" font="5">intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382:1714-22. </text>
<text top="679" left="54" width="4" height="13" font="5"> </text>
<text top="679" left="76" width="735" height="13" font="5">68.   Holcomb CN, Hollis RH, Graham LA, et al. Association of Coronary Stent Indication With Postoperative Outcomes </text>
<text top="696" left="108" width="335" height="13" font="5">Following Noncardiac Surgery. JAMA Surg. 2015;1-8. </text>
<text top="713" left="54" width="4" height="13" font="5"> </text>
<text top="730" left="54" width="4" height="13" font="5"> </text>
<text top="744" left="54" width="4" height="21" font="0"> </text>
</page>
<outline>
<item page="1">2016 Duration of Dual Antiplatelet Therapy Guideline Focused Update Data Supplement</item>
<item page="2">Data Supplement 1. RCTs of Shorter (3–6 Month) Duration of DAPT in Patients Treated With Stent Implantation</item>
<item page="4">Data Supplement 2. RCTs of Prolonged/Extended (&gt;12 Month) Duration of DAPT in Patients Treated With Stent Implantation</item>
<item page="6">Data Supplement 3. Meta-Analyses of Duration of DAPT</item>
<item page="9">Data Supplement 4. RCTs, RCT Subgroup Analyses, and Meta-Analyses of RCTs of DAPT Post–MI or Post–ACS</item>
<item page="15">Data Supplement 5. RCTs and RCT Subgroup Analyses Comparing Clopidogel With Prasugrel or Ticagrelor In Patients With ACS</item>
<item page="17">Data Supplement 6.  Studies and Comparisons of Short-Term or Chronic Aspirin Dose in Patients With Coronary Artery Disease</item>
<item page="20">Data Supplement 7.  RCTs Comparing Antiplatelet Therapy With Anticoagulant Therapy in Patients Undergoing Coronary Stenting</item>
<item page="21">Data Supplement 8.  Nonrandomized Studies of DAPT Duration After BMS or DES</item>
<item page="22">Data Supplement 9.  Randomized Studies of 1 Versus 12 Months of DAPT After BMS</item>
<item page="22">Data Supplement 10.  Studies and Meta-Analyses Comparing Graft Patency Post–CABG in Patients Treated With Either Antiplatelet Monotherapy or DAPT</item>
<item page="25">Data Supplement 11.  Studies Comparing Outcome Post–CABG in Patients Treated With Either Aspirin or DAPT</item>
<item page="27">Data Supplement 12. Studies of Timing of Noncardiac Surgery After PCI</item>
<item page="31">References</item>
</outline>
</pdf2xml>
